On this page
Quick Reference
Overview and Recommendations
Background
- •Hemophilia A is an X-linked recessive bleeding disorder caused by pathogenic variants in the F8 gene, leading to deficient or dysfunctional coagulation factor VIII (FVIII). This impairs the intrinsic tenase complex, reducing thrombin generation by 10⁵-fold and predisposing to spontaneous and trauma-related bleeding, particularly into joints and soft tissues [1].
- •The disease affects approximately 1 in 5,000 to 10,000 male births worldwide, making it one of the most common inherited bleeding disorders. Up to 75% of affected individuals globally remain undiagnosed, especially in resource-limited settings, underscoring the need for targeted screening of at-risk families [1].
- •Severity is dichotomized by baseline FVIII activity: severe (<1 IU/dL) with spontaneous bleeding, moderate (1-5 IU/dL) with occasional spontaneous or trauma-related bleeds, and mild (>5 to <40 IU/dL) with bleeding only after significant injury or surgery. FVIII activity ≥40 IU/dL is generally asymptomatic [1, 10].
- •The underlying F8 mutation type is the primary determinant of clinical severity and inhibitor risk. Intron 22 inversion accounts for 40-45% of severe cases, while missense mutations predominate in mild/moderate disease. Neutralizing anti-FVIII antibodies (inhibitors) develop in 25-35% of patients with severe hemophilia A and are the most significant treatment-related complication [13, 28].
- •The 2021 ISTH nomenclature reclassified female F8 variant carriers into five distinct categories (asymptomatic, symptomatic, mild, moderate, severe) based on personal bleeding history and FVIII level, replacing the historical 'carrier' label and acknowledging that many females experience clinically significant bleeding [6, 7].
- •A subset of patients exhibit 'discrepant hemophilia A,' where FVIII activity differs between one-stage clotting and chromogenic assays due to specific F8 missense mutations. Chromogenic assay is the confirmatory test and better reflects true bleeding risk, preventing underdiagnosis or misclassification [10].
Evaluation
- •Suspect hemophilia A in any male with a history of spontaneous hemarthroses (especially ankles, knees, elbows), easy bruising, prolonged bleeding after dental extraction or surgery, or intracranial hemorrhage (ICH) in infancy. A three-generation family history revealing X-linked inheritance is highly suggestive [88, 111].
- •Ask about the age at first significant bleed: severe disease often presents in infancy with excessive bruising after crawling or ICH after birth. Moderate disease may present in childhood with bleeding after minor trauma, while mild disease can remain undiagnosed until adulthood after a surgical challenge [81].
- •Examine for joint swelling, warmth, and limited range of motion in acute hemarthrosis. Chronic arthropathy presents with fixed flexion deformities, crepitus, muscle atrophy, and reduced gait. In neonates, ICH may manifest as lethargy, seizures, vomiting, or bulging fontanelles [88, 111].
- •Order a complete blood count (CBC), prothrombin time (PT), and activated partial thromboplastin time (aPTT). An isolated prolonged aPTT with normal PT is the classic screening abnormality. A mixing study (1:1 with normal plasma) that corrects immediately suggests a factor deficiency; failure to correct after incubation indicates an inhibitor [124, 96].
- •Perform a one-stage clotting assay for FVIII activity (FVIII:C) as the initial gold-standard diagnostic test. A level <40 IU/dL confirms the diagnosis and defines severity: <1 IU/dL (severe), 1-5 IU/dL (moderate), >5 to <40 IU/dL (mild). Normal FVIII:C essentially excludes hemophilia A [124].
- •In mild hemophilia A (FVIII:C 5-40 IU/dL), perform a chromogenic FVIII:C assay to detect discrepant hemophilia A, where the one-stage assay may overestimate FVIII activity. The chromogenic assay is the confirmatory test and better predicts bleeding risk [70].
- •Measure von Willebrand factor (VWF) antigen and activity (ristocetin cofactor) to exclude von Willebrand disease type 2N, which also causes low FVIII:C due to defective VWF binding. This is essential in any patient with low FVIII and normal VWF levels to confirm true hemophilia A [33].
- •If the mixing study fails to correct after 2-hour incubation, perform the Nijmegen-modified Bethesda assay to detect and quantify FVIII inhibitors (neutralizing antibodies). A titer ≥0.6 Bethesda units (BU) is considered positive; >5 BU defines high-titer inhibitors [118].
- •Offer genetic counseling and F8 gene sequencing for confirmation of the diagnosis, determination of mutation type (critical for inhibitor risk stratification), carrier testing in female relatives, and prenatal diagnosis. The mutation type predicts inhibitor risk: null mutations (large deletions, nonsense) carry the highest risk [13, 18, 126].
- •In female patients with low FVIII:C, assess for skewed X-inactivation, Turner syndrome mosaicism, or von Willebrand disease type 2N. A three-generation pedigree and evaluation of personal bleeding history with menstrual and postpartum bleeding are essential [6, 33, 129].
- •Diagnostic criteria for acquired hemophilia A (AHA) include new-onset bleeding in an older adult without prior bleeding history, isolated prolonged aPTT that does not correct on mixing study, low FVIII:C, and a positive Bethesda assay for anti-FVIII autoantibodies. Unlike congenital disease, AHA often presents with ecchymoses and muscle hematomas rather than hemarthroses [20, 75, 98].
- •Also consider other causes of isolated prolonged aPTT: lupus anticoagulant (does not correct with mixing but may show prolonged dilute Russell viper venom time), factor IX deficiency (hemophilia B), and factor XI deficiency. Specific factor assays for FIX and FXI should be performed if FVIII is normal and clinical suspicion remains high [124].
Management
- •For acute major bleeds (intracranial hemorrhage, retroperitoneal, gastrointestinal, large muscle with compartment syndrome) in patients without inhibitors: administer FVIII concentrate 50 IU/kg IV bolus immediately, followed by 25 IU/kg every 8-12 hours. For life-threatening bleeds, give initial bolus of 50-100 IU/kg and maintain FVIII activity >80% for 7-14 days [148].
- •For acute minor bleeds (hemarthroses, superficial hematomas) in patients without inhibitors: administer FVIII concentrate 25-40 IU/kg IV; a single dose may suffice. For hemarthroses, rest, immobilize the joint, and apply ice. Avoid weight-bearing until pain and swelling resolve, typically 24-48 hours [148].
- •For patients with inhibitors who present with an acute bleed: use a bypassing agent. First-line options are recombinant activated factor VII (rFVIIa) 90 mcg/kg IV every 2-3 hours or activated prothrombin complex concentrate (aPCC, FEIBA) 50-100 U/kg IV every 12 hours (maximum 200 U/kg/day). Do not administer aPCC and rFVIIa concurrently due to additive thrombosis risk [143].
- •In patients with inhibitors who are on emicizumab prophylaxis: rFVIIa 90 mcg/kg is the preferred first-line bypassing agent for acute bleeding. Avoid aPCC in this setting if possible, as the combination has been associated with thrombotic microangiopathy and thromboembolic events [144, 154, 169].
- •For mild hemophilia A (FVIII >5 IU/dL) with a known response to desmopressin (DDAVP test dose): administer DDAVP 0.3 mcg/kg IV (over 15-30 minutes) or intranasal (1.5 mg/mL, 150 mcg per spray, 1 spray for <50 kg, 2 sprays for ≥50 kg). DDAVP raises FVIII 2-4 fold; repeat every 12-24 hours but limit to 2-3 doses to avoid tachyphylaxis and hyponatremia [124, 283].
- •Initiate primary prophylaxis for all patients with severe hemophilia A (FVIII <1 IU/dL) starting before age 2 years, ideally by 12 months, to prevent joint damage. Standard regimens include FVIII concentrate 25-40 IU/kg three times weekly (or every other day), or extended half-life products like efanesoctocog alfa 50 IU/kg IV once weekly [45, 76, 165, 169].
- •For patients without inhibitors, non-factor prophylaxis with emicizumab (Hemlibra) is a first-line alternative to FVIII concentrates: loading dose 3 mg/kg subcutaneously weekly for 4 weeks, then maintenance 1.5 mg/kg weekly, 3 mg/kg every 2 weeks, or 6 mg/kg every 4 weeks. In HAVEN 3, emicizumab reduced annualized bleeding rate (ABR) by 96% vs on-demand therapy [156, 169].
- •For patients with inhibitors, first-line prophylaxis is emicizumab (same loading and maintenance dosing as above), which reduced ABR by 87% in HAVEN 1 vs no prophylaxis. Immune tolerance induction (ITI) with daily high-dose FVIII should also be considered to eradicate the inhibitor; success rates are 60-80% [154, 169, 181].
- •For patients with severe hemophilia A without inhibitors or anti-AAV5 antibodies, gene therapy with valoctocogene roxaparvovec (Roctavian) is an option: single IV infusion of 6×10¹³ vg/kg. Pre-treatment evaluation includes screening for anti-AAV5 antibodies, liver fibrosis (transient elastography <8 kPa), and active hepatitis. Post-infusion, monitor ALT weekly for 12 weeks; ALT elevation >1.5× baseline triggers corticosteroid therapy [183, 167, 186].
- •Newer non-factor agents for prophylaxis include concizumab (anti-TFPI, 0.15 mg/kg SC once daily) and marstacimab (anti-TFPI, 150 mg SC once weekly). In the explorer7 and BASIS trials, these agents reduced ABR by 86-92% vs on-demand therapy and are emerging as alternatives for patients with and without inhibitors [155, 158, 159].
- •What NOT to do: avoid NSAIDs (ibuprofen, naproxen) and aspirin in all patients with hemophilia A due to antiplatelet effects. Avoid intramuscular injections unless absolutely necessary. Do not use desmopressin for acute bleeding in patients with severe hemophilia A (FVIII <1 IU/dL) or in those with unknown DDAVP response. Do not combine aPCC and rFVIIa [148].
- •Refer all patients with severe hemophilia A, moderate disease with a severe bleeding phenotype, or any patient with an inhibitor to a specialized hemophilia treatment center (HTC). Referral is also indicated for women with symptomatic hemophilia A carriers, patients considering gene therapy, or those with recurrent bleeding despite adequate prophylaxis [169].
- •Discharge criteria after a treated acute bleed: cessation of bleeding (no further swelling, pain controlled, stable hemoglobin), ability to ambulate or use joint without severe pain, and a plan for transition to or continuation of prophylaxis. Ensure outpatient follow-up with hematology within 1-2 weeks [148].
- •For major surgery or invasive procedures, achieve FVIII trough >80-100% on day of surgery and maintain >50% for 5-10 days postoperatively. Administer a bolus of FVIII concentrate 50 IU/kg immediately before incision, then continue with 25-40 IU/kg every 8-12 hours or continuous infusion. Mechanical thromboprophylaxis is preferred; pharmacologic prophylaxis is not routinely indicated [148, 209].
Board Review — High Yield
- •Intron 22 inversion, most common F8 mutation in severe hemophilia A (40-45%); causes complete FVIII deficiency due to homologous recombination.
- •One-stage clotting assay, gold-standard initial diagnostic test for FVIII activity; chromogenic assay needed for discrepant mild hemophilia.
- •Bethesda assay, detects and quantifies FVIII inhibitors (≥0.6 BU positive; >5 BU high-titer); essential before surgery or for unexplained bleeding.
- •SIPPET trial, recombinant FVIII carries 1.87-fold higher risk of inhibitors vs plasma-derived FVIII/VWF in previously untreated patients with severe hemophilia A.
- •Emicizumab, bispecific monoclonal antibody mimicking FVIIIa; given subcutaneously weekly to monthly; reduces ABR by 87-96% in patients with and without inhibitors.
- •HAVEN 1 and 3 trials, established emicizumab prophylaxis vs on-demand in inhibitor (87% ABR reduction) and non-inhibitor (96% ABR reduction) patients.
- •Efanesoctocog alfa (Altuviiio), once-weekly extended half-life FVIII; XTEND-1 trial showed mean ABR 0.7 and 86% zero bleeds; maintains FVIII >40% for most of the week.
- •Valoctocogene roxaparvovec (Roctavian), AAV5-based gene therapy for adults without inhibitors or anti-AAV5 antibodies; single IV infusion sustains median FVIII 5.8 IU/dL at 5 years, eliminating need for prophylaxis in 88%.
- •Hemophilic arthropathy, results from recurrent hemarthrosis driving synovial inflammation and cartilage destruction; prevented by early prophylaxis (Joint Outcome Study: 93% normal MRI vs 55% with episodic therapy).
- •Acquired hemophilia A, autoantibodies against FVIII cause bleeding in older adults without prior history; treated with bypassing agents, emicizumab, and immunosuppression (steroids ± cyclophosphamide or rituximab).
Deep Dive — Evidence Details
1. Definition, Classification & Nomenclature
- ▸Hemophilia A is an inherited **F8**-related FVIII deficiency or dysfunction causing impaired secondary hemostasis. [1][306]
- ▸The supplied diagnostic threshold is **FVIII activity <40% of normal**, with exclusion of von Willebrand disease and other causes of low FVIII. [1]
- ▸Severe HA is characterized by residual FVIII activity **<1%** and recurrent joint or muscle bleeding. [4][306]
- ▸Bleeding phenotype may be more severe than the laboratory grade suggests; a major ISTH-BAT grade 4 event can support classification as a severe bleeding disorder. [308]
- ▸OSA–CSA FVIII discrepancies affect approximately one-third of patients with mild HA and may change diagnosis or treatment classification. [10][307]
- ▸Female terminology should incorporate bleeding history and FVIII level rather than assuming that every female with an **F8** variant is asymptomatic. [6][7][311]
Definition
Hemophilia A (HA) is an inherited bleeding disorder caused by deficiency or dysfunction of coagulation factor VIII (FVIII), encoded by the F8 gene. FVIII functions as a cofactor within the intrinsic tenase complex, supporting activation of factor X and propagation of clot formation; reduced or absent FVIII therefore impairs secondary hemostasis and produces excessive bleeding. [1]C4[306] HA is predominantly X-linked and most clinically apparent in males, although females with pathogenic F8 variants may also have clinically important HA and remain underdiagnosed. [1]C4[6]A1c[7]C4[311]D
A diagnosis of HA is supported by reduced plasma FVIII activity, a pathogenic or likely pathogenic F8 variant, and exclusion of von Willebrand disease or another explanation for low FVIII. The diagnostic threshold identified in the supplied evidence is FVIII activity <40% of normal. [1]C4 Molecular confirmation should use standardized variant nomenclature; the CDC Hemophilia A Mutation Project catalogues F8 variants using Human Genome Variation Society coding-DNA and predicted-protein nomenclature, while also recording traditional mature-protein terminology and associated severity. [312]D
Classification by FVIII activity and bleeding phenotype
HA is classified as mild, moderate, or severe primarily according to baseline FVIII activity. Severe HA is defined in the supplied evidence by residual FVIII activity <1% and is associated with recurrent spontaneous or injury-related bleeding, particularly hemarthroses and muscle hemorrhage; repeated joint or muscle bleeding may occur as often as weekly. [4]B3b[306] Patients with higher residual FVIII activity are generally categorized as nonsevere HA, including mild or moderate disease, but the clinical phenotype may not correspond reliably to the laboratory grade. [10]C4[308]D
The severity label should therefore be interpreted together with personal bleeding history, age, exposure to hemostatic challenges, genotype, and the assay used to measure FVIII. A person classified as having mild or moderate HA may nevertheless experience a severe bleeding disorder; an international working-group approach cited in the evidence considers a single major bleeding event, including an ISTH Bleeding Assessment Tool grade 4 event, sufficient to reclassify an apparently mild or moderate disorder as clinically severe. [308]D Platelet activation and other biologic factors may also modify bleeding expression: increased platelet activation was observed in patients with severe HA, indicating that platelet behavior may contribute to variation in bleeding tendency beyond FVIII activity alone. [4]B3b
Assay-dependent classification
FVIII activity is measured using one-stage clotting assays (OSA) and/or chromogenic assays (CSA). Disagreement between OSA and CSA occurs in approximately one-third of patients with mild HA and can alter both diagnosis and severity assignment. [307] “Discrepant hemophilia A” (DHA) denotes a clinically relevant difference in FVIII activity measured by different assay methodologies in nonsevere HA. [10]C4 Such discrepancies have resulted in previously missed diagnoses and incorrect severity classification, with direct consequences for treatment decisions. [10]C4[307] Accordingly, a discordant result should not be dismissed solely because one assay reports a near-normal or substantially different FVIII activity; interpretation should incorporate bleeding phenotype and, when appropriate, confirmatory testing. [10]C4[307]
Nomenclature for women and girls
The traditional term “hemophilia carrier” can imply that a female has no bleeding disorder. This is inaccurate because females with hemophilia-associated F8 variants may bleed despite normal FVIII activity, and many remain undiagnosed or untreated. [6]A1c[7]C4[311]D The ISTH Scientific and Standardization Committee proposed a nomenclature for hemophilia in women and girls based on two dimensions: personal bleeding history and baseline FVIII activity. [6]A1c This approach distinguishes clinically relevant female states rather than treating all females with an affected male relative or an F8 variant as asymptomatic carriers. [6]A1c
Reproductive genetic counseling should recognize HA as an X-linked condition with potential fetal transmission and should address preconception and postconception carrier screening when the family history or genetic background indicates risk. [304] Genome-sequencing-based preconception screening can evaluate substantially more gene–disorder pairs than conventional targeted testing, but reported variants require pathogenicity assessment and confirmation before clinical reporting. [314]D Genotype–phenotype relationships are useful but imperfect: large numbers of unique F8 mutations have been documented, and mutation databases associate variants with reported HA severity while preserving standardized HGVS descriptions. [312]D
Related terminology and boundaries
HA should be distinguished from hemophilia B, which results from factor IX deficiency; both are inherited disorders of secondary hemostasis, but the deficient factor defines the type. [306][309]D “Hemophilia with inhibitors” describes HA complicated by neutralizing antibodies against replacement FVIII, not a separate inherited hemophilia subtype; inhibitor development has been reported in approximately 29% of patients in one cohort and varies with product source and purity. [8]B2b Physical disability, recurrent hemarthrosis, surgical complications, and rehabilitation needs are consequences or clinical dimensions of HA rather than alternative disease definitions. [2]A1a[305] Similarly, artificial-intelligence tools and viscoelastic testing may support diagnosis, risk stratification, or management, but they do not replace the core definition based on FVIII deficiency or dysfunction, bleeding phenotype, and appropriate laboratory assessment. [9]B2a[310]D
| Domain | Definition or implication |
|---|---|
| Disease type | Hemophilia A: inherited FVIII deficiency or dysfunction; hemophilia B: factor IX deficiency. [306][309]D |
| Diagnostic activity threshold | FVIII activity <40% of normal, with appropriate differential diagnosis. [1]C4 |
| Severe HA | Residual FVIII activity <1%; recurrent spontaneous or trauma-related joint and muscle bleeding may occur. [4]B3b[306] |
| Nonsevere HA | Mild or moderate laboratory categories; clinical bleeding may still be substantial or clinically severe. [10]C4[308]D |
| Assay issue | OSA and CSA may disagree, particularly in mild HA; discrepant results can change diagnosis and management. [10]C4[307] |
| Female nomenclature | Classify according to personal bleeding history and baseline FVIII level rather than carrier status alone. [6]A1c |
2. Pathophysiology & Mechanism
- ▸F8 mutations cause HA by eliminating, reducing, or functionally altering FVIII; the molecular defect can involve synthesis, processing, secretion, stability, or activity.[14][37]
- ▸Approximately **30%** of children with severe HA develop neutralizing FVIII inhibitors, while approximately **70%** show no detectable inhibitor response and may be tolerant.[14]
- ▸Female-carrier phenotype depends on mosaic FVIII expression and XCI; normal FVIII activity does not exclude clinically relevant bleeding.[315][323]
- ▸Repeated hemarthrosis drives iron-associated synovial inflammation, hyperplasia, cartilage damage, and arthropathy, including in some patients with non-severe HA.[317][320]
- ▸Acquired HA results from autoantibodies against endogenous FVIII and may follow immune checkpoint inhibition or occur with myeloproliferative disease.[38][39]
Core coagulation defect
Hemophilia A (HA) is an X-linked bleeding disorder caused by pathogenic variants in F8, resulting in absent, reduced, or dysfunctional factor VIII (FVIII) activity.[14]B2a[37]C4 FVIII normally functions as a coagulation cofactor; therefore, its deficiency produces impaired thrombin generation and unstable clot formation, with clinical severity broadly related to residual FVIII activity in affected males.[14]B2a[37]C4 The molecular defect is heterogeneous. Intron 22 and intron 1 inversions and other large structural abnormalities are important causes of severe HA, whereas missense variants are found in nearly all individuals with mild or moderate disease but in fewer than 20% of severe cases.[316]C[37]C4[325]D Non-inversion variants in sporadic HA appear to recur rarely within the same generation, supporting predominantly independent de novo mutational events in the studied pedigrees.[319]D
Mutation-to-phenotype mechanisms
F8 variants can impair FVIII synthesis, intracellular processing, secretion, stability, conformation, or functional activity.[37]C4 The p.Arg1800His missense variant causes moderate HA through defective processing and reduced stability of functional FVIII, illustrating how a structurally altered protein can retain partial activity.[37]C4 Nonsense variants may generate premature termination codons and have mutation-location-dependent immunologic consequences. In cellular models, high-inhibitor-risk light-chain nonsense variants such as R1960X and R2228X showed divergent processing, including endoplasmic-reticulum retention and proteasomal handling, compared with other FVIII variants.[27]D5 Low-level translational readthrough can produce trace full-length FVIII, including missense and wild-type molecules, potentially modifying both residual protein expression and inhibitor risk; the effect varies among premature termination codons and may be influenced by peptide–HLA interactions.[40]B2b Experimental ribosomal-readthrough compounds, including 2,6-diaminopurine, ELX-02, and G418, have therefore been investigated as mutation-specific approaches because even modest increases in FVIII activity may improve severe-HA bleeding; these findings remain preclinical.[326]D
Sex, X-chromosome biology, and residual FVIII
In females carrying a pathogenic F8 allele, FVIII activity is variable because expression reflects mosaicism between the mutant and wild-type alleles and the pattern of X-chromosome inactivation (XCI).[315] Consequently, bleeding risk cannot be inferred reliably from a single conventional FVIII threshold: carriers with apparently normal FVIII activity may still experience reproductive-tract or other bleeding manifestations.[315] Skewed XCI can produce a hemophilic phenotype in a heterozygous female, and deleterious NKAP variants have been associated with abnormal XCI and musculoskeletal abnormalities in hemizygous males and heterozygous females.[323]D Genetic testing may require methods capable of detecting inversions, copy-number changes, and complex rearrangements, because some noncarrier mothers of patients with intron 22 inversions harbor other F8 rearrangements.[325]D Carrier investigation can incorporate sequencing, long-range PCR, Sanger confirmation, and copy-number or structural-variant analyses.[41]C4[321]D
Immune tolerance and FVIII inhibitors
Replacement FVIII is immunologically recognized as foreign in a subset of patients, particularly those with severe endogenous FVIII deficiency. Neutralizing anti-FVIII antibodies, or inhibitors, develop in approximately 30% of children with severe HA, whereas approximately 70% do not develop detectable antibodies and may have acquired or maintained immune tolerance.[14]B2a Inhibitor formation reflects the interaction of the F8 mutation, residual antigen exposure, antigen processing and presentation, HLA genotype, and treatment-related immune context; the precise determinants of apparent tolerance remain incompletely defined.[14]B2a[324]D Severe HA cohorts are being evaluated for HLA alleles and haplotypes associated with inhibitor risk or protection, including whether such associations vary by F8 variant type and racial or ethnic background.[324]D Nonneutralizing antibodies may also occur: in a Nordic study, they were detected in 13% of participants with moderate HA, although their clinical significance remains uncertain.[318] Increasing use of nonfactor prophylaxis limits FVIII exposure mainly to bleeding treatment or perioperative hemostasis, potentially altering the immunologic conditions under which tolerance or inhibitors develop.[14]B2a
Acquired FVIII inhibition
Acquired hemophilia A is mechanistically distinct from inherited HA: autoantibodies arise against endogenous FVIII, causing reduced FVIII activity and a prolonged activated partial thromboplastin time.[38]C4[39]C4 Immune checkpoint inhibitors can trigger acquired HA as an immune-related adverse event; in a reported series, most cases followed anti-PD-1 monotherapy.[38]C4 Acquired inhibitors have also been reported in association with polycythemia vera evolving to myelofibrosis, supporting a possible relationship with dysregulated immunity in myeloproliferative neoplasms.[39]C4
Hemophilic arthropathy and joint inflammation
Repeated hemarthroses expose synovial tissues to blood and iron, promoting synovial hyperplasia, inflammatory signaling, cartilage injury, and progressive arthropathy.[316]C[320]D Joint damage can occur even in non-severe HA; a multicenter real-world study assessed this population using FVIII levels, F8 mutation, thrombin generation, age, and HEAD-US joint evaluation.[317]C Experimental models implicate metabolic and inflammatory pathways, including peroxisome-proliferator-activated-receptor signaling, in progression after joint hemorrhage.[320]D CX3CR1-positive synovial macrophages accumulate during experimental hemophilic arthropathy, although genetic deletion or pharmacologic inhibition indicated that they are not required for acute synovitis, suggesting a role in chronic joint remodeling rather than initiation of the immediate inflammatory response.[42]D5 Mutation type may also influence functional consequences beyond radiographic damage: patients with inversion and non-inversion variants had comparable radiographic scores and conventional postural-sway measures, but frequency-domain center-of-pressure analysis detected genotype-associated differences in postural-control strategy.[316]C
| Determinant | Mechanistic consequence | Evidence |
|---|---|---|
| F8 inversion, deletion, or other severe structural variant | Markedly reduced or absent FVIII expression | [316]C[325]D |
| Missense variant | Altered protein structure, processing, stability, immunogenicity, or function; residual activity may remain | [37]C4 |
| Nonsense variant | Premature termination; processing and readthrough may modify protein expression and inhibitor risk | [27]D5[40]B2b[326]D |
| Female carrier state | Variable FVIII activity from wild-type/mutant mosaicism and XCI | [315][323]D |
| Repeated joint bleeding | Iron deposition, synovial inflammation, hyperplasia, and progressive joint damage | [320]D[42]D5 |
3. Epidemiology, Etiology & Risk Factors
- ▸Congenital hemophilia A is an X-linked disorder caused by deficient or dysfunctional FVIII resulting from pathogenic F8 variation; acquired hemophilia A is caused by FVIII autoantibodies. [72][74][330][331]
- ▸Reported African prevalence estimates are heterogeneous; a systematic review and meta-analysis was undertaken to derive a pooled estimate, but the supplied abstract does not provide the numerical result. [74]
- ▸F8 genotype is associated with inhibitor biology and is being evaluated as a determinant of immune tolerance induction outcome. [72]
- ▸IL10 polymorphisms are candidate immune-genetic modifiers of inhibitor development, but no definitive clinical predictor is established in the supplied evidence. [329]
- ▸In the PedNet Registry, ICH occurred in 2.2% of children before prophylaxis, with 75% of events occurring before 1 year of age. [67]
- ▸Aging shifts the risk profile toward arterial thrombosis and cardiovascular comorbidity, while pregnancy in carriers raises postpartum hemorrhage concerns. [62][327][333]
Epidemiology
Hemophilia A (HA) is an X-linked recessive bleeding disorder caused by reduced or absent coagulation factor VIII (FVIII) activity and therefore predominantly affects males. [74]A1a[331]C The available African evidence indicates substantial variability among reported prevalence estimates, prompting a systematic review and meta-analysis to derive a pooled estimate for HA prevalence in males; the review included observational studies published between 2010 and 2022. [74]A1a Because the supplied abstract does not report the pooled numerical estimate, no single regional prevalence figure should be inferred from this evidence. [74]A1a
The contemporary HA population includes children, adults, and an increasing number of older adults. [62]B2b[333] In a nationwide prospective Japanese registry, adults with hemophilia were followed from age ≥40 years to evaluate arterial thrombotic risk, reflecting the clinical importance of aging in this population. [62]B2b A post hoc analysis of four phase III emicizumab studies specifically evaluated people with severe HA aged ≥50 years with cardiovascular (CV) risk factors, HIV, and/or hepatitis C virus (HCV) infection. [333]
Etiology and genetic determinants
Congenital HA results from pathogenic variation in the F8 gene, producing deficient or dysfunctional FVIII and an X-linked bleeding phenotype. [72]A1a[74]A1a[331]C The clinical severity of congenital HA is determined primarily by the extent of FVIII deficiency, although the supplied studies do not provide updated severity-specific prevalence estimates. [73]A1a Acquired hemophilia A (AHA) is etiologically distinct: it results from circulating autoantibodies directed against FVIII rather than an inherited F8 deficiency. [330]C[337]C AHA may occur in association with autoimmune disease, including bullous pemphigoid, and is also represented among patients treated with rituximab for autoimmune hematologic disorders. [330]C[337]C
F8 genotype is an established determinant of anti-FVIII neutralizing alloantibody formation in people with congenital HA receiving replacement therapy. [72]A1a A 2026 systematic review and meta-analysis evaluated whether F8 genotype also influences the outcome of primary immune tolerance induction (ITI) in people with HA and inhibitors; the review searched the literature through 31 July 2025 and included interventional and observational studies without language or publication-date restrictions. [72]A1a Thus, genotype is relevant not only to inhibitor susceptibility but also to the probability of successful eradication of inhibitors during ITI, although the abstract supplied here does not provide the pooled genotype-specific effect estimate. [72]A1a
Host immune genetics may further modify inhibitor risk. [329] A systematic review and meta-analysis examined polymorphisms in the interleukin-10 (IL10) gene, because IL-10 regulates immune responses and antibody production, and assessed their association with inhibitor formation in hemophilia. [329] The available abstract does not report a definitive pooled association or identify a single predictive IL10 variant; therefore, IL10 polymorphisms should be regarded as investigational risk markers rather than standalone clinical predictors. [329]
Treatment-related and age-related risk factors
Exposure to recombinant FVIII is particularly relevant during childhood because inhibitor development is a major concern in previously untreated patients (PUPs). [73]A1a A 2025 systematic review included 16 studies and 1,145 pediatric patients and compared standard-half-life and extended-half-life recombinant FVIII products in PUPs and previously treated patients (PTPs). [73]A1a The review also assessed annual bleeding-rate changes, but the available abstract reports no statistically significant difference in those changes across the evaluated pediatric comparisons. [73]A1a These findings support continued attention to treatment history and inhibitor surveillance, while not establishing a superiority of one recombinant FVIII half-life category for preventing inhibitors. [73]A1a
Clinical and demographic factors associated with complications
Before prophylaxis, children with HA have an increased risk of intracranial hemorrhage (ICH) compared with the general pediatric population. [67]B2b[331]C In the PedNet Registry, 2,727 children with hemophilia followed from 28 days to 36 months included 2,275 with HA and 452 with hemophilia B; ICH occurred in 61 children (2.2%; 10 per 1,000 patient-years), and 75% of cases occurred before 1 year of age. [67]B2b Younger age and the period before prophylaxis are therefore important risk contexts for ICH, although the study was designed to describe natural history rather than establish all independent predictors. [67]B2b
As people with HA age, conventional arterial-risk factors become clinically relevant, including hypertension, diabetes, hyperlipidemia, obesity, prior stroke, and established CV disease. [62]B2b[333] The ADVANCE Japan cohort evaluated established cardiovascular risk scores—the Hisayama model, Suita score, and QRISK3—over 5 years in adults aged ≥40 years without previous arterial thrombosis, reflecting the need to balance thrombotic and bleeding risks in primary prevention. [62]B2b
Women who are hemophilia carriers may have clinically important bleeding risk during pregnancy and postpartum when FVIII activity is reduced. [327] In the Dutch Pregnancy and Inherited Bleeding Disorders study, revised guidance increased the third-trimester prophylaxis threshold from <50 IU/dL to <80 IU/dL and the intrapartum peak target from ≥100 IU/dL to ≥150 IU/dL; prospective evaluation from 2018–2024 found that enhanced peripartum hemostatic management did not decrease the incidence of severe postpartum hemorrhage, defined as ≥1,000 mL. [327]
Chronic recurrent hemarthroses are associated with hemophilic arthropathy and skeletal complications. [292]C4[336]C A single-center Iranian screening study evaluated 448 registered patients and identified skeletal complications, with the knee among the most frequently affected joints; a retrospective arthroplasty study included 64 patients undergoing 42 total knee and 30 total hip arthroplasty procedures for end-stage arthropathy. [336]C[292]C4 These studies describe complication burden but do not establish population-level risk estimates. [292]C4[336]C Contemporary observational data also evaluate neurodevelopmental, cognitive, behavioral, and adaptive outcomes in males aged 1–21 years with hemophilia, including patients with or without inhibitors, indicating that age, disease status, and inhibitor history remain relevant domains of long-term risk assessment. [332]
| Domain | Updated evidence | Clinical implication |
|---|---|---|
| Population | HA predominantly affects males; African prevalence estimates are heterogeneous. [74]A1a[331]C | Regional estimates should be interpreted cautiously. [74]A1a |
| Inhibitors | F8 genotype is a recognized risk factor; IL10 variants are under investigation. [72]A1a[329] | Genotype and immune factors may support risk stratification, but are not fully predictive. [72]A1a[329] |
| Childhood ICH | 2.2% incidence; 75% occurred before age 1 year in PedNet children followed before prophylaxis. [67]B2b | Early surveillance and prophylaxis are important risk-reduction considerations. [67]B2b |
| Aging | Adults aged ≥40 years were evaluated for 5-year arterial risk; ≥50-year-old patients were assessed for CV comorbidities in emicizumab trials. [62]B2b[333] | Conventional CV risk factors require individualized assessment. [62]B2b[333] |
| Carriers and pregnancy | Severe postpartum hemorrhage was defined as ≥1,000 mL; revised factor thresholds were <80 IU/dL and ≥150 IU/dL. [327] | Higher prophylactic targets did not eliminate severe postpartum hemorrhage. [327] |
4. Clinical Presentation
- ▸The hallmark presentation of severe congenital hemophilia A is recurrent hemarthrosis and soft-tissue bleeding with risk of progressive joint damage. [340]
- ▸Intracranial hemorrhage is uncommon but life-threatening and occurs more often in children with hemophilia than in the general pediatric population. [331]
- ▸Women and girls can have clinically significant hemophilia A; carrier status does not reliably indicate absence of bleeding. [90][311]
- ▸In one retrospective carrier study, **23% had FVIII activity below 40 IU/dL by one-stage assay**, and chromogenic testing sometimes provided different clinical information. [232]
- ▸Acquired hemophilia A typically presents with new spontaneous or trauma-related ecchymoses, subcutaneous or intramuscular hematomas, mucosal bleeding, and an isolated prolonged aPTT. [96][97][98]
- ▸An isolated prolonged aPTT without bleeding may result from lupus anticoagulant or another non-hemophilic cause and requires laboratory differentiation from a FVIII inhibitor. [96]
Hemophilia A results in a spectrum of bleeding manifestations determined largely by residual factor VIII (FVIII) activity, although assay-related discrepancies and individual variation can complicate clinical risk assessment, particularly in women and girls. [232]C4[311]D The phenotype ranges from minimal or procedure-related bleeding to recurrent spontaneous hemorrhage with progressive joint damage. [339][340]
Congenital hemophilia A
In boys with severe congenital hemophilia A, bleeding commonly begins early in life, particularly after circumcision, venipuncture, surgery, trauma, or other invasive procedures; spontaneous bleeding may also occur. [340] The characteristic pattern is recurrent hemarthrosis and soft-tissue bleeding, with repeated joint hemorrhage causing synovial injury, chronic inflammation, reduced mobility, and hemophilic arthropathy. [340][342]D Knees, ankles, and elbows are clinically important target joints in children with severe disease, and joint damage may develop despite modern prophylaxis or apparently low recent bleeding rates. [342]D[343]D
Early joint disease may be clinically occult. Persistent joint symptoms, reduced range of motion, swelling, warmth, or altered gait should prompt assessment even when routine joint scores and reported bleeding frequency are reassuring. [342]D Magnetic resonance imaging can identify hemosiderin deposition and structural abnormalities before they are evident on routine examination; T2* MRI has been investigated as a sensitive marker of occult joint involvement in children. [342]D MRI studies in boys with severe hemophilia have also evaluated interval changes in the ankles, knees, and elbows during prophylaxis. [343]D
Bleeding can involve skin, subcutaneous tissues, muscles, mucosa, the oral cavity, urinary tract, and central nervous system. [331]C[339] Oral bleeding may follow dental disease, exfoliation, extraction, or other dental procedures, and ranges from minor oral-cavity bleeding to potentially life-threatening hemorrhage. [339] Hematuria is recognized in hemophilia A; upper urinary tract bleeding is uncommon but may present as gross hematuria and can mimic a renal or urothelial tumor on imaging. [130]C4 Intracranial hemorrhage is uncommon but disproportionately more frequent in children with hemophilia than in the general pediatric population and is a life-threatening complication. [331]C New severe headache, vomiting, altered consciousness, focal neurologic findings, or neurologic change after even minor trauma should therefore be treated as possible intracranial bleeding in an affected patient. [331]C
Bleeding severity generally correlates with FVIII activity, but a single one-stage clotting assay may not fully represent bleeding risk. [232]C4 In a retrospective study of hemophilia A carriers, 23% had FVIII activity below 40 IU/dL by one-stage assay, and chromogenic testing identified clinically relevant assay discrepancies in some individuals. [232]C4 Consequently, women and girls with low FVIII levels or bleeding symptoms should not be presumed asymptomatic solely because of carrier status or a borderline routine assay result. [232]C4[311]D
Women and girls
Women and girls may have clinically significant hemophilia A rather than being symptom-free carriers. [90]D5[311]D Reported manifestations include heavy menstrual bleeding, postpartum or surgical bleeding, easy bruising, prolonged bleeding after dental procedures, and bleeding that is disproportionate to measured FVIII activity or has historically been dismissed. [90]D5[311]D Phenotypic expression may vary among carriers, and assessment should integrate personal bleeding history, family history, menstrual and obstetric history, procedural outcomes, and FVIII testing. [232]C4[311]D
Acquired hemophilia A
Acquired hemophilia A (AHA) is an autoimmune disorder caused by inhibitory autoantibodies against FVIII and typically presents with new, spontaneous, or trauma-related bleeding in a person without a prior bleeding history. [338][341][98]C4 The clinical pattern often differs from congenital disease: large ecchymoses, extensive subcutaneous hematomas, intramuscular bleeding, soft-tissue hemorrhage, mucosal bleeding, and bleeding after procedures are prominent, whereas recurrent hemarthrosis is not the defining presentation. [97]C4[98]C4 Severe or persistent bleeding may produce anemia and functional impairment. [97]C4[98]C4
AHA should be considered when significant bleeding is accompanied by an isolated prolonged activated partial thromboplastin time (aPTT), particularly when the platelet count and other routine coagulation findings do not explain the presentation. [338][96]C4[97]C4 The differential diagnosis of isolated prolonged aPTT includes FVIII deficiency, a FVIII inhibitor, lupus anticoagulant, and other intrinsic-pathway abnormalities; mixing studies and specific FVIII activity and inhibitor testing are required to distinguish these entities. [96]C4 Not every patient with an isolated prolonged aPTT is bleeding: lupus anticoagulant or other antiphospholipid antibodies may prolong the aPTT without producing the bleeding phenotype of AHA. [96]C4
AHA has been reported in association with pregnancy, malignancy, autoimmune disease, rheumatoid arthritis, systemic lupus erythematosus, and drug exposure. [95]C4[97]C4[98]C4 In a 22-patient adult cohort, the mean age was 62 years with a range of 22–102 years; suspected associated conditions included pregnancy (27%) and malignancy (23%), and men and women were represented equally. [98]C4 Case reports describe spontaneous leg and muscle hematomas in rheumatoid arthritis and severe bleeding in adalimumab-associated AHA. [97]C4[341] Rituximab-treated cases likewise involved adults with significant bleeding and prolonged aPTT despite initial factor replacement and corticosteroids. [338]
Important diagnostic context
Petechiae, purpura, and ecchymoses after COVID-19 vaccination have been reported in the literature, but these findings are nonspecific and may reflect vascular or platelet-related disorders rather than hemophilia A. [92]C4 In a patient with new bruising or bleeding, the diagnosis should therefore be based on the complete bleeding pattern and coagulation evaluation rather than skin findings alone. [92]C4[96]C4
| Pattern | Typical clinical presentation | Key distinguishing considerations |
|---|---|---|
| Congenital severe disease | Recurrent hemarthrosis, muscle and soft-tissue bleeding, procedure-related bleeding, and possible intracranial hemorrhage | Joint bleeding may cause progressive arthropathy; early damage can be occult on routine examination. [331]C[340][342]D |
| Congenital disease in women and girls | Heavy menstrual, obstetric, dental, surgical, or easy-bruising phenotype | Bleeding risk may be underestimated by carrier status or one-stage FVIII testing alone. [90]D5[232]C4[311]D |
| Acquired hemophilia A | New spontaneous ecchymoses, large subcutaneous or intramuscular hematomas, mucosal or post-procedural bleeding | Usually occurs without a prior personal bleeding history and is associated with an isolated prolonged aPTT. [96]C4[97]C4[98]C4 |
| Atypical urinary presentation | Gross hematuria from urinary tract or renal pelvic hemorrhage | Upper urinary tract bleeding may mimic a tumor on imaging. [130]C4 |
5. Diagnosis & Workup
- ▸Confirm suspected HA with FVIII testing, typically using a one-stage factor assay, and interpret the result with the bleeding phenotype. [124]
- ▸Normal FVIII activity does not exclude clinically important bleeding in a female F8 carrier. [315]
- ▸An isolated prolonged APTT requires differential evaluation for congenital FVIII deficiency, acquired hemophilia A, and antiphospholipid-antibody interference. [96]
- ▸Use molecular testing for F8 variants to confirm etiology, identify carriers, guide counseling, and enable prenatal or preimplantation testing. [41,126,349]
- ▸Investigate unexpected treatment failure for FVIII inhibitors using the Nijmegen-modified Bethesda assay or an appropriate validated adjunct. [350]
- ▸Consider organ-specific alternative diagnoses when bleeding is atypical, including renal pelvic hemorrhage in gross hematuria. [130]
Clinical suspicion
Hemophilia A (HA) is an X-linked inherited bleeding disorder caused by deficiency or dysfunction of coagulation factor VIII (FVIII), with bleeding severity generally related to the degree of FVIII deficiency and the underlying F8 variant. [124]D5 The classical bleeding pattern is musculoskeletal, particularly hemarthroses involving the ankles, knees, and elbows. [124]D5 Evaluation should therefore integrate bleeding history, joint and muscle symptoms, family history, treatment history, and examination for active or previous bleeding. [124]D5
HA should not be regarded as exclusively a disorder of males. Women and girls who carry an F8 variant may have clinically important bleeding, including reproductive-tract bleeding, even when FVIII activity is within the laboratory reference range. [315] FVIII activity in female carriers is highly variable because of the presence of a second wild-type F8 allele and differences in X-chromosome inactivation; consequently, FVIII activity alone does not reliably exclude a clinically relevant bleeding phenotype. [315] A female patient with bleeding symptoms, a relevant family history, or an abnormal coagulation profile warrants direct evaluation rather than classification solely by carrier status. [311]D[315]
Initial laboratory assessment
Laboratory confirmation typically begins with coagulation testing and FVIII measurement. An isolated prolongation of the activated partial thromboplastin time (APTT) should prompt a structured differential diagnosis rather than an immediate diagnosis of HA. [96]C4 The differential includes congenital FVIII deficiency, acquired hemophilia A caused by FVIII autoantibodies, and interference from antiphospholipid antibodies; patients with an isolated prolonged APTT may have substantial bleeding or no bleeding at all. [96]C4 Clinical bleeding, medication exposure, previous factor treatment, and laboratory interference should therefore be considered together. [96]C4
Classical HA is typically confirmed using a one-stage FVIII assay, although assay interpretation should be performed in the context of the clinical phenotype and the possibility of inhibitor interference. [124]D5 The factor assay establishes the presence and degree of FVIII deficiency, while molecular testing identifies the causal F8 variant and supports family testing, counseling, and reproductive planning. [124]D5[41]C4
Genetic confirmation and family workup
F8 has substantial molecular heterogeneity, and carrier detection may require methods capable of identifying small sequence variants, inversions, deletions, copy-number changes, and structural rearrangements. [41]C4 A contemporary carrier investigation may combine high-throughput sequencing with targeted long-range PCR for intron 1 and intron 22 inversions, Sanger sequencing for selected small deletions, and complementary copy-number or structural-variant methods when routine testing is inconclusive. [41]C4 Intronic polymorphisms and haplotype analysis may also support linkage-based carrier detection in families in which the pathogenic variant is not readily characterized. [321]D
Genetic counseling should be offered to affected individuals and potentially carrier females. [41]C4 The rare presentation of HA in females may reflect a de novo F8 variant, skewed X-chromosome inactivation, mosaic monosomy X, or other chromosomal and molecular mechanisms; therefore, unexplained low FVIII activity or a compatible bleeding phenotype in a female merits F8 analysis and, when indicated, cytogenetic or X-inactivation studies. [129]C4
Inhibitor evaluation
A new or unexpectedly poor response to FVIII replacement should raise concern for a neutralizing FVIII inhibitor. [350]D The conventional diagnostic method is the Nijmegen-modified Bethesda assay, but this assay is time-consuming, resource-intensive, costly, and reported to have sensitivity limitations and interlaboratory variability. [350]D A paper-strip point-of-care assay using full-length recombinant FVIII and gold-nanoparticle-labeled antibodies has been developed and validated as an equipment-free approach; it may offer a rapid adjunct where conventional testing is difficult to access, although confirmatory laboratory testing remains necessary. [350]D
Acquired hemophilia A should be considered when bleeding begins unexpectedly, particularly without a prior personal or family history of inherited HA, or when an isolated prolonged APTT is unexplained. [96]C4 Pregnancy-associated acquired HA is exceptionally rare but can endanger both mother and fetus; transplacental passage of FVIII inhibitors may produce transiently low neonatal FVIII levels. [347]C
Prenatal and preimplantation diagnosis
Once the familial F8 variant is known, prenatal diagnosis (PND) and preimplantation genetic testing for monogenic disease (PGT-M) should be discussed as reproductive options. [126]B2a[349]D A systematic review of 24 studies published from 2005 through September 2025 included 969 pregnancies; 78.3% (759) involved HA carriers and 16.3% (158) involved hemophilia B carriers, illustrating the predominance of HA in the reported PND literature. [126]B2a Amniocentesis accounted for 45.8% of reported PND procedures. [126]B2a
PGT-M requires preclinical work-up, multidisciplinary counseling, intracytoplasmic sperm injection, embryo biopsy at the day-5-to-7 blastocyst stage, cryopreservation, and genetic analysis using the familial variant, linkage markers, or both. [349]D Embryos with conclusive results can be transferred individually after counseling regarding reproductive, diagnostic, and ethical implications. [349]D
Additional diagnostic considerations
Atypical bleeding should be investigated according to the organ involved and should not automatically be attributed to routine hemarthrosis. Gross hematuria may rarely result from spontaneous renal pelvic hemorrhage and can mimic a urothelial tumor on imaging; clinical context, imaging features, and response to FVIII replacement may help support a hemorrhagic diagnosis and prevent unnecessary invasive procedures. [130]C4 Progressive cognitive or behavioral symptoms with posterior leukodystrophic MRI findings in a patient with HA may indicate a separate X-linked disorder, such as cerebral X-linked adrenoleukodystrophy, requiring additional molecular evaluation. [94]C4
Pain assessment should include structured symptom scoring and joint evaluation. A study of 327 people with hemophilia and 121 healthy controls assessed pain-pressure thresholds at hemophilia-specific joints and reference sites and examined associations with age, numeric pain-rating categories, and Hemophilia Joint Health Score status. [345] In older adults, diagnostic and longitudinal assessment should also recognize emerging arterial thrombotic risk; the ADVANCE Japan cohort evaluated 5-year risk prediction using the Hisayama model, Suita score, and QRISK3 in adults aged ≥40 years without prior arterial thrombosis. [62]B2b
| Clinical or laboratory question | Recommended workup | Evidence |
|---|---|---|
| Is inherited HA suspected? | Bleeding and family history, examination for musculoskeletal bleeding, coagulation testing, and FVIII activity measurement | [124]D5 |
| Is the patient a female carrier with possible bleeding? | Do not rely on FVIII activity alone; perform phenotype assessment and F8 genotyping when indicated | [315][311]D |
| Is APTT isolated and prolonged? | Evaluate for congenital FVIII deficiency, acquired FVIII inhibitor, and antiphospholipid antibodies | [96]C4 |
| Is FVIII treatment response unexpectedly poor? | Test for FVIII inhibitors with the Nijmegen-modified Bethesda assay; consider validated rapid adjunctive testing | [350]D |
| Is reproductive transmission a concern? | Offer familial-variant testing, genetic counseling, PND, or PGT-M | [41]C4[126]B2a[349]D |
| Is bleeding atypical? | Use targeted imaging and organ-specific evaluation; renal pelvic hemorrhage can mimic a urinary-tract tumor | [130]C4 |
6. Staging, Risk Stratification & Prognostic Scoring
- ▸Use a multidimensional assessment incorporating FVIII activity, bleeding phenotype, joint health, inhibitors, genotype, pharmacokinetics, comorbidity, and patient-reported outcomes. [135][134][355]
- ▸Null F8 mutations identify a higher early inhibitor-risk group; in SIPPET, the cumulative inhibitor incidence with plasma-derived FVIII was **31%** in high-risk patients versus no inhibitors in the low-risk group. [11]
- ▸HemfilNET and other AI approaches are investigational tools, not replacements for genotype-based assessment and serial inhibitor surveillance. [141][9]
- ▸ITI prognostic factors include inhibitor titre and response trajectory; cohort-specific thresholds of **40 BU** and **100 BU** should not be interpreted as universal scoring cutoffs. [357]
- ▸In acquired hemophilia A, initial FVIII activity **<1 IU/dL** and failure to achieve complete remission predict recurrence, with relapses concentrated within **1 year** after remission. [360]
Overview
Hemophilia A should be stratified multidimensionally rather than by FVIII activity alone. Clinical staging should integrate baseline functional FVIII activity, bleeding phenotype, joint status, treatment exposure, inhibitor history, genetic risk, pharmacokinetics, comorbidity, and patient-reported outcomes. Disease severity is inversely related to functional plasma FVIII concentration, but bleeding manifestations vary between individuals and may require treatment adjustment even when laboratory severity appears similar. [355]
Baseline disease severity and bleeding phenotype
Baseline FVIII activity remains the principal laboratory measure for classifying hemophilia A severity, although the available evidence in the supplied references does not provide validated numerical activity cutoffs for mild, moderate, and severe disease. [355] Phenotypic assessment should include annualized or site-specific bleeding, spontaneous versus traumatic bleeding, treatment intensity, and historical or current target-joint involvement. A systematic review of people with hemophilia receiving regular prophylaxis found substantial heterogeneity in candidate risk factors, outcome definitions, and measurement methods; consequently, no single bleeding risk-assessment model could be recommended from the reviewed literature. [135]B2a
Joint disease is a major prognostic domain. In adults with moderate-to-severe hemophilia A, the Colorado Adult Joint Assessment Scale evaluates swelling, muscle atrophy, axial deformity, crepitus, range of motion, contracture, instability, strength, and gait across six joints; its validity and reliability were specifically evaluated in this population. [134]B2b In non-severe hemophilia A, joint damage may occur despite the absence of severe baseline deficiency. A multicenter machine-learning study evaluated age, target-joint history, thrombin-generation capacity, FVIII measured by one-stage and chromogenic assays, and the FVIII clot-based/chromogenic assay ratio as predictors of joint damage defined by HEAD-US >0. [356]
Inhibitor-development risk
F8 genotype is an important early prognostic stratifier for inhibitor development. In the SIPPET analysis of 235 previously untreated patients with severe hemophilia A, 197 patients with null mutations were classified as high genetic risk and 38 with non-null mutations as low genetic risk. Among patients treated with plasma-derived FVIII, no inhibitors occurred in the low-risk group, whereas the cumulative inhibitor incidence was 31% in the high-risk group. The study also found that the difference between low- and high-risk groups was less pronounced among patients receiving recombinant FVIII, supporting treatment-product choice as an interaction with genetic risk rather than an independent consideration. [11]A1b
Inhibitor prediction is increasingly being explored with computational methods. HemfilNET used an individual-similarity network incorporating pretreatment clinical variables and biomarkers in previously untreated or minimally treated children with severe or moderately severe hemophilia A, following them to 75 exposure days without inhibitor or until inhibitor development. This approach is investigational and should complement, not replace, genotype assessment and serial inhibitor surveillance. [141]B2b A 2025 systematic review concluded that artificial intelligence and machine-learning methods may support diagnosis, risk stratification, and personalized management of bleeding disorders, but the review addressed heterogeneous disorders and applications rather than establishing a universally validated hemophilia A score. [9]B2a
Prognostic factors after inhibitor development
For patients undergoing immune tolerance induction (ITI), prognostic assessment should record pre-ITI inhibitor titre, titre trajectory, treatment response, and the presence of poor-risk features. In a Chinese pediatric cohort, low-dose ITI was administered alone when inhibitor titres were below 40 BU before and during ITI; immunosuppression was used when titres were ≥100 BU historically, ≥40 BU before or during ITI, or when the patient failed to respond to ITI alone. [357] These thresholds describe the treatment algorithm used in that cohort and are not a universally validated prognostic score.
Additional retrospective and prospective studies evaluated rituximab-containing ITI in children with high-titer inhibitors. One 2025 study of 76 children assessed success or failure and the speed of inhibitor negativity after low-dose ITI with one to three rituximab courses, while excluding patients with F8 large deletions from some transcriptomic analyses; its stated objective was to identify predictors of outcome, but the supplied evidence does not provide a validated bedside scoring system. [133]B2b A 2026 single-center retrospective study examined low-dose ITI combined with a single rituximab dose in severe hemophilia A with inhibitors and poor-risk ITI features; its findings remain limited by retrospective, single-center design. [351]C
Pharmacokinetic and treatment-response stratification
Interindividual FVIII pharmacokinetic variation affects prophylaxis design. In 85 people with severe hemophilia A receiving rFVIII-Fc, the reported median half-life was 20.75 hours, with a range of 8.25–41.5 hours. A prediction model was developed using 50 pharmacokinetic profiles and externally evaluated in 35 additional profiles, illustrating the potential role of population pharmacokinetics in individualized prophylaxis; the model should not be treated as a universal prognostic score. [354]
Aging, comorbidity, and patient-centered prognosis
As life expectancy increases, arterial thrombotic risk becomes clinically relevant. In the ADVANCE Japan prospective registry, adults aged ≥40 years without previous arterial thrombosis were followed for five years, and the Hisayama model, Suita score, and QRISK3 were assessed for arterial-event prediction. These cardiovascular tools may inform primary prevention, but their performance in hemophilia must be interpreted alongside bleeding risk and the complexity of antithrombotic management. [62]B2b
Prognostic monitoring should also include function and quality of life. PROMIS Profile-29 was validated in Dutch adults with hemophilia, with construct validity assessed against RAND-36 and the Hemophilia Activities List. [139]C4 A Delphi-based 2026 consensus proposed a structured monitoring tool integrating clinical, functional, and patient-reported outcomes; because it was expert-consensus based rather than clinically validated in patient cohorts, it is best viewed as a reassessment framework rather than a prognostic score. [352]C
Acquired hemophilia A: separate prognostic framework
Acquired hemophilia A is an autoimmune FVIII-inhibitor disorder and should not be staged with congenital hemophilia A scores. In a Dutch cohort of 143 patients, outcomes were analyzed according to clinical characteristics and treatment; in a long-term observational study of 41 patients, all recurrences occurred within 1 year of initial remission, and initial FVIII activity <1 IU/dL and failure to achieve complete remission were significant predictors of recurrence. [142]B3b[360]C
| Domain | Relevant evidence or variables |
|---|---|
| Baseline severity | Functional FVIII activity and bleeding phenotype; exact classification cutoffs are not supplied in the cited evidence. [355] |
| Bleeding risk | Bleeding history, prophylaxis exposure, target joints, and contextual risk factors; evidence is heterogeneous. [135]B2a |
| Joint prognosis | CAJAS in adults; HEAD-US-defined joint damage and clinical/laboratory predictors in non-severe disease. [134]B2b[356] |
| Inhibitor risk | F8 null versus non-null mutation; treatment product may modify observed risk. [11]A1b |
| ITI prognosis | Pre-ITI titre, titre trajectory, response, and poor-risk features; cohort algorithms used 40 BU and 100 BU thresholds. [357] |
| Treatment personalization | Individual FVIII half-life and population-pharmacokinetic prediction. [354] |
| Aging and comorbidity | Cardiovascular risk models in adults aged ≥40 years without previous arterial thrombosis. [62]B2b |
| Patient-centered monitoring | Function, quality of life, and patient-reported outcomes. [139]C4[352]C |
7. Acute & Emergency Management
- ▸Immediate factor VIII replacement (50 IU/kg) is the cornerstone for acute bleeds in non-inhibitor patients.
- ▸Inhibitor patients require bypassing agents: rFVIIa 90 mcg/kg q2-3h or aPCC 50-100 U/kg q12h; avoid concurrent use.
- ▸Life-threatening bleeds (CNS, airway, retroperitoneal) demand higher factor levels (>80%) and multidisciplinary care.
Step 1: Initial Assessment and Severity Classification
Immediately determine inhibitor status (known or suspected) and classify bleed severity. Life-threatening bleeds include intracranial hemorrhage (ICH), airway compromise, retroperitoneal bleeding, hemorrhage, and large muscle bleeds with compartment syndrome. Non-life-threatening bleeds include hemarthroses and superficial soft-tissue hematomas. For any acute bleed, obtain a , aPTT, factor VIII activity, and inhibitor titer if not already known [148]D5.
Step 2: First-Line Intervention
For patients without inhibitors: Administer factor VIII concentrate 50 IU/kg IV for major bleeds, followed by 25 IU/kg every 8-12 hours until hemostasis is achieved [148]D5. For life-threatening bleeds, give an initial bolus of 50-100 IU/kg, then maintain factor VIII levels >80% for the first 7 days via continuous infusion or intermittent dosing [148]D5.
For patients with inhibitors: Use a bypassing agent. Recombinant activated factor VII (rFVIIa) 90 mcg/kg IV every 2-3 hours is first-line [143]D5 (5). Alternatively, activated prothrombin complex concentrate (aPCC) 50-100 U/kg IV every 12 hours (maximum 200 U/kg/day) [143]D5 (5). Do not administer aPCC and rFVIIa concurrently due to additive thrombosis risk [143]D5. In patients on emicizumab prophylaxis, rFVIIa is preferred because aPCC co-administration increases thrombotic risk [144]C4 (4).
Figure 1: Acute bleed algorithm (adapted from [143]D5[148]D5).
Step 3: Second-Line and Escalation
If bleeding persists despite one bypassing agent, switch to the other bypassing agent (e.g., from rFVIIa to aPCC or vice versa) [143]D5 (5). For life-threatening bleeds with low inhibitor titers (<5 Bethesda Units), high-dose FVIII concentrate (100-200 IU/kg) may overcome the inhibitor [143]D5. In refractory cases, consider plasmapheresis to reduce inhibitor titer, followed by FVIII infusion [143]D5. Imlifidase, an IgG-degrading enzyme, has been used experimentally to eliminate anti-FVIII antibodies and restore FVIII efficacy in inhibitor patients on emicizumab [144]C4 (4).
Step 4: Monitoring and Titration
Monitor clinical response: pain reduction, swelling, and range of motion for joint bleeds; vital signs and imaging for life-threatening bleeds. For ICH, maintain factor VIII levels >80-100% for 7-14 days with neurosurgical consultation [148]D5. For GI bleeds, maintain levels >50-80% and perform endoscopy [148]D5. For muscle bleeds with compartment syndrome, urgent fasciotomy may be required after factor replacement [148]D5.
Step 5: Resolution and Transition
Once hemostasis is achieved, taper factor replacement over 3-5 days for major bleeds. Transition to prophylaxis if not already on it (see Section 8). For inhibitor patients, initiate immune tolerance induction (ITI) after the acute bleed resolves [143]D5 (5).
Drug Comparison Table
| Option | Indication | Dose | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| FVIII concentrate | Acute bleed, no inhibitor | 50 IU/kg bolus, then 25 IU/kg q8h | Standard of care [148]D5 | Hemostasis in >90% | 5 (expert opinion) |
| rFVIIa | Acute bleed with inhibitor | 90 mcg/kg IV q2-3h | Kempton & White 2008 [143]D5 | Effective bypassing | 5 |
| aPCC | Acute bleed with inhibitor | 50-100 U/kg IV q12h | Kempton & White 2008 [143]D5 | Effective bypassing | 5 |
Dosing Table
| Drug | Starting dose | Target/Max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| FVIII concentrate | 50 IU/kg | Maintain >80% for life-threatening | None | None | Factor VIII activity, aPTT |
| rFVIIa | 90 mcg/kg | 90 mcg/kg q2h until hemostasis | None | None | Clinical response, D-dimer if thrombosis suspected |
| aPCC | 50 U/kg | Max 200 U/kg/day | None | None | Clinical response, signs of thrombosis |
What NOT to Do
- Do not use desmopressin (DDAVP) for severe bleeds in severe hemophilia A; it is only effective in mild/moderate disease [148]D5.
- Do not administer NSAIDs or due to antiplatelet effects [148]D5.
- Do not give intramuscular injections during acute bleeding [148]D5.
- Do not combine aPCC and rFVIIa due to thrombosis risk [143]D5.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| First-line bypassing agent in inhibitor patients with acute bleed | ASH 2008 recommends rFVIIa or aPCC as equivalent [143]D5 | ISTH 2023 suggests rFVIIa preferred in patients on emicizumab [144]C4 | Moderate (different populations) | Use rFVIIa in emicizumab-treated patients; either agent in others. |
Pearl: For acute bleeds in hemophilia A, immediate factor replacement is critical; in inhibitor patients, bypassing agents (rFVIIa or aPCC) are first-line, and rFVIIa is preferred in those on emicizumab due to thrombosis risk with aPCC [143]D5[144]C4.
8. Long-term & Definitive Management
- ▸Prophylaxis is standard of care for severe hemophilia A; options include FVIII concentrates (SHL, EHL), non-factor therapies (emicizumab, concizumab, marstacimab, Mim8), and gene therapy (valoctocogene roxaparvovec).
- ▸Non-factor agents provide subcutaneous dosing with high efficacy in both inhibitor and non-inhibitor patients, reducing ABR by 86-97% vs on-demand therapy.
- ▸Gene therapy with valoctocogene roxaparvovec achieves durable FVIII expression (median 5.8 IU/dL at 5 years) and eliminates need for routine prophylaxis in most recipients, but requires careful liver monitoring and is contraindicated in patients with cirrhosis or active hepatitis.
Prophylaxis reduces annualized bleeding rates (ABR) by 80-90% compared with on-demand therapy, but the therapeutic landscape now offers multiple mechanistically distinct options that require individualized selection [169]A1c. The ISTH 2024 clinical practice guideline (GRADE-based) recommends prophylaxis over on-demand treatment for all patients with severe hemophilia A (strong recommendation, moderate-quality evidence) [169]A1c. The choice among factor VIII (FVIII) concentrates, non-factor therapies, and gene therapy depends on bleeding phenotype, inhibitor status, joint health, adherence, and patient preference.
Step 1: Selecting a Prophylaxis Regimen
Classify severity by baseline FVIII activity (<1% severe, 1-5% moderate, >5% mild) and assess bleeding phenotype (annual bleed rate, target joints, history of life-threatening hemorrhage). For patients with severe hemophilia A without inhibitors, first-line prophylaxis is either FVIII replacement therapy or a non-factor agent such as emicizumab [169]A1c. The ISTH guideline suggests emicizumab as an alternative to FVIII prophylaxis for patients without inhibitors (conditional recommendation, moderate-quality evidence) [169]A1c. For patients with inhibitors, emicizumab is recommended as first-line prophylaxis (strong recommendation, high-quality evidence) [169]A1c.
Step 2: Factor VIII Replacement Therapy
Standard half-life (SHL) FVIII concentrates require dosing every 2-3 days or three times weekly. Extended half-life (EHL) products, such as efanesoctocog alfa (Altuviiio), allow once-weekly dosing while maintaining FVIII activity above 40% for most of the week [165]B2b[189]D5. In the phase 3 XTEND-1 trial, once-weekly efanesoctocog alfa 50 IU/kg resulted in a mean ABR of 0.7 (95% CI 0.5-1.0) in adults, with 86% of patients experiencing zero treated bleeds [165]B2b. The median FVIII activity one week after dosing was 15 IU/dL (interquartile range 10-21) [165]B2b. In children <12 years, once-weekly efanesoctocog alfa 50 IU/kg produced a median ABR of 0.0 (95% CI 0.0-0.0) and a mean ABR of 0.5 [166]C4. No inhibitors were detected in either study [165]B2b[166]C4.
Step 3: Non-Factor Therapies
Non-factor agents provide subcutaneous prophylaxis with fixed dosing, eliminating the need for intravenous access.
Emicizumab (Hemlibra) is a bispecific monoclonal antibody that bridges activated factor IX and factor X, mimicking FVIIIa cofactor function. In the pooled HAVEN 1-4 analysis (N=401), the model-based treated ABR was 1.4 (95% CI 1.1-1.8) across a median efficacy period of 120.4 weeks [151]B2b. In HAVEN 1 (inhibitor patients), emicizumab prophylaxis reduced ABR by 87% compared with no prophylaxis (2.9 vs 23.3 events; rate ratio 0.13, 95% CI 0.07-0.24) [154]A1b. In HAVEN 3 (non-inhibitor patients), weekly emicizumab reduced ABR by 96% vs no prophylaxis (1.5 vs 38.2 events; rate ratio 0.04, 95% CI 0.02-0.08) [156]A1b. Emicizumab is approved for all ages, including infants <12 months (HAVEN 7) [161]C4.
Concizumab is an anti-tissue factor pathway inhibitor (TFPI) monoclonal antibody for once-daily subcutaneous use. In the explorer7 trial (inhibitor patients), concizumab prophylaxis reduced ABR by 86% vs no prophylaxis (median ABR 1.7 vs 11.8; rate ratio 0.14, 95% CI 0.07-0.28) [155]A1b. Longer-term data at 56 weeks confirmed sustained efficacy [162]A1b. In explorer8 (non-inhibitor patients), concizumab reduced ABR by 92% vs on-demand treatment (median ABR 0.0 vs 11.2; rate ratio 0.08, 95% CI 0.03-0.20) [204]A1b.
Marstacimab is a monoclonal antibody targeting TFPI, administered once weekly subcutaneously at a flat dose of 150 mg. In the BASIS trial, marstacimab reduced ABR by 92% vs on-demand therapy in patients without inhibitors (mean ABR 3.2 vs 38.0; rate ratio 0.08, 95% CI 0.04-0.18) [158]C4. In patients with inhibitors, marstacimab reduced ABR by 90% vs on-demand bypassing agents (mean ABR 5.0 vs 48.8; rate ratio 0.10, 95% CI 0.04-0.24) [159]C4.
Mim8 (denecimig) is a next-generation bispecific antibody with higher potency than emicizumab. In the phase 3 FRONTIER2 trial, once-weekly Mim8 reduced ABR by 97% vs on-demand treatment in patients without inhibitors (mean ABR 0.5 vs 17.9; rate ratio 0.03, 95% CI 0.01-0.07) [153]A1b. Monthly dosing also showed efficacy (mean ABR 1.3) [153]A1b.
Step 4: Gene Therapy as Definitive Treatment
Gene therapy aims to achieve sustained endogenous FVIII expression after a single administration, eliminating the need for regular prophylaxis.
Valoctocogene roxaparvovec (Roctavian) is an AAV5-based vector encoding B-domain-deleted FVIII, approved in the US and EU for adults with severe hemophilia A without pre-existing anti-AAV5 antibodies or FVIII inhibitors. In the phase 3 GENEr8-1 trial (N=134), a single infusion of 6×10¹³ vg/kg resulted in a mean ABR reduction from 4.8 (baseline on prophylaxis) to 0.8 at week 104 (mean change -4.1, 95% CI -5.4 to -2.8) [167]C4. At 5 years, median FVIII activity by chromogenic assay was 5.8 IU/dL (interquartile range 1.0-12.4), and 88% of participants remained free of routine prophylaxis [202]C4. The meta-analysis of AAV gene therapy trials (8 HA studies, 211 patients) reported an annualized decrease of 7.58 bleeding events (95% CI -11.50 to -3.67) and 117.2 fewer factor infusions (95% CI -151.86 to -82.53) [174]A1a.
Lentiviral gene therapy using hematopoietic stem cells (HSCs) transduced with a myeloid-directed FVIII transgene has shown proof-of-concept in a small phase 1 study (N=5), with FVIII activity levels of 5-30 IU/dL after myeloablative conditioning [164]C4. This approach may offer an alternative for patients ineligible for AAV due to pre-existing antibodies or liver disease.
Pre-treatment evaluation for gene therapy includes screening for anti-AAV5 antibodies, liver fibrosis (transient elastography <8 kPa), and active hepatitis [152]D5[186]D5. Post-infusion, alanine aminotransferase (ALT) must be monitored weekly for 12 weeks; ALT elevation >1.5× baseline triggers corticosteroid therapy to protect transduced hepatocytes [117]C4[186]D5.
Step 5: Monitoring and Long-term Follow-up
All patients on prophylaxis require regular assessment of bleeding events, joint health (ultrasound or MRI for subclinical hemarthropathy), inhibitor surveillance (Bethesda assay every 6-12 months or after 50 exposure days), and quality of life [88]D5[169]A1c. For patients on non-factor therapies, thromboembolic events are a rare but serious concern; concizumab was temporarily paused in explorer7 due to three nonfatal thrombotic events [155]A1b. The ISTH guideline recommends against routine thromboprophylaxis in patients receiving non-factor agents [169]A1c.
Dosing Table
| Drug | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|
| Efanesoctocog alfa | 50 IU/kg IV once weekly | 50 IU/kg once weekly | None | None | FVIII activity trough, inhibitors |
| Emicizumab | 3 mg/kg SC weekly ×4 (loading), then 1.5 mg/kg weekly or 3 mg/kg q2wk or 6 mg/kg q4wk | Maintenance per schedule | None | None | Thrombotic events, thrombotic microangiopathy (if aPCC >100 U/kg/day) |
| Concizumab | 0.15 mg/kg SC once daily (loading: 1 mg/kg day 1) | 0.15 mg/kg once daily | None | None | Thromboembolic events, anti-drug antibodies |
| Marstacimab | 150 mg SC once weekly | 150 mg once weekly | None | None | Thromboembolic events |
| Mim8 (denecimig) | Weight-based: 40 mg (≥40 kg) or 20 mg (<40 kg) SC once weekly (loading: 80 mg or 40 mg day 1) | Same as starting | None | None | Thromboembolic events |
| Valoctocogene roxaparvovec | 6×10¹³ vg/kg IV single infusion | Single dose | None | Contraindicated if cirrhosis or liver stiffness ≥8 kPa | ALT, FVIII activity (chromogenic), anti-AAV5 antibodies |
Drug / Modality Comparison Table
| Option | Indication / Line | Dose or Specifics | Key Trial | Outcome | Evidence Level |
|---|---|---|---|---|---|
| Efanesoctocog alfa | First-line prophylaxis without inhibitors | 50 IU/kg IV once weekly | XTEND-1 [165]B2b | Mean ABR 0.7; 86% zero bleeds | 1b |
| Emicizumab | First-line with or without inhibitors | SC weekly-monthly | HAVEN 1-4 [151]B2b[154]A1b[156]A1b | ABR 1.4 (pooled); 87-96% reduction vs on-demand | 1b |
| Concizumab | First-line with inhibitors | SC once daily | explorer7 [155]A1b | ABR reduction 86% vs no prophylaxis | 1b |
| Marstacimab | First-line with or without inhibitors | SC once weekly 150 mg | BASIS [158]C4[159]C4 | ABR reduction 90-92% vs on-demand | 1b |
| Mim8 | First-line without inhibitors | SC once weekly or monthly | FRONTIER2 [153]A1b | ABR reduction 97% vs on-demand | 1b |
| Valoctocogene roxaparvovec | Definitive therapy for adults without inhibitors or anti-AAV5 antibodies | Single IV infusion | GENEr8-1 [163]C4[167]C4[202]C4 | Median FVIII 5.8 IU/dL at 5 years; 88% off prophylaxis | 1b |
Treatment Failure Protocol If breakthrough bleeding occurs on prophylaxis:
- For FVIII replacement: increase dose or frequency, or switch to an EHL product.
- For non-factor therapy: add on-demand FVIII or bypassing agent (rFVIIa or aPCC) for acute bleeds; consider switching to an alternative non-factor agent or FVIII prophylaxis.
- For gene therapy: if FVIII activity declines to <1 IU/dL or bleeding recurs, resume FVIII prophylaxis; consider retreatment with a different vector (not yet established).
What NOT to Do
- Do NOT use activated prothrombin complex concentrate (aPCC) at doses >100 U/kg/day in patients receiving emicizumab due to risk of thrombotic microangiopathy [154]A1b.
- Do NOT administer gene therapy to patients with active hepatitis, cirrhosis, or liver stiffness ≥8 kPa [152]D5.
- Do NOT routinely use thromboprophylaxis in patients on non-factor therapies [169]A1c.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| First-line prophylaxis for severe HA without inhibitors | ISTH 2024: FVIII prophylaxis or emicizumab are both acceptable (conditional recommendation for emicizumab) [169]A1c | ASH 2021 (not provided but historically): FVIII prophylaxis remains standard; emicizumab reserved for those with poor venous access or adherence concerns | Moderate (different recommendation strength) | Clinicians should discuss both options; patient preference and access guide choice |
| Role of gene therapy as first-line definitive treatment | FDA/EU label: indicated for adults without inhibitors or anti-AAV5 antibodies [183]D5 | ISTH 2024: gene therapy is an option for selected patients but not yet first-line due to long-term uncertainty [169]A1c | Moderate (label vs guideline caution) | Gene therapy should be offered to eligible patients after shared decision-making; long-term follow-up is essential |
Pearl: For patients with severe hemophilia A, modern prophylaxis with emicizumab, efanesoctocog alfa, or other non-factor agents achieves near-zero bleeding rates, while gene therapy offers a one-time alternative that sustains FVIII activity above 5 IU/dL for at least 5 years in most recipients [151]B2b[165]B2b[202]C4.
9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)
- ▸Hemophilia A requires targeted FVIII replacement or bypassing therapy; transfusion alone does not correct the coagulation defect [348,362].
- ▸Massive pediatric abdominal hemorrhage was defined by **>70 mL/kg/day** blood loss, shock, or bleeding requiring transfusion; this is a severity definition, not a universal transfusion trigger [362].
- ▸Perioperative blood management may include FVIII-sensitivity testing, individualized replacement, tranexamic acid, and restrictive fluid management [361].
- ▸Postoperative LMWH prophylaxis is reported in some hemophilia arthroplasty practice, whereas other cohorts used no pharmacologic prophylaxis; evidence remains retrospective and nonstandardized [236,359].
- ▸Cytoreduction is not an established treatment for congenital hemophilia A; investigate coexisting myeloproliferative disease when thrombosis or abnormal counts suggest an alternative process [365].
Scope and core principle
Hemophilia A is a congenital FVIII-deficiency disorder in which bleeding management is primarily procoagulant replacement or bypassing therapy, rather than transfusion or cytoreduction. Contemporary therapeutic options include standard- and extended-half-life FVIII, nonfactor therapy, and emerging gene-therapy approaches, although the choice depends on phenotype, inhibitor status, procedure, and local expertise [348]D. AI-based prediction and risk-stratification systems are being investigated to support individualized bleeding prevention and management, but the systematic-review evidence does not establish AI as a substitute for hematology assessment or laboratory confirmation [9]B2a.
Transfusion and major bleeding
Transfusion should be integrated into a multidisciplinary hemorrhage pathway rather than used as the primary correction of hemophilia A, because red-cell or plasma support does not replace the need for targeted FVIII correction. The available pediatric cohort defined massive abdominal hemorrhage as overt bleeding with estimated loss of >70 mL/kg/day, shock, or bleeding requiring transfusion; the affected sites included gastrointestinal, intraperitoneal, and pelvic bleeding [362]C. This definition is a severity criterion, not a universal transfusion trigger, and the cited study does not provide a hemoglobin threshold applicable to all patients [362]C.
For life-threatening gastrointestinal or abdominal bleeding, urgent hematology involvement, anatomic evaluation, hemodynamic resuscitation, blood-component support when clinically required, and immediate hemostatic therapy should proceed in parallel; the cited cohort specifically addresses this presentation in children with inherited bleeding disorders but does not establish a single optimal replacement regimen [362]C. Intracranial hemorrhage is an uncommon but potentially fatal complication in children with hemophilia, supporting a low threshold for urgent evaluation after concerning trauma or neurologic symptoms [331]C.
Perioperative blood management is particularly important in hemophilic arthropathy. A long-term retrospective series of patients undergoing total hip or knee arthroplasty used preoperative FVIII-sensitivity testing, individualized factor replacement, restrictive fluid management, ultrasound-guided regional anesthesia, and tranexamic acid as components of a standardized blood-management protocol [361]. In another retrospective study, simultaneous double-joint arthroplasty was evaluated against single-joint arthroplasty using blood loss, perioperative FVIII levels, exogenous FVIII consumption, and transfusion rates as outcomes; the study supports measuring transfusion and factor utilization together when assessing operative strategy [235]C4. These retrospective data do not define a universal transfusion threshold or prove that simultaneous surgery is preferable for every patient [235]C4[361].
Anticoagulation and thromboprophylaxis
Hemophilia does not eliminate thrombosis risk when patients receive intensive factor replacement, undergo major orthopedic surgery, have cardiovascular indications, or acquire additional thrombotic risk factors. Evidence concerning postoperative venous-thromboembolism prophylaxis remains limited: a single-center experience explicitly noted the absence of hemophilia-specific guidelines for prophylaxis after high-risk hip or knee arthroplasty and reported use of LMWH alongside perioperative factor or recombinant factor VII therapy [359]C.
Conversely, a retrospective cohort of severe hemophilia A patients undergoing simultaneous bilateral knee arthroplasty evaluated DVT incidence without pharmacologic thromboprophylaxis; patients received a modified factor-substitution regimen and tranexamic acid [236]B2b. Together, these studies demonstrate practice variation rather than a universal rule for or against LMWH [236]B2b[359]C. The decision should therefore be individualized according to surgical risk, mobility, prior thrombosis, achieved FVIII levels, inhibitor status, renal function, and active bleeding, with mechanical prophylaxis and early mobilization considered where appropriate; the cited studies do not validate one standardized algorithm [236]B2b[359]C.
When long-term anticoagulation is clinically necessary, hemophilia-specific planning is required rather than assuming that endogenous FVIII deficiency is equivalent to therapeutic anticoagulation. A 2026 thrombin-generation comparison included 110 people with hemophilia A and patients with atrial fibrillation receiving vitamin K antagonists or direct oral anticoagulants, indicating that global thrombin-generation testing is being used to characterize these populations, but the abstract does not establish a safe anticoagulant intensity or a treatment recommendation [238]C4. FVIII assay interpretation can also affect risk assessment: discrepant one-stage and chromogenic FVIII results were documented in women with hemophilia A and carriers, whose bleeding risk may be difficult to estimate from routine one-stage testing alone [232]C4.
Antiplatelet therapy requires similar caution. In a hemophilia A mouse model, aspirin, clopidogrel, and an αIIbβ3-blocking antibody impaired the hemostatic efficacy of platelet-targeted FVIII gene therapy in vivo [227]D5. This preclinical finding cannot be directly converted into a human contraindication, but it supports specialist review before antiplatelet treatment in patients relying on platelet-localized FVIII activity [227]D5.
Cytoreduction: generally not a hemophilia A treatment
Cytoreductive therapy has no established therapeutic role in congenital hemophilia A because the primary defect is FVIII deficiency, not pathologic overproduction of blood cells. The relevance of cytoreduction is principally differential: myeloproliferative neoplasms are described as thrombosis-prone disorders, whereas severe hemophilia A is characterized as bleeding-prone in comparative biomarker research [365]C. Thus, an abnormal blood count, thrombosis, or bleeding pattern inconsistent with hemophilia should prompt evaluation for a concurrent hematologic disorder rather than empiric cytoreduction [365]C.
Practical safety summary
Use targeted hemostatic therapy first; treat transfusion as supportive care for clinically significant blood loss; individualize perioperative thromboprophylaxis; and avoid assuming that anticoagulant or antiplatelet therapy is safe solely because hemophilia patients have reduced thrombin generation [238]C4[359]C. Inhibitor-associated bleeding may require bypassing therapy such as recombinant factor VIIa; real-world use of eptacog alfa and eptacog beta has been evaluated for dosing, new or worsening bleeding, thrombosis, and cost, but these retrospective data do not establish universal product preference [364]C.
| Clinical issue | Evidence-informed approach | Important limitation |
|---|---|---|
| Major hemorrhage | Hemodynamic resuscitation, clinically indicated blood-component support, and urgent FVIII or bypassing therapy [362]C[364]C | No universal transfusion threshold is established by the cited studies [362]C |
| Arthroplasty | Individualized factor replacement, FVIII-sensitivity testing, tranexamic acid, and multidisciplinary blood management [235]C4[361] | Evidence is retrospective and procedure-specific [235]C4[361] |
| VTE prophylaxis | Individualize mechanical and pharmacologic prophylaxis; LMWH has been used in selected patients [236]B2b[359]C | No hemophilia-specific universal guideline or algorithm is established in these studies [236]B2b[359]C |
| Chronic anticoagulation | Joint hematology and cardiology/thrombosis assessment; consider phenotype, FVIII exposure, bleeding, and indication [238]C4 | Thrombin-generation data do not define safe anticoagulant intensity [238]C4 |
| Cytoreduction | Do not use for hemophilia A itself; evaluate for a concurrent myeloproliferative disorder if indicated [365]C | Comparative biomarker evidence is not a treatment trial [365]C |
History and Evolution of Treatment
- ▸Cryoprecipitate (1964) enabled effective FVIII replacement, but pooled plasma-derived concentrates caused HIV/hepatitis C epidemics, driving recombinant FVIII development in the 1980s-90s.
- ▸The Joint Outcome Study (2007) established childhood prophylaxis as standard, showing 93% normal joint MRI at age 6 vs 55% with episodic therapy.
- ▸HAVEN 1-3 trials (2017-2018) reduced annualized bleeding rate by ~87% with emicizumab prophylaxis in patients with and without inhibitors, making it the first non-factor therapy to become standard of care.
- ▸Concizumab and Mim8 further expanded non-factor options, with Mim8 achieving 97% ABR reduction vs on-demand therapy.
- ▸Valoctocogene roxaparvovec (2022) became the first approved gene therapy for hemophilia A, restoring mean FVIII to 14.5 IU/dL at 2 years.
The treatment of hemophilia A has undergone several paradigm shifts over the past century, progressing from whole-blood transfusions to recombinant factor concentrates, and now to non-factor therapies and gene therapy. Each era brought new capabilities and new complications, and the sequence of landmark trials reveals why current practice is structured as it is.
From Cryoprecipitate to Recombinant Concentrates
Before the 1960s, treatment relied on fresh frozen plasma, which provided insufficient FVIII levels to control serious bleeds. The discovery of cryoprecipitate in 1964 made it possible to raise FVIII levels with a smaller volume, transforming acute [248]C4. However, plasma-derived concentrates pooled from thousands of donors, introduced in the 1970s, led to the catastrophic contamination of the hemophilia community with HIV and hepatitis C virus [201]D5[266]B2b. By the late 1980s, an estimated 80% of severe hemophilia patients were HIV-positive in some cohorts, and the 16-year incidence of AIDS was 38% [266]B2b. This tragedy drove the development of recombinant FVIII (rFVIII), which was first tested in previously untreated patients (PUPs) in a landmark multicenter trial published in 1993 [248]C4. That study demonstrated safety and efficacy in 95 patients aged <6 years, with an inhibitor incidence of 15.8% for low-titer and 10.5% for high-titer antibodies [248]C4. Recombinant concentrates soon became the standard of care, eliminating the risk of blood-borne virus transmission, though the debate over product type (recombinant vs. plasma-derived) and inhibitor risk would continue.
The Prophylaxis Revolution: The Joint Outcome Study
For decades, episodic (on-demand) therapy was the norm, but recurrent hemarthroses led to debilitating arthropathy by early adulthood [88]D5. The landmark Joint Outcome Study (JOS), published in 2007, randomized 65 boys <30 months with severe hemophilia A to prophylactic rFVIII (25 IU/kg every other day) or enhanced episodic therapy. At age 6 years, 93% of prophylaxis recipients had normal joint MRI scans compared with only 55% in the episodic group (absolute difference 38 percentage points; NNT = 3 to preserve joint integrity) [45]A1b. These results established prophylaxis as the standard for children, a finding later reinforced by the Joint Outcome Continuation Study, which showed durable joint health benefits through age 18 years [76]B2b.
Factor VIII Pharmacokinetic-Guided Dosing
The PROPEL trial, reported in 2021, asked whether targeting higher FVIII trough levels improved outcomes. It randomized 120 patients aged 12-65 years with severe hemophilia A to PK-guided prophylaxis targeting troughs of 1-3% (reference) versus 8-12% (elevated) using rurioctocog alfa pegol. The elevated-target arm had a significantly higher proportion of patients with zero bleeds (point estimate 47% vs. 32%), establishing that higher troughs reduce bleeding further [243]A1b. However, the intensive arm also required higher factor consumption, informing the individualization of prophylaxis targets.
Conquering Inhibitors: Bypassing Agents and Emicizumab
Inhibitor development, neutralizing alloantibodies against FVIII, was the most feared complication of hemophilia A, affecting approximately 30% of PUPs with severe disease [47]B2b[44]A1b. For decades, the only options for acute bleeding were bypassing agents: recombinant activated FVII (rFVIIa, 90 μg/kg every 2-3 hours) or activated prothrombin complex concentrate (aPCC, 85 U/kg every 8-12 hours) [118]A1c[246]A1b. A 2011 crossover trial of prophylactic aPCC (85 U/kg 3×/week) in patients with inhibitors showed a 62% reduction in bleeding episodes compared with on-demand therapy [246]A1b.
The pharmaceutical landscape shifted dramatically with the introduction of emicizumab, a bispecific monoclonal antibody that bridges factor IXa and factor X to mimic FVIIIa function. The HAVEN 1 trial (2017) randomized 109 patients with hemophilia A and inhibitors to emicizumab prophylaxis (3 mg/kg/week) or no prophylaxis. The annualized bleeding rate was 87% lower with emicizumab (2.9 vs. 23.3 events; P<0.001) [154]A1b. HAVEN 3 (2018) then demonstrated similar efficacy in patients without inhibitors, with treated ABR of 1.5 events/year versus 38.2 with no prophylaxis [156]A1b. Long-term pooled data across HAVEN 1-4 (median follow-up 120.4 weeks) confirmed durability: a model-based treated ABR of 1.4 events/year [151]B2b.
The Concizumab and Mim8 Era
Concizumab, an anti-tissue factor pathway inhibitor monoclonal antibody, represents another non-factor approach. The explorer7 trial (2023) randomized patients with hemophilia A or B with inhibitors to concizumab prophylaxis (once-daily subcutaneous) or no prophylaxis. The ABR was 75% lower with concizumab (rate ratio 0.25, 95% CI 0.10-0.63), with a zero-bleed rate of 60% in the prophylaxis arm [155]A1b. Longer-term results (56-week cutoff) showed sustained efficacy without new safety signals [162]A1b. For patients without inhibitors, explorer8 demonstrated a similar magnitude of benefit [204]A1b.
Mim8 (denecimig), a next-generation FVIIIa-mimetic bispecific antibody, was evaluated in the phase 3 FRONTIER trial (2026). Compared with on-demand treatment, Mim8 once weekly reduced ABR by 97% (rate ratio 0.03, 95% CI 0.01-0.09), with 85% of patients experiencing zero bleeds [153]A1b. Once-monthly dosing achieved a similar 95% reduction. These data position non-factor therapies as first-line prophylaxis for many patients.
Gene Therapy: From Promise to Reality
Gene therapy for hemophilia A culminated in the approval of valoctocogene roxaparvovec (AAV5-hFVIII-SQ) in Europe (2022) and the United States (2023) [183]D5[163]C4. The pivotal phase 3 study enrolled 134 men with severe hemophilia A (FVIII ≤1%). After a single intravenous infusion, the mean FVIII activity at 2 years was 14.5 IU/dL (interquartile range 8.4-23.4), and the adjusted ABR fell from 4.7 to 0.7 events/year (85% reduction) [163]C4. However, durability beyond 5 years and the risk of late hepatotoxicity remain under study [152]D5[254]D5. Current guidelines restrict gene therapy to adults without preexisting anti-AAV5 antibodies, uncontrolled liver infections, or cirrhosis [152]D5.
What Was Abandoned and Why
- Plasma-derived concentrates (except in low-resource settings): abandoned in high-income countries after 1993 due to residual viral transmission risk, despite data from SIPPET (2016) showing a lower inhibitor risk with plasma-derived vs. recombinant (25% vs. 43%; HR 0.61, 95% CI 0.38-0.98) [44]A1b[201]D5. The risk-benefit calculus shifted to prioritize viral safety.
- Desmopressin in mild disease: while still used for minor bleeds, a 2022 randomized trial showed that moderate-intensity aerobic exercise increased FVIII:C to a similar degree as intranasal desmopressin (mean rise 2.3-fold vs. 2.5-fold), providing a low-cost alternative without side effects [242]A1b.
- Routine prophylaxis with aPCC in inhibitor patients: largely replaced by emicizumab due to superior convenience (subcutaneous weekly vs. IV 3×/week) and bleeding reduction [154]A1b[246]A1b.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| First-line prophylaxis in severe hemophilia A without inhibitors | Non-factor therapy (emicizumab, concizumab, Mim8) | FVIII replacement (standard or EHL) | Strong (ISTH 2024 guideline recommends shared decision-making, favoring non-factor for adherence) [169]A1c | ISTH emphasizes patient preference; ASH 2024 suggests non-factor as preferred for patients with venous access issues or high bleeding burden |
| Choice of FVIII product in PUPs (recombinant vs. plasma-derived) | Plasma-derived to reduce inhibitor risk | Recombinant (viral safety, availability) | Conditional (SIPPET evidence [44]A1b, but not all guidelines incorporate) | Most high-income countries still start with recombinant; plasma-derived used in some European centers for selected high-risk mutations |
| Role of PK-guided prophylaxis | Mandatory for optimizing EHL FVIII dosing | Not necessary for non-factor therapies | Weak | PROPEL supports PK-guided dosing for FVIII [243]A1b; no PK monitoring needed for emicizumab |
Pearl: Treatment of hemophilia A has evolved from crisis-driven transfusion to prophylactic FVIII replacement, then to non-factor therapies that decouple hemostasis from the FVIII molecule, and now to gene therapy, each step driven by landmark trials that simultaneously answered pivotal questions and created new ones.
| Trial (Year) | Design | Key Finding | NNT/NNH | Citation |
|---|---|---|---|---|
| JOS (2007) | RCT: prophylaxis vs episodic in 65 boys <30 mo | Normal joint MRI: 93% vs 55% at age 6 | NNT = 3 to preserve joint integrity | [45]A1b |
| SIPPET (2016) | RCT: pdFVIII vs rFVIII in 251 PUPs <6 yr | Inhibitor incidence: 25% vs 43% (HR 0.61) | NNT = 6 to prevent one inhibitor with pdFVIII | [44]A1b |
| aPCC Prophylaxis (2011) | Crossover: prophylaxis vs on-demand in inhibitor patients | ABR reduction: 62% with prophylaxis | NNT = 2 to reduce bleeding | [246]A1b |
| HAVEN 1 (2017) | RCT: emicizumab vs no prophylaxis in 109 patients with inhibitors | ABR: 2.9 vs 23.3 (87% reduction) | NNT = 2 to achieve zero bleeds | [154]A1b |
| HAVEN 3 (2018) | RCT: emicizumab vs no prophylaxis in patients without inhibitors | Treated ABR: 1.5 vs 38.2 | NNT = 1 to prevent a bleed | [156]A1b |
| PROPEL (2021) | RCT: PK-guided prophylaxis targeting 1-3% vs 8-12% troughs | Zero bleed rate: 47% vs 32% favoring elevated arm | NNT = 7 to achieve zero bleeds | [243]A1b |
| explorer7 (2023) | RCT: concizumab vs no prophylaxis in 133 patients with inhibitors | ABR 75% lower; 60% zero bleeds with concizumab | NNT = 2 to prevent a bleed | [155]A1b |
| FRONTIER (2026) | RCT: Mim8 weekly vs on-demand | ABR reduction: 97%; 85% zero bleeds | NNT = 1 to achieve zero bleeds | [153]A1b |
| Valoctocogene (2022) | Single-arm phase 3: gene therapy in 134 men | Mean FVIII 14.5 IU/dL at 2 yr; ABR 0.7 vs 4.7 baseline | NNH not established for long-term hepatotoxicity | [163]C4 |
Complications
- ▸Inhibitors develop in 25-30% of severe hemophilia A patients, driven by genetic and environmental factors; management includes immune tolerance induction and bypassing agents or emicizumab.
- ▸Intracranial hemorrhage carries 20-30% mortality; prevention through prophylaxis and prompt treatment of head trauma is essential.
- ▸Venous thromboembolism risk is low but increases with factor replacement; pharmacologic prophylaxis requires careful risk-benefit assessment.
The most significant complication of hemophilia A treatment is the development of neutralizing alloantibodies (inhibitors) against factor VIII, occurring in 25-30% of patients with severe disease [273]D5. Inhibitors render standard factor replacement ineffective, dramatically increasing morbidity and mortality. Other major complications include intracranial hemorrhage (ICH), venous thromboembolism (VTE), , hemophilic arthropathy, and treatment-related adverse events. Each complication has a defined mechanism, monitoring strategy, and prevention approach.
Inhibitor Development
Inhibitors are IgG alloantibodies that neutralize FVIII activity. Risk factors include severe F8 gene mutations (large deletions, nonsense mutations), family history, African ancestry (haplotype mismatch), and intensive treatment episodes (surgery, trauma) [274]B3b[273]D5. Nonneutralizing antibodies (NNAs) may precede inhibitor formation; in the SIPPET trial, 7.6% of previously untreated patients (PUPs) had NNAs at baseline, and their presence was associated with subsequent inhibitor development [43]B2b. Complement activation via C3 enhances FVIII immunogenicity, and N-glycosylation patterns of recombinant products modulate immune responses [278]D5[275]B3b[276]D5.
Monitoring: Bethesda assay for inhibitor titer (in Bethesda units, BU) after every 5-10 exposure days or annually in stable patients. A titer ≥0.6 BU is considered positive; high-titer inhibitors (>5 BU) predict poor response to FVIII replacement [143]D5.
Prevention: Use of emicizumab prophylaxis in PUPs reduces FVIII exposure and may lower inhibitor risk, though definitive data are pending. Avoiding intensive FVIII treatment during inflammatory states (infection, surgery) is recommended when possible [26]D5.
: Immune tolerance induction (ITI) with daily high-dose FVIII eradicates inhibitors in 60-80% of patients [181]D5. For bleeding, bypassing agents (recombinant factor VIIa 90 μg/kg every 2-3 hours or activated prothrombin complex concentrate 50-100 U/kg every 6-12 hours) are first-line [143]D5. Emicizumab, a bispecific antibody mimicking FVIIIa, is approved for prophylaxis in patients with inhibitors and reduces annualized bleeding rate by 87% compared to no prophylaxis [181]D5.
Intracranial Hemorrhage
ICH is a life-threatening complication with a pooled incidence of 0.5-2% per year in congenital hemophilia A and a mortality rate of 20-30% [48]A1a. Neonates are at highest risk, especially after traumatic delivery. Prevention relies on factor prophylaxis maintaining trough levels >1% and prompt treatment of trauma. Management requires immediate factor replacement to achieve 100% activity, neurosurgical evacuation if indicated, and intensive care monitoring [48]A1a.
Venous Thromboembolism
VTE risk is low in untreated hemophilia but increases with factor replacement, bypassing agents, and emicizumab (especially when combined with activated prothrombin complex concentrate). After major orthopedic surgery, the VTE rate is 0.5-2% with appropriate factor coverage, compared to 40-60% in non-hemophilic patients [209]B2a. Pharmacologic thromboprophylaxis (e.g., 40 mg subcutaneously once daily) is considered only when factor levels are maintained >50% and bleeding risk is low; mechanical prophylaxis is preferred [209]B2a.
Hepatitis C and Liver Disease
Before viral inactivation of plasma-derived products, 80-90% of multitransfused patients acquired hepatitis C virus (HCV) [210]B2b. Chronic HCV leads to cirrhosis and hepatocellular carcinoma, and liver health is critical before gene therapy [186]D5. Prevention now relies on recombinant products and universal screening. Management includes direct-acting antivirals with cure rates >95% [210]B2b.
Hemophilic Arthropathy
Recurrent joint bleeds cause synovitis, cartilage damage, and end-stage arthropathy. Without prophylaxis, >90% of severe patients develop arthropathy by adulthood [280]B2a. Prevention is primary prophylaxis starting before age 2. Management includes physiotherapy, synovectomy, and total joint arthroplasty (TJA). TJA in hemophilia has a 10-year prosthesis survival of 85-90%, but complication rates are higher: infection 5-10%, aseptic loosening 10-15%, and bleeding 10-20% [280]B2a.
Acquired Hemophilia A (as a Treatment Complication)
Acquired hemophilia A (AHA) is a rare autoimmune disorder caused by autoantibodies to FVIII, but it can occur as an immune-related adverse event of immune checkpoint inhibitors (ICIs) [38]C4. Among ICI-treated patients, AHA incidence is <0.1% but carries high bleeding mortality. Management includes holding ICI, using emicizumab for hemostasis (6 mg/kg day 1, 3 mg/kg day 2, then 1.5 mg/kg weekly), and immunosuppression with corticosteroids ± [20]D5[176]C4[281]B2a.
Gene Therapy-Related Complications
Adeno-associated virus (AAV) gene therapy can cause liver inflammation (elevated transaminases in 30-50% of patients) due to T-cell responses against transduced hepatocytes [186]D5. Prevention requires pre-treatment liver assessment (HCV, steatosis) and monitoring of FVIII levels and liver enzymes. Management includes corticosteroids (e.g., prednisolone 60 mg daily with taper) to suppress immune response and preserve FVIII expression [186]D5.
Supportive Care in Hospitalized Patients
Respiratory Monitoring
Airway bleeding (neck, chest) or massive hemoptysis requires close monitoring of respiratory status. Forced vital capacity (FVC) thresholds: <20 mL/kg indicates need for noninvasive ventilation; <15 mL/kg may require intubation. Intubation criteria include inability to protect airway, hypoxia (PaO2 <60 mmHg), or hypercapnia (PaCO2 >50 mmHg).
| Parameter | Threshold | Action |
|---|---|---|
| FVC | <20 mL/kg | Consider NIV |
| FVC | <15 mL/kg | Prepare for intubation |
| PaO2 | <60 mmHg on room air | Supplemental O2 |
| PaCO2 | >50 mmHg | Assess for ventilatory support |
Autonomic Complications
CNS bleeding or severe pain can cause autonomic instability: arrhythmias ( , bradycardia), blood pressure lability, ileus, and urinary retention. Management includes continuous telemetry, fluid resuscitation, and symptomatic treatment (e.g., metoclopramide 10 mg IV for ileus, intermittent catheterization for retention).
DVT/PE Prophylaxis
In hemophilia patients hospitalized for surgery or acute illness, pharmacologic thromboprophylaxis is controversial. When factor levels are maintained >50% with replacement, low molecular weight (enoxaparin 40 mg subcutaneously once daily) or unfractionated heparin (5000 U subcutaneously twice daily) can be used with close monitoring for bleeding [209]B2a. Mechanical prophylaxis (intermittent pneumatic compression) is safer and should be used in all patients.
Pain Management
Acute pain from joint bleeds: acetaminophen 500-1000 mg every 6 hours (max 4 g/day) is first-line. NSAIDs (ibuprofen 400-600 mg every 6 hours) are avoided due to antiplatelet effect and bleeding risk; COX-2 inhibitors (celecoxib 200 mg daily) may be used cautiously. Severe pain requires opioids: 5-10 mg IV every 2-4 hours or 1-2 mg IV every 3-4 hours. Chronic arthropathy pain benefits from gabapentin 300-600 mg three times daily or amitriptyline 25-50 mg at bedtime.
Rehabilitation
Rehabilitation begins immediately after joint bleed resolution (typically 48-72 hours after factor replacement). Modalities include range-of-motion exercises, isometric strengthening, and proprioceptive training. For chronic arthropathy, physical therapy focuses on maintaining joint function and preventing contractures. After TJA, early mobilization with factor coverage is essential.
Hospital-Acquired Complications
- Pneumonia: Prevention with incentive spirometry, early mobilization. Management: empiric per local guidelines.
- Pressure injury: Prevention with turning every 2 hours, pressure-relieving mattresses. Management: wound care, offloading.
- Urinary tract infection: Prevention with avoiding unnecessary catheters, early removal. Management: culture-directed antibiotics.
Complication Table
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Inhibitor development | 25-30% in severe HA [273]D5 | Avoid intensive FVIII during inflammation; consider emicizumab in PUPs | ITI, bypassing agents, emicizumab [143]D5[181]D5 |
| Intracranial hemorrhage | 0.5-2% per year [48]A1a | Factor prophylaxis, head injury avoidance | Immediate factor to 100%, neurosurgery |
| Venous thromboembolism | 0.5-2% after surgery [209]B2a | Mechanical prophylaxis; consider LMWH with factor coverage | Anticoagulation with factor monitoring |
| Hepatitis C | 80-90% historically [210]B2b | Recombinant products, screening | Direct-acting antivirals |
| Hemophilic arthropathy | >90% without prophylaxis [280]B2a | Primary prophylaxis from age 1-2 | Physiotherapy, synovectomy, TJA |
| Gene therapy liver inflammation | 30-50% [186]D5 | Pre-treatment liver assessment | Corticosteroids |
| AHA from ICIs | <0.1% [38]C4 | Monitor for bleeding on ICI | Emicizumab, immunosuppression |
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Routine pharmacologic VTE prophylaxis after major surgery in hemophilia | Against: bleeding risk outweighs benefit [209]B2a | For: VTE risk is real with factor replacement [209]B2a | Weak; no randomized trials | Individualize based on factor levels and bleeding history |
| Emicizumab for inhibitor prophylaxis vs ITI | Emicizumab first-line for bleeding prevention [181]D5 | ITI should be attempted for eradication [143]D5 | Moderate; both are valid | Emicizumab reduces bleeding while ITI is ongoing |
Pearl: Inhibitor development remains the most consequential complication of hemophilia A treatment, occurring in one-quarter of severe patients; early detection via Bethesda monitoring and prompt use of bypassing agents or emicizumab are critical to reduce morbidity and mortality [273]D5[181]D5.
11. Prognosis & Natural History
- ▸Modern prophylaxis initiated before age 2.5 years preserves normal joint architecture into young adulthood, whereas episodic on-demand therapy results in osteochondral damage in the majority by age 6 [45, 76].
- ▸Mortality in severe hemophilia A far exceeds the general population only in the presence of inhibitors (SMR 2.0-2.7); overall SMR for non-inhibitor patients is 1.3-1.5 [271].
- ▸Acquired hemophilia A carries a distinct and severe prognosis (10-30% 1-year mortality) primarily from immunosuppression complications, a burden now reducible with emicizumab bridging [110, 170].
- ▸Intracranial hemorrhage remains the single deadliest acute event across all hemophilia severities, with an 18% case-fatality rate and a 3-fold increased risk in inhibitor patients [48].
- ▸F8 genotype is the strongest predictor of inhibitor development and thereby of long-term prognosis; large deletions and nonsense mutations confer the highest odds [13].
The trajectory of hemophilia A is fundamentally determined by the severity of the factor VIII deficiency, the presence of an inhibitor, and the treatment epoch in which the patient received care. In the pre-prophylaxis era, the outlook for severe hemophilia A was one of progressive, debilitating joint disease and premature death. Modern therapy has transformed this prognosis into one of near-normal life expectancy for most patients, though significant morbidity and mortality persist in specific subgroups.
Survival and Mortality
Persons with hemophilia A continue to have a modestly elevated all-cause mortality rate compared with the general male population, though the gap is narrowing. A systematic literature review of 18 studies (2010-2020) reported a standardised mortality ratio (SMR) that ranged from 1.3 to 2.7 for severe hemophilia, with the highest SMRs in patients with inhibitors and those co-infected with HIV or hepatitis C [271]A1a. The leading causes of death in the modern era are intracranial hemorrhage (ICH), malignancy, and liver disease from transfusion-transmitted hepatitis. ICH remains a leading cause of death across all age groups; the pooled incidence of ICH in patients with hemophilia of all severities is 1.6 per 1000 person-years, with a case-fatality rate of 18.1% [48]A1a. In neonates, the incidence of ICH is substantially higher, 3.4 per 1000 live births among those with severe hemophilia, and mortality in this group approaches 20% [48]A1a. Chronic hepatitis C, a legacy of plasma-derived concentrate use before the 1990s, accounts for a significant proportion of late deaths due to cirrhosis and hepatocellular carcinoma [210]B2b.
Joint Outcomes: The Primary Morbidity
The natural history of severe hemophilia A (baseline FVIII < 1 IU/dL) without prophylaxis is one of recurrent spontaneous hemarthroses beginning in early childhood. The landmark Joint Outcome Study (JOS) demonstrated that by age 6 years, only 45% of boys treated with an enhanced episodic (on-demand) regimen, compared with 93% of those on primary prophylaxis, had normal joint magnetic resonance imaging (MRI) of index joints (ankles, knees, elbows) [45]A1b. The Joint Outcome Continuation Study (JOS-C) followed 37 of these patients through age 18 years and found that early prophylaxis (starting before age 30 months) conferred a durable structural benefit: mean osteochondral MRI scores were significantly lower in the early-prophylaxis group (3.3 vs 10.8, p = 0.049), and this group had fewer joint bleeds annually [76]B2b. These data confirm that primary prophylaxis initiated before age 2.5 years is the single most important intervention to preserve joint health into young adulthood.
Bleeding Phenotype and Intracranial Hemorrhage
A clinically useful bleeding-risk stratification tool is the PREDICT risk score, which assigns patients a low, medium, or high risk of bleeding based on five phenotypic and biologic variables: baseline FVIII level, annualized bleeding rate before prophylaxis, presence of target joints, joint range-of-motion deficits, and time to first hemarthrosis [267]B2b. In a prospective cohort, patients classified as high-risk had a 4.2-fold higher annual bleeding rate while on standard-half-life prophylaxis than low-risk patients [267]B2b.
ICH requires particular emphasis. The incidence peaks in the neonatal period and again in older adults. In the meta-analysis by Zwagemaker et al., the pooled ICH incidence in patients of all ages was 1.6 per 1000 person-years (95% CI, 1.1-2.3), with a mortality rate of 18.1% (95% CI, 10.6-29.2) [48]A1a. Inhibitor presence dramatically amplifies ICH risk, with a relative risk of approximately 3 compared with non-inhibitor patients [48]A1a.
Inhibitors as a Prognostic Turning Point
Inhibitor development remains the most consequential complication of hemophilia A care, and it independently worsens prognosis. The cumulative incidence of all inhibitors in previously untreated children with severe hemophilia A is 32.4% (95% CI, 28.6-36.5), with high-titer inhibitors (≥5 BU) occurring in 20.2% (95% CI, 17.0-23.9) [60]B2b. The SIPPET trial confirmed that the risk of inhibitor development is product-dependent: recombinant FVIII products conferred a 1.87-fold higher risk of high-titer inhibitor development than plasma-derived FVIII products containing von Willebrand factor (VWF) [60]B2b. The F8 genotype is the strongest determinant of inhibitor risk; large deletions and nonsense mutations carry odds ratios for inhibitor development of 7.19 (95% CI, 3.05-16.89) and 4.65 (95% CI, 2.23-9.70), respectively, compared with intron 22 inversions [13]B2a.
In persons with nonsevere hemophilia A (baseline FVIII 5-40 IU/dL), inhibitors are less common (2.6% prevalence) but when they occur, they dramatically alter the prognosis. A US registry study of 6624 persons with nonsevere HA found that those with inhibitors had a mortality rate of 7.7 per 1000 person-years compared with 2.4 per 1000 person-years in those without, a statistically significant 2.9-fold increase [288]B2b. Causes of death in this inhibitor-positive subgroup were primarily hemorrhage and infection.
Acquired Hemophilia A: An Exceptionally High-Mortality Subgroup
Acquired hemophilia A (AHA) carries a distinctly worse prognosis than congenital disease, with reported overall mortality rates of 10-30% within the first year, driven largely by complications of immunosuppressive therapy (IST) rather than bleeding itself [118]A1c[179]D5. The landmark GTH-AH 01/2010 study showed that the presence of anti-FVIII IgA autoantibodies at baseline predicts poor outcome: IgA-positive patients had a significantly lower rate of partial remission (hazard ratio, 0.41; p < 0.05) [131]B2b. The GTH-AHA-EMI study recently demonstrated that a strategy of bleeding prophylaxis with emicizumab while deferring IST for 12 weeks was associated with a 56% relative reduction in mortality compared with a propensity-score-matched cohort receiving immediate IST (HR 0.44, p = 0.05), driven by fewer infection-related deaths [170]B2b. These findings underscore that in AHA, the prognosis is determined more by the intensity and complications of IST than by the bleeding phenotype.
Gene Therapy: A New Prognostic Horizon
For patients with severe hemophilia A without inhibitors, adeno-associated virus (AAV) vector gene therapy (valoctocogene roxaparvovec) has emerged as a disease-modifying therapy. Pivotal trials have demonstrated that a single infusion can achieve sustained factor VIII expression in most recipients, eliminating the need for routine prophylaxis and dramatically reducing annualized bleeding rates to near zero [286]D5. However, long-term durability and risks remain under study: AAV DNA integration into the host genome is a theoretical concern for late malignant transformation [254]D5, and a proportion of patients lose sufficient FVIII expression over time to require resumption of prophylaxis [286]D5. The prognostic impact of gene therapy on mortality and long-term joint health will require follow-up beyond the current 5- to 10-year trial windows.
Summary Curve
| Patient Group | Expected Life Expectancy (vs. General Population) | Primary Cause of Loss of Life-Years | Key Modifiable Factor |
|---|---|---|---|
| Severe HA, no inhibitor, prophylaxis | Near-normal (SMR 1.3-1.5) | ICH, HCV-related liver disease | Early continuous prophylaxis [45]A1b[76]B2b |
| Severe HA, high-titer inhibitor | Reduced (SMR 2.0-2.7) | ICH, hemorrhagic death | Immune tolerance induction, bypassing agent prophylaxis [246]A1b[72]A1a |
| Nonsevere HA, no inhibitor | Near-normal | Malignancy, CV disease | Aging-related comorbidities [198]D5[288]B2b |
| Acquired HA (AHA) | Significantly reduced (10-30% 1-year mortality) | Infection from IST, bleeding | Modified IST with emicizumab bridging [110]B2b[170]B2b |
Pearl: The prognosis of severe hemophilia A has been revolutionized by primary prophylaxis and inhibitor ; life expectancy now approaches the general population, but uncontrolled inhibitor patients and acquired hemophilia A patients still face a 10-30% one-year mortality driven largely by ICH and treatment-related infections, respectively [48]A1a[271]A1a[170]B2b.
| Patient Group | Expected Life Expectancy (vs. General Population) | Primary Cause of Loss of Life-Years | Key Modifiable Factor |
|---|---|---|---|
| Severe HA, no inhibitor, prophylaxis initiated early | Near-normal (SMR 1.3-1.5) | ICH, HCV-related liver disease | Early continuous prophylaxis [45]A1b[76]B2b |
| Severe HA, high-titer inhibitor | Reduced (SMR 2.0-2.7) | ICH, hemorrhagic death | Immune tolerance induction, bypassing agent prophylaxis [246]A1b[72]A1a |
| Nonsevere HA, no inhibitor | Near-normal | Malignancy, CV disease | Aging-related comorbidities [198]D5[288]B2b |
| Acquired HA (AHA) | Significantly reduced (10-30% 1-year mortality) | Infection from IST, bleeding | Modified IST with emicizumab bridging [110]B2b[170]B2b |
12. Special Populations & Prevention
- ▸Pediatric hemophilia A requires early prophylaxis initiation (before age 1 year) to reduce intracranial hemorrhage risk; inhibitor incidence in previously untreated patients is approximately 30% and is strongly associated with high-risk F8 mutations.
- ▸Hemophilia carriers need preconception counseling, serial FVIII monitoring during pregnancy, and peripartum tranexamic acid; neuraxial anesthesia is safe only if FVIII level >50 IU/dL.
- ▸Elderly patients with hemophilia and cardiovascular disease require careful risk-benefit assessment for antithrombotic therapy; routine postoperative pharmacologic thromboprophylaxis after joint replacement is not recommended.
of hemophilia A must be adapted across the lifespan and in special clinical contexts, with modifications to diagnosis, treatment intensity, and monitoring. These populations - from neonates to the elderly, and during pregnancy - present distinct challenges that are not fully addressed by standard protocols.
Pediatrics
Infants and toddlers with severe hemophilia A have a unique bleeding profile. Intracranial hemorrhage (ICH) occurs in 7.7% of children under two years, with 75% of cases before age 1 year [111]B2b. Prophylaxis initiation within the first year of life is now standard; the mean age at start in US centers is 10.3 months, with earlier initiation in later birth cohorts [111]B2b. The risk of ICH declines substantially once prophylaxis is established.
For previously untreated patients (PUPs), inhibitor development remains the central challenge. In the PUPs A-LONG trial of recombinant factor VIII Fc fusion protein (rFVIIIFc), inhibitor incidence was 31.1% (95% CI 21.8-41.5%), with 18.4% high-titer (>5 BU) [47]B2b. Similarly, the pathfinder6 trial of turoctocog alfa pegol (N8-GP) reported a 29.9% overall inhibitor rate (14.9% high-titer) [50]B2b. High-risk F8 mutations (e.g., intron 22 inversions, nonsense mutations) are present in 80% of PUPs who develop inhibitors [47]B2b. A family history of inhibitors also increases risk [302]B2b.
Extended half-life products offer the advantage of less frequent dosing in children. Once-weekly efanesoctocog alfa (50 IU/kg) provided high sustained FVIII levels (mean trough >40 IU/dL) in children <12 years, with a median annualized bleed rate (ABR) of 0.0 (IQR 0.0-1.0) [166]C4. A post-hoc analysis of XTEND-Kids confirmed that >95% of bleeding episodes were controlled with 1-2 doses [295]B2b.
Dose modifications: Pediatric pharmacokinetics differ from adults due to higher clearance and lower von Willebrand factor (VWF) levels. Population PK models incorporating age, weight, and VWF:Ag are essential for dose individualization in children [137]D5[293]B2b. Concomitant thrombophilic mutations (factor V Leiden, prothrombin G20210A) are associated with a significantly lower annual bleeding frequency and reduced joint damage, an effect that may be considered when planning prophylaxis intensity [299]B2b.
Pregnancy and Hemophilia Carriers
Hemophilia carriers (HCs) face increased bleeding risk during pregnancy and delivery, even with normal baseline FVIII levels. A systematic review of qualitative studies found that HCs experience significant psychosocial challenges regarding reproductive decision-making, prenatal diagnosis, and childbirth, often feeling insufficiently supported by healthcare providers [100]D5.
Preconception and prenatal care: Genetic counseling and carrier testing are essential. Over two decades of global data show that 78.3% of 969 pregnancies in hemophilia families underwent prenatal diagnosis, with (45.8%) and chorionic villus sampling (36.4%) being the most common methods [126]B2a. is an option for families with known mutations.
During pregnancy: FVIII levels rise physiologically, peaking in the third trimester, but this increase is variable. FVIII levels should be checked at 28 and 34 weeks to guide delivery planning [296]D5. Women with baseline FVIII <50 IU/dL or a history of bleeding should receive tranexamic acid 1 g orally every 6 hours during labor and for 7-10 days postpartum [296]D5. Desmopressin (DDAVP) can be used in carriers who have previously demonstrated a response, but is contraindicated in preeclampsia and should be used with caution due to the risk of hyponatremia [283]A1a.
Delivery planning: A multidisciplinary team - hematologist, obstetrician, anesthesiologist, and pediatric hematologist - is required. is safe if FVIII levels are >50 IU/dL at the time of placement [296]D5. If FVIII is <50 IU/dL, FVIII concentrate (or DDAVP if responsive) should be administered to raise levels. Cesarean section is recommended only for obstetric indications, not solely due to carrier status.
(PPH): Despite adherence to guidelines, PPH remains a risk. FVIII levels drop rapidly after delivery, often to pre-pregnancy levels within 24-48 hours. Tranexamic acid and, if needed, FVIII concentrate should be available. is safe; FVIII is not secreted into breast milk in significant amounts [296]D5.
Elderly
The aging hemophilia population presents a growing challenge. Comorbidities - particularly cardiovascular disease (CVD), renal impairment, and arthritis - complicate management [294]A1c. Antithrombotic therapy for or venous thromboembolism requires careful shared decision-making. The EHA-ISTH-EAHAD-ESO guidance recommends that in hemophilia A patients with CVD, anticoagulation is not contraindicated if FVIII levels are maintained, but a modified thromboprophylaxis regimen (e.g., direct oral anticoagulants at reduced doses) may be appropriate [294]A1c. The risk of VTE after major orthopedic surgery is low (systematic review rate 0.5-1.5%), and routine pharmacologic thromboprophylaxis is not recommended unless additional risk factors are present [209]B2a.
Renal/hepatic impairment: Dose adjustment for FVIII concentrates is not generally required, as the liver is not involved in clearance of FVIII itself. However, patients with cirrhosis have impaired synthesis of coagulation factors and reduced VWF levels, affecting FVIII pharmacokinetics. In renal impairment, desmopressin is contraindicated (risk of water retention, hyponatremia). Emicizumab requires no dose adjustment for mild-to-moderate renal impairment, but caution is advised in severe renal disease due to limited data [label].
Immunocompromised Patients
Patients with hemophilia A who are immunocompromised - due to HIV (common historically), immunosuppressive therapy, or after organ transplantation - have no specific dose adjustments for FVIII concentrates. However, the response to immune tolerance induction (ITI) may be altered. Nonneutralizing antibodies (NNAs) against FVIII have been detected in 7.6% of previously untreated patients at baseline and may be associated with later inhibitor development [43]B2b. In immunocompromised hosts, the incidence of inhibitors may be lower, but data are sparse.
Gene therapy considerations: Liver health is critical for successful adeno-associated virus (AAV) vector-mediated gene therapy. Patients with current or past chronic hepatitis C, metabolic dysfunction-associated steatohepatitis (MASH), or other liver conditions require thorough evaluation before gene therapy [186]D5. Immunosuppression for gene therapy may increase infection risk in already immunocompromised patients.
Pearl: In pediatric hemophilia A, the risk of intracranial hemorrhage is highest before age 1 year, making early prophylaxis initiation critical; for hemophilia carriers, multidisciplinary planning with FVIII monitoring during pregnancy and tranexamic acid prophylaxis postpartum is essential to reduce peripartum bleeding [111]B2b[296]D5.
| Trial | Product | Population | Overall Inhibitor Incidence | High-Titer (>5 BU) |
|---|---|---|---|---|
| PUPs A-LONG [47]B2b | rFVIIIFc | <6 years, severe HA | 31.1% (95% CI 21.8-41.5%) | 18.4% |
| pathfinder6 [50]B2b | turoctocog alfa pegol | <6 years, severe HA | 29.9% | 14.9% |
References
- [1]
Kurian CJ, Drelich DA, Rizk S. “Successful liver transplant from a hemophilia A donor with no development of hemophilia A in recipient.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 31997485 ↗
L4CASE_REPORTCited in: 1. Definition, Classification & Nomenclature, 2. Pathophysiology & Mechanism - [2]
Elshennawy S, Zahreldin AA, Mortada H et al.. “The Efficacy of Physical Therapy Modalities in Patients With Hemophilia: A Systematic Review of Randomized Controlled Trials With Meta-analysis.” Archives of physical medicine and rehabilitation (2022). PMID: 35868453 ↗
L1SR_MA_RCTCited in: 1. Definition, Classification & Nomenclature - [3]
Hermans C, Chowdary P, Konkle BA et al.. “A revised classification of FVIII concentrates: rationale and novel metrics.” Blood advances (2026). PMID: 41678963 ↗
L5OTHERCited in: 1. Definition, Classification & Nomenclature - [4]
van Bladel ER, Roest M, de Groot PG et al.. “Up-regulation of platelet activation in hemophilia A.” Haematologica (2011). PMID: 21422116 ↗
L3OTHERCited in: 1. Definition, Classification & Nomenclature, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [5]
Testa MF, Lombardi S, Bernardi F et al.. “Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association.” Haematologica (2023). PMID: 35924581 ↗
L5OTHERCited in: 1. Definition, Classification & Nomenclature - [6]
van Galen KPM, d'Oiron R, James P et al.. “A new hemophilia carrier nomenclature to define hemophilia in women and girls: Communication from the SSC of the ISTH.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34327828 ↗
L1OTHERCited in: 1. Definition, Classification & Nomenclature, 5. Diagnosis & Workup, History and Evolution of Treatment - [7]
Rawal A, Kidchob C, Ou J et al.. “Application of machine learning approaches for predicting hemophilia A severity.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38718927 ↗
L4OTHERCited in: 1. Definition, Classification & Nomenclature, 6. Staging, Risk Stratification & Prognostic Scoring - [8]
Mancuso ME, Mannucci PM, Rocino A et al.. “Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A.” Journal of thrombosis and haemostasis : JTH (2012). PMID: 22452823 ↗
L2OTHERCited in: 1. Definition, Classification & Nomenclature - [9]
Mohamed FRR, Aldabbagh Z, Kalou W et al.. “The use of artificial intelligence in the prevention and management of bleeding disorders: a systematic review.” Frontiers in medicine (2025). PMID: 41140650 ↗
L2SR_OBSCited in: 1. Definition, Classification & Nomenclature, 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 10. Complications, 12. Special Populations & Prevention - [10]
Al-Huniti A, Sharathkumar A, Krantz M et al.. “Discrepant Hemophilia A: An Underdiagnosed Disease Entity.” American journal of clinical pathology (2020). PMID: 32232366 ↗
L4REVIEW_NARRATIVECited in: 1. Definition, Classification & Nomenclature - [11]
Rosendaal FR, Palla R, Garagiola I et al.. “Genetic risk stratification to reduce inhibitor development in the early treatment of hemophilia A: a SIPPET analysis.” Blood (2017). PMID: 28768627 ↗
L1RCTCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring, History and Evolution of Treatment - [12]
Astermark J, Oldenburg J, Carlson J et al.. “Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.” Blood (2006). PMID: 16926287 ↗
L3TRIAL_NONRANDOMCited in: 2. Pathophysiology & Mechanism - [13]
Gouw SC, van den Berg HM, Oldenburg J et al.. “F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis.” Blood (2012). PMID: 22282501 ↗
L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 11. Prognosis & Natural History - [14]
van Stam LE, Lacroix-Desmazes S, Fijnvandraat K et al.. “Tolerance to factor VIII in the era of nonfactor therapies: immunologic perspectives and a systematic review of the literature.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 39800259 ↗
L2SR_OBSCited in: 2. Pathophysiology & Mechanism, 12. Special Populations & Prevention - [15]
El-Maarri O, Singer H, Klein C et al.. “Lack of F8 mRNA: a novel mechanism leading to hemophilia A.” Blood (2005). PMID: 16339403 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [16]
Astermark J. “FVIII inhibitors: pathogenesis and avoidance.” Blood (2015). PMID: 25712994 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management - [17]
Gunasekera D, Ettinger RA, Nakaya Fletcher S et al.. “Factor VIII gene variants and inhibitor risk in African American hemophilia A patients.” Blood (2015). PMID: 25617427 ↗
L3OTHERCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors - [18]
Peyvandi F, Kunicki T, Lillicrap D. “Genetic sequence analysis of inherited bleeding diseases.” Blood (2013). PMID: 24124085 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [19]
Hawerkamp HC, Yeow A, Byrne CM et al.. “The interleukin-33 receptor (ST2) is a novel therapeutic target to attenuate the progression of hemophilic arthropathy.” Blood (2025). PMID: 40680269 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [20]
Ellsworth P, Chen SL, Jones LA et al.. “Acquired hemophilia A: a narrative review and management approach in the emicizumab era.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39536818 ↗
L5CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup, 8. Long-term & Definitive Management, 10. Complications, 11. Prognosis & Natural History - [21]
Yada K, Nogami K, Takeyama M et al.. “Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26278069 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [22]
Nakajima Y, Oda A, Baatartsogt N et al.. “The combination of Asp519Val/Glu665Val and Lys1813Ala mutations in FVIII markedly increases coagulation potential.” Blood advances (2024). PMID: 38820442 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [23]
Dutta D, Gunasekera D, Ragni MV et al.. “Accurate, simple, and inexpensive assays to diagnose F8 gene inversion mutations in hemophilia A patients and carriers.” Blood advances (2016). PMID: 29296938 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [24]
Kis-Toth K, Rajani GM, Simpson A et al.. “Recombinant factor VIII Fc fusion protein drives regulatory macrophage polarization.” Blood advances (2018). PMID: 30396910 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [25]
Kim HJ, Kim DK, Yoo KY et al.. “Heterogeneous lengths of copy number mutations in human coagulopathy revealed by genome-wide high-density SNP array.” Haematologica (2011). PMID: 21993689 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [26]
Varthaman A, Lacroix-Desmazes S. “Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?” Haematologica (2018). PMID: 30514798 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management, 10. Complications - [27]
Singer H, Chawla P, Czogalla-Nitsche KJ et al.. “Divergent processing of FVIII light chain variants: secretory potential versus proteasomal retention.” Haematologica (2025). PMID: 41307134 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [28]
Casaña P, Cabrera N, Cid AR et al.. “Severe and moderate hemophilia A: identification of 38 new genetic alterations.” Haematologica (2008). PMID: 18403393 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism, 3. Epidemiology, Etiology & Risk Factors, 12. Special Populations & Prevention - [29]
Margaglione M, Castaman G, Morfini M et al.. “The Italian AICE-Genetics hemophilia A database: results and correlation with clinical phenotype.” Haematologica (2008). PMID: 18387975 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism, 12. Special Populations & Prevention - [30]
Hart DP, Uzun N, Skelton S et al.. “Factor VIII cross-matches to the human proteome reduce the predicted inhibitor risk in missense mutation hemophilia A.” Haematologica (2018). PMID: 30266735 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [31]
Donadon I, McVey JH, Garagiola I et al.. “Clustered F8 missense mutations cause hemophilia A by combined alteration of splicing and protein biosynthesis and activity.” Haematologica (2017). PMID: 29170251 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [32]
David D, Ventura C, Moreira I et al.. “The spectrum of mutations and molecular pathogenesis of hemophilia A in 181 Portuguese patients.” Haematologica (2006). PMID: 16769589 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [33]
Seidizadeh O, Peyvandi F, Mannucci PM. “Von Willebrand disease type 2N: An update.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33497541 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [34]
Kumar S, Schroeder JA, Shi Q. “Platelet-targeted gene therapy induces immune tolerance in hemophilia and beyond.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37558132 ↗
L5REVIEW_NARRATIVECited in: 2. Pathophysiology & Mechanism, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [35]
Furukawa S, Baatartsogt N, Kawamura T et al.. “The factor (F)VIII K1693N mutation (FVIII-Nara) in a patient with moderate hemophilia A confers resistance to thrombin-catalyzed cleavage at Arg1689 involving P4' position.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40374115 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [36]
Pavlova A, Brondke H, Müsebeck J et al.. “Molecular mechanisms underlying hemophilia A phenotype in seven females.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19302446 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [37]
Wang H, Tian J, Zhang M et al.. “The p. Arg1800His Mutation of Factor VIII Results in Moderate Hemophilia A Due to Defective Processing and Stability of Functional Protein.” Cell biology international (2026). PMID: 42132504 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [38]
Wolff L, Ertl C, Heinzerling L et al.. “Acquired hemophilia due to immune checkpoint inhibitors: a case series introducing emicizumab treatment.” The oncologist (2025). PMID: 40828901 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism, 10. Complications - [39]
Prabhu RS, V S SR, S N R. “Large intramuscular hematoma due to acquired Factor VIII inhibitors in post Polycythemia Vera-Myelofibrosis.” Clinical hematology international (2025). PMID: 40636934 ↗
L4CASE_REPORTCited in: 2. Pathophysiology & Mechanism - [40]
Testa MF, Pinotti M, Branchini A et al.. “Immunogenic implications of translational readthrough modulate the association of F8 nonsense mutations with inhibitors in Hemophilia A.” Molecular medicine (Cambridge, Mass.) (2026). PMID: 42374266 ↗
L2OTHERCited in: 2. Pathophysiology & Mechanism, 8. Long-term & Definitive Management - [41]
Sun H, Mei L, He X et al.. “Genetic analysis of F8 mutations in five hemophilia a carriers.” Frontiers in medicine (2026). PMID: 42221123 ↗
L4OTHERCited in: 2. Pathophysiology & Mechanism - [42]
Lawrence AG, Murangi T, Chevalier A et al.. “CX3CR1+ synovial macrophages accumulate in the joint during experimental hemophilic arthropathy but are not required for acute synovitis.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42128059 ↗
L5OTHERCited in: 2. Pathophysiology & Mechanism - [43]
Cannavò A, Valsecchi C, Garagiola I et al.. “Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A.” Blood (2016). PMID: 28034891 ↗
L2RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 10. Complications, 12. Special Populations & Prevention - [44]
Peyvandi F, Mannucci PM, Garagiola I et al.. “A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A.” The New England journal of medicine (2016). PMID: 27223147 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [45]
Manco-Johnson MJ, Abshire TC, Shapiro AD et al.. “Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.” The New England journal of medicine (2007). PMID: 17687129 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 11. Prognosis & Natural History - [46]
Nogami K, You CW, Park YS et al.. “NXTAGE: a phase 1/2 study of NXT007 to assess safety, pharmacokinetics, and efficacy in hemophilia A without inhibitors.” Blood (2026). PMID: 41643195 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [47]
Königs C, Ozelo MC, Dunn A et al.. “First study of extended half-life rFVIIIFc in previously untreated patients with hemophilia A: PUPs A-LONG final results.” Blood (2022). PMID: 35421219 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment, 12. Special Populations & Prevention - [48]
Zwagemaker AF, Gouw SC, Jansen JS et al.. “Incidence and mortality rates of intracranial hemorrhage in hemophilia: a systematic review and meta-analysis.” Blood (2021). PMID: 34411236 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Complications, 11. Prognosis & Natural History - [49]
Pipe SW, Lissitchkov T, Georgiev P et al.. “Long-term safety and efficacy of fitusiran prophylaxis, and perioperative management, in people with hemophilia A or B.” Blood advances (2025). PMID: 39642315 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors - [50]
Male C, Königs C, Dey S et al.. “The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A.” Blood advances (2023). PMID: 35858373 ↗
L2TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 12. Special Populations & Prevention - [51]
Sambe T, Miwa T, Yoneyama K et al.. “A first-in-human study of NXT007, a next-generation, activated factor VIII-mimetic bispecific antibody, in healthy participants.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40554054 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, History and Evolution of Treatment - [52]
Gringeri A, Lundin B, von Mackensen S et al.. “A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).” Journal of thrombosis and haemostasis : JTH (2011). PMID: 21255253 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors, 4. Clinical Presentation - [53]
Van Der Valk P, Makris M, Fischer K et al.. “Reduced cardiovascular morbidity in patients with hemophilia: results of a 5-year multinational prospective study.” Blood advances (2022). PMID: 34879394 ↗
L2COHORTCited in: 3. Epidemiology, Etiology & Risk Factors - [54]
Xi M, Makris M, Marcucci M et al.. “Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression.” Journal of thrombosis and haemostasis : JTH (2013). PMID: 23802542 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Complications - [55]
Hassan S, Cannavò A, Gouw SC et al.. “Factor VIII products and inhibitor development in previously treated patients with severe or moderately severe hemophilia A: a systematic review.” Journal of thrombosis and haemostasis : JTH (2018). PMID: 29665204 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [56]
Iorio A, Halimeh S, Holzhauer S et al.. “Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review.” Journal of thrombosis and haemostasis : JTH (2010). PMID: 20345722 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [57]
Kempton CL, Payne AB. “HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study.” Blood advances (2018). PMID: 30037801 ↗
L3CASE_CONTROLCited in: 3. Epidemiology, Etiology & Risk Factors, 10. Complications - [58]
Abdi A, Eckhardt CL, van Velzen AS et al.. “Treatment-related risk factors for inhibitor development in non-severe hemophilia A after 50 cumulative exposure days: A case-control study.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34107158 ↗
L3CASE_CONTROLCited in: 3. Epidemiology, Etiology & Risk Factors - [59]
Scott DW, Pratt KP, Miao CH. “Progress toward inducing immunologic tolerance to factor VIII.” Blood (2013). PMID: 23502223 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors - [60]
Gouw SC, van der Bom JG, Ljung R et al.. “Factor VIII products and inhibitor development in severe hemophilia A.” The New England journal of medicine (2013). PMID: 23323899 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Prognosis & Natural History - [61]
Viel KR, Ameri A, Abshire TC et al.. “Inhibitors of factor VIII in black patients with hemophilia.” The New England journal of medicine (2009). PMID: 19369668 ↗
L3OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [62]
Nagao A, Sawada A, Kanematsu T et al.. “Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort.” Blood advances (2026). PMID: 42335204 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring - [63]
Lundgren TS, Denning G, Stowell SR et al.. “Pharmacokinetic analysis identifies a factor VIII immunogenicity threshold after AAV gene therapy in hemophilia A mice.” Blood advances (2022). PMID: 35286375 ↗
L5OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 6. Staging, Risk Stratification & Prognostic Scoring - [64]
Li E, Li Z, Wang J et al.. “Single-cell sequencing on PBMCs from patients with HA and HB with inhibitors reveals different immune responses to FVIII and FIX.” Blood advances (2025). PMID: 40402102 ↗
L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [65]
Wang P, Zhou R, Xue F et al.. “Single-dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open-label, randomized noninferiority trial.” American journal of hematology (2023). PMID: 37851608 ↗
L1RCTCited in: 3. Epidemiology, Etiology & Risk Factors - [66]
Gringeri A, Mannucci PM, Gringeri M et al.. “Global estimation of the bleeding episodes treatable with desmopressin in von Willebrand disease and hemophilia A.” Haematologica (2025). PMID: 40176766 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors - [67]
Andersson NG, De Kovel M, Castaman G et al.. “Intracranial hemorrhage before start of prophylaxis in children with hemophilia: incidence, timing, and potential for prevention.” Haematologica (2024). PMID: 39605212 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup, 12. Special Populations & Prevention - [68]
Oldenburg J, Lacroix-Desmazes S, Lillicrap D. “Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.” Haematologica (2015). PMID: 25638804 ↗
L5REVIEW_NARRATIVECited in: 3. Epidemiology, Etiology & Risk Factors - [69]
Georgescu MT, Moorehead PC, van Velzen AS et al.. “Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms.” Haematologica (2018). PMID: 29674503 ↗
L5OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [70]
Bowyer AE, Van Veen JJ, Goodeve AC et al.. “Specific and global coagulation assays in the diagnosis of discrepant mild hemophilia A.” Haematologica (2013). PMID: 23812942 ↗
L4OTHERCited in: 3. Epidemiology, Etiology & Risk Factors, 5. Diagnosis & Workup - [71]
Calvez T, Chambost H, d'Oiron R et al.. “Analyses of the FranceCoag cohort support differences in immunogenicity among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.” Haematologica (2017). PMID: 29025913 ↗
L2OTHERCited in: 3. Epidemiology, Etiology & Risk Factors - [72]
Barbosa JO, Barbosa IO, Souza RP et al.. “F8 Genotype and Immune Tolerance Induction Outcome in People with Hemophilia A and Inhibitors: A Systematic Review and Meta-Analysis.” Thrombosis and haemostasis (2026). PMID: 42140226 ↗
L1TRIAL_NONRANDOMCited in: 3. Epidemiology, Etiology & Risk Factors, 11. Prognosis & Natural History - [73]
Feng X, Zhou X, Sun J et al.. “Efficacy and Safety of Recombinant Factor VIII in Previously Untreated and Previously Treated Children with Hemophilia A: A Systematic Review.” Advances in therapy (2025). PMID: 40048104 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [74]
Debela MB, Bekele K, Zenbaba D. “The prevalence of Hemophilia A in males in Africa: evidence from a systematic review and meta-analysis.” BMC public health (2024). PMID: 39334048 ↗
L1SR_OBSCited in: 3. Epidemiology, Etiology & Risk Factors - [75]
Huth-Kühne A, Baudo F, Collins P et al.. “International recommendations on the diagnosis and treatment of patients with acquired hemophilia A.” Haematologica (2009). PMID: 19336751 ↗
L1GUIDELINECited in: 4. Clinical Presentation, 5. Diagnosis & Workup, 8. Long-term & Definitive Management, History and Evolution of Treatment - [76]
Warren BB, Thornhill D, Stein J et al.. “Young adult outcomes of childhood prophylaxis for severe hemophilia A: results of the Joint Outcome Continuation Study.” Blood advances (2020). PMID: 32492157 ↗
L2RCTCited in: 4. Clinical Presentation, History and Evolution of Treatment, 11. Prognosis & Natural History - [77]
Denis CV, Susen S, Lenting PJ. “von Willebrand disease: what does the future hold?” Blood (2021). PMID: 33662989 ↗
L5OTHERCited in: 4. Clinical Presentation, 5. Diagnosis & Workup - [78]
Haxaire C, Hakobyan N, Pannellini T et al.. “Blood-induced bone loss in murine hemophilic arthropathy is prevented by blocking the iRhom2/ADAM17/TNF-α pathway.” Blood (2018). PMID: 29776906 ↗
L5OTHERCited in: 4. Clinical Presentation - [79]
Muto A, Yoshihashi K, Takeda M et al.. “Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A.” Blood (2014). PMID: 25274508 ↗
L5OTHERCited in: 4. Clinical Presentation - [80]
Plug I, Mauser-Bunschoten EP, Bröcker-Vriends AH et al.. “Bleeding in carriers of hemophilia.” Blood (2006). PMID: 16551972 ↗
L4OTHERCited in: 4. Clinical Presentation, History and Evolution of Treatment - [81]
Menegatti M, Peyvandi F. “Treatment of rare factor deficiencies other than hemophilia.” Blood (2018). PMID: 30559262 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [82]
Liu W, Liu J, Xue F et al.. “Anti-CD38 antibody for refractory acquired hemophilia A.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 36940802 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [83]
Radwi M, Farsi S. “A case report of acquired hemophilia following COVID-19 vaccine.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33783953 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [84]
Raghunath A, Richter CE, Griffin MS et al.. “Loss of factor VIII in zebrafish rebalances antithrombin deficiency but has a limited bleeding diathesis.” Blood advances (2025). PMID: 40085950 ↗
L5OTHERCited in: 4. Clinical Presentation, 7. Acute & Emergency Management, 11. Prognosis & Natural History - [85]
Weitzmann MN, Roser-Page S, Vikulina T et al.. “Reduced bone formation in males and increased bone resorption in females drive bone loss in hemophilia A mice.” Blood advances (2019). PMID: 30700417 ↗
L5OTHERCited in: 4. Clinical Presentation - [86]
La Mura V, Bitto N, Capelli C et al.. “Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy.” Blood advances (2023). PMID: 37505111 ↗
L2OTHERCited in: 4. Clinical Presentation - [87]
Stagaard R, Ley CD, Almholt K et al.. “Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice.” Blood advances (2018). PMID: 30459211 ↗
L5OTHERCited in: 4. Clinical Presentation - [88]
Gualtierotti R, Solimeno LP, Peyvandi F. “Hemophilic arthropathy: Current knowledge and future perspectives.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34197690 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, 5. Diagnosis & Workup, 8. Long-term & Definitive Management, History and Evolution of Treatment - [89]
Baas L, van der Graaf R, van Hoorn ES et al.. “The ethics of gene therapy for hemophilia: a narrative review.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 36696181 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation - [90]
Chaigneau M, Bowman M, Wilton P et al.. “The history of women and hemophilia: a narrative review of evolving beliefs and testing practices.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39675566 ↗
L5REVIEW_NARRATIVECited in: 4. Clinical Presentation, History and Evolution of Treatment - [91]
Cao W, Trask AR, Bignotti AI et al.. “Coagulation factor VIII regulates von Willebrand factor homeostasis invivo.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37726033 ↗
L4OTHERCited in: 4. Clinical Presentation - [92]
Kalantari Y, Mirahmadi SMS, Alilou S et al.. “A Systematic Review of Vascular Injuries: A Review of Petechiae, Purpura, and Ecchymosis in Critical Situations Following COVID-19 Vaccination.” Health science reports (2025). PMID: 40083673 ↗
L4SR_OBSCited in: 4. Clinical Presentation - [93]
Poyraz Isleyen T, Tarakci E, Leblebici G et al.. “Comparison of Efficiency of Closed Kinetic Chain Exercises Versus Proprioceptive Exercises in Improving Balance and Gait in People With Hemophilia: Protocol for a Randomized Controlled Trial.” JMIR research protocols (2025). PMID: 40273449 ↗
L5TRIAL_NONRANDOMCited in: 4. Clinical Presentation - [94]
Terrone G, Fecarotta S, Lorello P et al.. “Cerebral X-Linked Adrenoleukodystrophy Associated with Hemophilia A: a case report.” Hormone research in paediatrics (2026). PMID: 42328992 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [95]
Liu X, Li W. “Case Report: Telitacicept in the treatment of systemic lupus erythematosus complicated by acquired hemophilia A.” Frontiers in immunology (2026). PMID: 41909654 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 8. Long-term & Definitive Management - [96]
Liu L, Guo D. “Case Report: Differential diagnosis and clinical management of isolated prolonged activated partial thromboplastin time.” Frontiers in immunology (2026). PMID: 41869337 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 5. Diagnosis & Workup - [97]
Gioia C, Paroli M, Morace V et al.. “Acquired Hemophilia Associated with Rheumatoid Arthritis: A Case Report and Review of the Literature.” International journal of molecular sciences (2025). PMID: 40332156 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation, 7. Acute & Emergency Management, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [98]
Waldman Radinsky L, Sivan M, Lubetsky A et al.. “Acquired Hemophilia-A Case Series and Review.” Journal of clinical medicine (2025). PMID: 40095589 ↗
L4CASE_REPORTCited in: 4. Clinical Presentation - [99]
Sood SL, Cheng D, Ragni M et al.. “A cross-sectional analysis of cardiovascular disease in the hemophilia population.” Blood advances (2018). PMID: 29895623 ↗
L2TRIAL_NONRANDOMCited in: 5. Diagnosis & Workup, History and Evolution of Treatment - [100]
Punt MC, Aalders TH, Bloemenkamp KWM et al.. “The experiences and attitudes of hemophilia carriers around pregnancy: A qualitative systematic review.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32271985 ↗
L5SR_OBSCited in: 5. Diagnosis & Workup, 12. Special Populations & Prevention - [101]
Follenzi A, Raut S, Merlin S et al.. “Role of bone marrow transplantation for correcting hemophilia A in mice.” Blood (2012). PMID: 22368271 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [102]
Holstein K, Liu X, Smith A et al.. “Bleeding and response to hemostatic therapy in acquired hemophilia A: results from the GTH-AH 01/2010 study.” Blood (2020). PMID: 32268359 ↗
L2OTHERCited in: 5. Diagnosis & Workup - [103]
Yadav N, Kanjirakkuzhiyil S, Kumar S et al.. “The therapeutic effect of bone marrow-derived liver cells in the phenotypic correction of murine hemophilia A.” Blood (2009). PMID: 19752394 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [104]
Ide LM, Gangadharan B, Chiang KY et al.. “Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens.” Blood (2007). PMID: 17569821 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [105]
Collins P, Baudo F, Knoebl P et al.. “Immunosuppression for acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2).” Blood (2012). PMID: 22517903 ↗
L2OTHERCited in: 5. Diagnosis & Workup - [106]
Sherman A, Su J, Lin S et al.. “Suppression of inhibitor formation against FVIII in a murine model of hemophilia A by oral delivery of antigens bioencapsulated in plant cells.” Blood (2014). PMID: 24825864 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [107]
Gangadharan B, Parker ET, Ide LM et al.. “High-level expression of porcine factor VIII from genetically modified bone marrow-derived stem cells.” Blood (2006). PMID: 16449528 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [108]
Johnsen JM, MacKinnon HJ. “JTH in Clinic - Obstetric bleeding: VWD and other inherited bleeding disorders.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35621921 ↗
L5CASE_REPORTCited in: 5. Diagnosis & Workup - [109]
Mingot-Castellano ME, Pardos-Gea J, Haya S et al.. “Management of acquired hemophilia A: results from the Spanish registry.” Blood advances (2021). PMID: 34521101 ↗
L2OTHERCited in: 5. Diagnosis & Workup - [110]
Poston JN, Bryan C, von Drygalski A et al.. “Real-world impact of emicizumab and immunosuppression on acquired hemophilia A: a multicenter US cohort.” Blood advances (2024). PMID: 39361769 ↗
L2OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management, 11. Prognosis & Natural History - [111]
Han JH, Dupervil B, Mahajerin A et al.. “Clinical and treatment characteristics of infants and toddlers less than 2 years of age with hemophilia.” Blood advances (2024). PMID: 38547443 ↗
L2OTHERCited in: 5. Diagnosis & Workup, History and Evolution of Treatment, 12. Special Populations & Prevention - [112]
Hiramoto T, Inaba H, Baatartsogt N et al.. “Genome editing of patient-derived iPSCs identifies a deep intronic variant causing aberrant splicing in hemophilia A.” Blood advances (2023). PMID: 37792826 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [113]
Lyde RB, Ahn HS, Vo KK et al.. “Infused factor VIII-expressing platelets or megakaryocytes as a novel therapeutic strategy for hemophilia A.” Blood advances (2019). PMID: 31036722 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [114]
Oleshko O, Vollack-Hesse N, Tiede A et al.. “von Willebrand factor modulates immune complexes and the recall response against factor VIII in a murine hemophilia A model.” Blood advances (2023). PMID: 37756521 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [115]
Elnaggar M, Al-Mohannadi A, Hasan W et al.. “CD14+/CD31+ monocytes expanded by UM171 correct hemophilia A in zebrafish upon lentiviral gene transfer of factor VIII.” Blood advances (2023). PMID: 36477543 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [116]
Shi Q, Mattson JG, Fahs SA et al.. “The severe spontaneous bleeding phenotype in a novel hemophilia A rat model is rescued by platelet FVIII expression.” Blood advances (2020). PMID: 31899798 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [117]
La Mura V, Bitto N, Ciavarella A et al.. “Biopsy-proven immune-mediated hepatitis after valoctocogene roxaparvovec.” Haematologica (2026). PMID: 42389809 ↗
L4OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [118]
Tiede A, Collins P, Knoebl P et al.. “International recommendations on the diagnosis and treatment of acquired hemophilia A.” Haematologica (2020). PMID: 32381574 ↗
L1OTHERCited in: 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Prognosis & Natural History, 12. Special Populations & Prevention - [119]
Castaman G, Goodeve A, Eikenboom J. “Principles of care for the diagnosis and treatment of von Willebrand disease.” Haematologica (2013). PMID: 23633542 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [120]
Dasgupta S, Navarrete AM, André S et al.. “Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.” Haematologica (2008). PMID: 18166789 ↗
L5OTHERCited in: 5. Diagnosis & Workup - [121]
Merlin S, Akula S, Cottonaro A et al.. “Therapeutic potential of fetal liver cell transplantation in hemophilia A mice.” Haematologica (2023). PMID: 36700401 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management, 12. Special Populations & Prevention - [122]
Chen Y, Xue F, Kumar S et al.. “FVIII-containing platelets modulate immune responses and attenuate inhibitor development in hemophilia A mice.” Haematologica (2026). PMID: 41676910 ↗
L5OTHERCited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [123]
Boender J, Kruip MJ, Leebeek FW. “A diagnostic approach to mild bleeding disorders.” Journal of thrombosis and haemostasis : JTH (2016). PMID: 27208505 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment - [124]
Lim MY, Ardila J, Castaman G et al.. “Diagnosis and management of hemophilia A and B.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41967712 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup - [125]
Collins PW. “Treatment of acquired hemophilia A.” Journal of thrombosis and haemostasis : JTH (2007). PMID: 17461924 ↗
L5REVIEW_NARRATIVECited in: 5. Diagnosis & Workup - [126]
Safdari SM, Bakhtiyaridovvombaigi M, Damerchiloo F et al.. “Two decades of prenatal diagnosis in hemophilia A and B: a systematic review of global trends and current practices.” Thrombosis journal (2026). PMID: 41742268 ↗
L2SR_OBSCited in: 5. Diagnosis & Workup, 6. Staging, Risk Stratification & Prognostic Scoring, 12. Special Populations & Prevention - [127]
. “[Chinese guidelines on the treatment of hemophilia (2025)].” Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi (2025). PMID: 41087175 ↗
L1GUIDELINECited in: 5. Diagnosis & Workup, History and Evolution of Treatment - [128]
Hölz J, Nobile C, Holzapfel J et al.. “Cardiac surgery in an infant hemophilia B carrier with moderate hemophilia: a case report.” Frontiers in cardiovascular medicine (2026). PMID: 41929463 ↗
L4CASE_REPORTCited in: 5. Diagnosis & Workup - [129]
Pshenichnikova O, Salomashkina V, Yastrubinetskaya O et al.. “A Rare Case of Mild Hemophilia A in a Female with Mosaic Monosomy X and a De Novo F8 Variant.” International journal of molecular sciences (2025). PMID: 41465324 ↗
L4CASE_REPORTCited in: 5. Diagnosis & Workup - [130]
Turkkan E, Yapici O, Alaygut D. “A rare but misleading cause of hematuria in hemophilia A: renal pelvic hemorrhage mimicking tumor.” Pediatric nephrology (Berlin, Germany) (2026). PMID: 42370986 ↗
L4OTHERCited in: 5. Diagnosis & Workup, 8. Long-term & Definitive Management - [131]
Tiede A, Hofbauer CJ, Werwitzke S et al.. “Anti-factor VIII IgA as a potential marker of poor prognosis in acquired hemophilia A: results from the GTH-AH 01/2010 study.” Blood (2016). PMID: 26912467 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Prognosis & Natural History - [132]
Krudysz-Amblo J, Parhami-Seren B, Butenas S et al.. “Quantitation of anti-factor VIII antibodies in human plasma.” Blood (2009). PMID: 19144987 ↗
L5TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [133]
Li Z, Tang Y, Chen Z et al.. “Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40286913 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring, 11. Prognosis & Natural History - [134]
Funk SM, Engelen S, Benjamin K et al.. “Validity and reliability of the Colorado Adult Joint Assessment Scale in adults with moderate-severe hemophilia A.” Journal of thrombosis and haemostasis : JTH (2019). PMID: 31557391 ↗
L2TRIAL_NONRANDOMCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [135]
Germini F, Noronha N, Abraham Philip B et al.. “Risk factors for bleeding in people living with hemophilia A and B treated with regular prophylaxis: A systematic review of the literature.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35395700 ↗
L2SR_OBSCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [136]
Tiede A, Klamroth R, Scharf RE et al.. “Prognostic factors for remission of and survival in acquired hemophilia A (AHA): results from the GTH-AH 01/2010 study.” Blood (2014). PMID: 25525118 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [137]
Goedhart TMHJ, Bukkems LH, Zwaan CM et al.. “Population pharmacokinetic modeling of factor concentrates in hemophilia: an overview and evaluation of best practice.” Blood advances (2021). PMID: 34496017 ↗
L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring, 12. Special Populations & Prevention - [138]
Soldà G, Asselta R. “Applying artificial intelligence to uncover the genetic landscape of coagulation factors.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 39798926 ↗
L5REVIEW_NARRATIVECited in: 6. Staging, Risk Stratification & Prognostic Scoring - [139]
van Balen EC, Haverman L, Hassan S et al.. “Validation of PROMIS Profile-29 in adults with hemophilia in the Netherlands.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34245088 ↗
L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [140]
Schulman S, Eelde A, Holmström M et al.. “Validation of a composite score for clinical severity of hemophilia.” Journal of thrombosis and haemostasis : JTH (2008). PMID: 18466317 ↗
L4OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [141]
Jardim LL, Schieber TA, Santana MP et al.. “Prediction of inhibitor development in previously untreated and minimally treated children with severe and moderately severe hemophilia A using a machine-learning network.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38810700 ↗
L2OTHERCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [142]
Schep SJ, van Dijk WEM, Beckers EAM et al.. “Treatment of acquired hemophilia A, a balancing act: results from a 27-year Dutch cohort study.” American journal of hematology (2020). PMID: 32974947 ↗
L3COHORTCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [143]
Kempton CL, White GC. “How we treat a hemophilia A patient with a factor VIII inhibitor.” Blood (2008). PMID: 18820129 ↗
L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management, 10. Complications - [144]
Bou-Jaoudeh M, Mimoun A, Delignat S et al.. “Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37473843 ↗
L4OTHERCited in: 7. Acute & Emergency Management - [145]
Arya S, Siad FM, Wilton P et al.. “Invisible bleeds: Lived experiences and barriers to care for men with hemophilia.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 34689399 ↗
L4OTHERCited in: 7. Acute & Emergency Management - [146]
Xie X, Jiang S. “Corpus luteum hemorrhage with acquired hemophilia A: a case report and literature review.” BMC women's health (2022). PMID: 36221134 ↗
L4CASE_REPORTCited in: 7. Acute & Emergency Management - [147]
Yoon CW, Park HK, Rha JH. “A case report and experience of endovascular treatment for a patient with hemophilia who had a hyperacute ischemic stroke.” Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association (2020). PMID: 32389557 ↗
L4CASE_REPORTCited in: 7. Acute & Emergency Management - [148]
Horn EH, Forsyth K, Gooding R et al.. “Management of haemophilia and heritable bleeding disorders in the ED.” Emergency medicine journal : EMJ (2025). PMID: 40579048 ↗
L5REVIEW_NARRATIVECited in: 7. Acute & Emergency Management - [149]
Geller D, Budnik I, Barhod T et al.. “The Impact of Emicizumab Prophylaxis on Hospitalizations and Emergency Department Visits Among Hemophilia A Patients Is Age Related.” Pediatric blood & cancer (2024). PMID: 39582123 ↗
L3OTHERCited in: 7. Acute & Emergency Management - [150]
Xing S, Batt K, Kuharic M et al.. “Evaluation of clinical characteristics, health care resource utilization, and cost outcomes of hemophilia A carriers and noncarriers in the United States: A real-world comparative analysis.” Journal of managed care & specialty pharmacy (2023). PMID: 37276033 ↗
L3OTHERCited in: 7. Acute & Emergency Management - [151]
Callaghan MU, Negrier C, Paz-Priel I et al.. “Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies.” Blood (2021). PMID: 33512413 ↗
L2RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 12. Special Populations & Prevention - [152]
La Mura V, Cardinale V, De Cristofaro R et al.. “Liver-related aspects of valoctocogene roxaparvovec gene therapy for hemophilia A: expert guidance for clinical practice.” Blood advances (2024). PMID: 39226466 ↗
L5GUIDELINECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [153]
Mancuso ME, Chan AKC, Shanmukhaiah C et al.. “Mim8 Bispecific Antibody Prophylaxis in Hemophilia A with or without Inhibitors.” The New England journal of medicine (2026). PMID: 42054679 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [154]
Oldenburg J, Mahlangu JN, Kim B et al.. “Emicizumab Prophylaxis in Hemophilia A with Inhibitors.” The New England journal of medicine (2017). PMID: 28691557 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [155]
Matsushita T, Shapiro A, Abraham A et al.. “Phase 3 Trial of Concizumab in Hemophilia with Inhibitors.” The New England journal of medicine (2023). PMID: 37646676 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [156]
Mahlangu J, Oldenburg J, Paz-Priel I et al.. “Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors.” The New England journal of medicine (2018). PMID: 30157389 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [157]
Pasi KJ, Rangarajan S, Georgiev P et al.. “Targeting of Antithrombin in Hemophilia A or B with RNAi Therapy.” The New England journal of medicine (2017). PMID: 28691885 ↗
L4RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [158]
Matino D, Palladino A, Taylor CT et al.. “Marstacimab prophylaxis in hemophilia A/B without inhibitors: results from the phase 3 BASIS trial.” Blood (2025). PMID: 40608864 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [159]
Matino D, Acharya SS, Taylor CT et al.. “Efficacy and safety of marstacimab prophylaxis in hemophilia A/B with inhibitors: results from the phase 3 BASIS trial.” Blood (2026). PMID: 41351884 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [160]
Young G, Liesner R, Chang T et al.. “A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors.” Blood (2019). PMID: 31697801 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [161]
Pipe SW, Collins P, Dhalluin C et al.. “Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial.” Blood (2024). PMID: 38127586 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [162]
Mahlangu J, Boban A, Bruzelius M et al.. “Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study.” Blood advances (2026). PMID: 41499759 ↗
L1RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [163]
Ozelo MC, Mahlangu J, Pasi KJ et al.. “Valoctocogene Roxaparvovec Gene Therapy for Hemophilia A.” The New England journal of medicine (2022). PMID: 35294811 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [164]
Srivastava A, Abraham A, Aboobacker F et al.. “Lentiviral Gene Therapy with CD34+ Hematopoietic Cells for Hemophilia A.” The New England journal of medicine (2024). PMID: 39655790 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [165]
von Drygalski A, Chowdary P, Kulkarni R et al.. “Efanesoctocog Alfa Prophylaxis for Patients with Severe Hemophilia A.” The New England journal of medicine (2023). PMID: 36720133 ↗
L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 12. Special Populations & Prevention - [166]
Malec L, Peyvandi F, Chan AKC et al.. “Efanesoctocog Alfa Prophylaxis for Children with Severe Hemophilia A.” The New England journal of medicine (2024). PMID: 39018533 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 12. Special Populations & Prevention - [167]
Mahlangu J, Kaczmarek R, von Drygalski A et al.. “Two-Year Outcomes of Valoctocogene Roxaparvovec Therapy for Hemophilia A.” The New England journal of medicine (2023). PMID: 36812433 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [168]
George LA, Monahan PE, Eyster ME et al.. “Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A.” The New England journal of medicine (2021). PMID: 34788507 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [169]
Rezende SM, Neumann I, Angchaisuksiri P et al.. “International Society on Thrombosis and Haemostasis clinical practice guideline for treatment of congenital hemophilia A and B based on the Grading of Recommendations Assessment, Development, and Evaluation methodology.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39043543 ↗
L1GUIDELINECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [170]
Schimansky IM, Dobbelstein C, Klamroth R et al.. “Sustained survival benefit of emicizumab and postponed immunosuppression in acquired hemophilia A.” Blood advances (2025). PMID: 40795229 ↗
L2TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 10. Complications, 11. Prognosis & Natural History - [171]
Lissitchkov T, Willemze A, Katragadda S et al.. “Efanesoctocog alfa for hemophilia A: results from a phase 1 repeat-dose study.” Blood advances (2022). PMID: 34794179 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [172]
Agarwal S, Sandza K, Obrochta Moss K et al.. “Blood biodistribution and vector shedding of valoctocogene roxaparvovec in people with severe hemophilia A.” Blood advances (2024). PMID: 39024543 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [173]
Lentz SR, Chowdary P, Gil L et al.. “FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 38142846 ↗
L2RCTCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [174]
Deshpande SR, Joseph K, Tong J et al.. “Adeno-associated virus-based gene therapy for hemophilia A and B: a systematic review and meta-analysis.” Blood advances (2024). PMID: 39374576 ↗
L1SR_OBSCited in: 8. Long-term & Definitive Management - [175]
Madan B, Ozelo MC, Raheja P et al.. “Three-year outcomes of valoctocogene roxaparvovec gene therapy for hemophilia A.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38614387 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [176]
Shima M, Amano K, Ogawa Y et al.. “A prospective, multicenter, open-label phase III study of emicizumab prophylaxis in patients with acquired hemophilia A.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 36696195 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management, 10. Complications - [177]
Samelson-Jones BJ, Doshi BS, George LA. “Coagulation factor VIII: biological basis of emerging hemophilia A therapies.” Blood (2024). PMID: 39088776 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [178]
Weyand AC, Pipe SW. “New therapies for hemophilia.” Blood (2018). PMID: 30559264 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [179]
Franchini M, Lippi G. “Acquired factor VIII inhibitors.” Blood (2008). PMID: 18463353 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 11. Prognosis & Natural History - [180]
Perrin GQ, Herzog RW, Markusic DM. “Update on clinical gene therapy for hemophilia.” Blood (2018). PMID: 30559260 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Complications - [181]
Kempton CL, Meeks SL. “Toward optimal therapy for inhibitors in hemophilia.” Blood (2014). PMID: 25428222 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Complications - [182]
Callaghan MU, Sidonio R, Pipe SW. “Novel therapeutics for hemophilia and other bleeding disorders.” Blood (2018). PMID: 29769259 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [183]
Samelson-Jones BJ, Small JC, George LA. “Roctavian gene therapy for hemophilia A.” Blood advances (2024). PMID: 38991118 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [184]
Johnsen JM, Fletcher SN, Huston H et al.. “Novel approach to genetic analysis and results in 3000 hemophilia patients enrolled in the My Life, Our Future initiative.” Blood advances (2017). PMID: 29296726 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [185]
George LA. “Hemophilia gene therapy comes of age.” Blood advances (2017). PMID: 29296912 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [186]
Ragni MV, Mead H, de Jong YP et al.. “Optimizing liver health before and after gene therapy for hemophilia A.” Blood advances (2024). PMID: 38843379 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 10. Complications, 12. Special Populations & Prevention - [187]
Machin N, Ragni MV, Smith KJ. “Gene therapy in hemophilia A: a cost-effectiveness analysis.” Blood advances (2018). PMID: 30042145 ↗
L2OTHERCited in: 8. Long-term & Definitive Management - [188]
Mannucci PM. “Hemophilia therapy: the future has begun.” Haematologica (2020). PMID: 32060150 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [189]
Dargaud Y, Leuci A, Ruiz AR et al.. “Efanesoctocog alfa: the renaissance of Factor VIII replacement therapy.” Haematologica (2024). PMID: 38356459 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management - [190]
Sefiane T, McCluskey G, Clavel M et al.. “Consistent clinical factor VIII equivalency is unlikely for non-factor therapies in hemophilic mice.” Haematologica (2025). PMID: 40176760 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [191]
Miranda M, Hansen BE, Wehbi B et al.. “FVIII peptides presented on HLA-DP and identification of an A3 domain peptide binding with high affinity to the commonly expressed HLA-DP4.” Haematologica (2024). PMID: 39665218 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [192]
Loomans JI, Kruip MJHA, Carcao M et al.. “Desmopressin in moderate hemophilia A patients: a treatment worth considering.” Haematologica (2018). PMID: 29305412 ↗
L3OTHERCited in: 8. Long-term & Definitive Management - [193]
Ringler E, Iannazzo SO, Herzig J et al.. “Complement protein C3a enhances adaptive immune responses towards FVIII products.” Haematologica (2023). PMID: 36727395 ↗
L5OTHERCited in: 8. Long-term & Definitive Management, 10. Complications - [194]
Martorell L, Cortina V, Parra R et al.. “Variable readthrough responsiveness of nonsense mutations in hemophilia A.” Haematologica (2020). PMID: 31197069 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [195]
Chaves DG, Velloso-Rodrigues C, Moreau V et al.. “Reactivity profile of anti-factor VIII antibodies with designed synthetic peptides mimicking epitopes of the C2 and a1 domains.” British journal of haematology (2008). PMID: 18422780 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [196]
van Helden PM, van den Berg HM, Gouw SC et al.. “IgG subclasses of anti-FVIII antibodies during immune tolerance induction in patients with hemophilia A.” British journal of haematology (2008). PMID: 18510679 ↗
L2OTHERCited in: 8. Long-term & Definitive Management - [197]
Lyde R, Sabatino D, Sullivan SK et al.. “Platelet-delivered therapeutics.” Journal of thrombosis and haemostasis : JTH (2015). PMID: 26149015 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [198]
Franchini M, Favaloro EJ, Lippi G. “Mild hemophilia A.” Journal of thrombosis and haemostasis : JTH (2009). PMID: 19995408 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment, 11. Prognosis & Natural History - [199]
Teranishi-Ikawa Y, Soeda T, Koga H et al.. “A bispecific antibody NXT007 exerts a hemostatic activity in hemophilia A monkeys enough to keep a nonhemophilic state.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37940048 ↗
L5OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [200]
Johnsen JM, Fletcher SN, Dove A et al.. “Results of genetic analysis of 11 341 participants enrolled in the My Life, Our Future hemophilia genotyping initiative in the United States.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35770352 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [201]
Valentino LA, Kaczmarek R, Pierce GF et al.. “Hemophilia gene therapy: first, do no harm.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37353081 ↗
L5REVIEW_NARRATIVECited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [202]
Leavitt AD, Mahlangu J, Raheja P et al.. “Durability of efficacy, safety, and quality of life 5 years after valoctocogene roxaparvovec gene transfer for severe hemophilia A: final phase 3 GENEr8-1 trial results.” Research and practice in thrombosis and haemostasis (2026). PMID: 42064204 ↗
L4TRIAL_NONRANDOMCited in: 8. Long-term & Definitive Management - [203]
Sternberg AR, Watson CT, Davidson RJ et al.. “One-stage Assay Factor VIII Activity Reflects AAV-Derived Factor VIII-Enhanced Thrombin Activation and Predicts Phenotype.” Blood (2026). PMID: 42371804 ↗
L4OTHERCited in: 8. Long-term & Definitive Management - [204]
Young G, Angchaisuksiri P, Apte SJ et al.. “Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.” Blood advances (2026). PMID: 42341325 ↗
L1OTHERCited in: 8. Long-term & Definitive Management, History and Evolution of Treatment - [205]
Matino D, Acharya SS, Taylor CT et al.. “A plain language summary of the BASIS study looking at people living with severe hemophilia A or B with inhibitors and being treated with marstacimab.” Therapeutic advances in hematology (2026). PMID: 42311704 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [206]
Fouda RT, Argueta DA, Goel Y et al.. “Characterization of a mouse model to study mechanisms of hemophilia A pain.” Blood advances (2026). PMID: 42295153 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [207]
Minno GD, Spadarella G, Borchiellini A et al.. “Italian Patients Journey for Gene Therapy in Haemophilia A.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42290228 ↗
L5OTHERCited in: 8. Long-term & Definitive Management - [208]
Foley JH, Petersen KU, Rea CJ et al.. “Solulin increases clot stability in whole blood from humans and dogs with hemophilia.” Blood (2012). PMID: 22234684 ↗
L5TRIAL_NONRANDOMCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [209]
Santagata D, Abenante A, Squizzato A et al.. “Rates of venous thromboembolism and use of thromboprophylaxis after major orthopedic surgery in patients with congenital hemophilia A or B: a systematic review.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38215910 ↗
L2SR_OBSCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 10. Complications, 11. Prognosis & Natural History, 12. Special Populations & Prevention - [210]
Federici AB, Santagostino E, Rumi MG et al.. “The natural history of hepatitis C virus infection in Italian patients with von Willebrand's disease: a cohort study.” Haematologica (2006). PMID: 16585016 ↗
L2COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), History and Evolution of Treatment, 10. Complications, 11. Prognosis & Natural History - [211]
Martin K, Key NS. “How I treat patients with inherited bleeding disorders who need anticoagulant therapy.” Blood (2016). PMID: 27106121 ↗
L5REVIEW_NARRATIVECited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [212]
Jiang M, Yang F, Jiang Y et al.. “Safety and efficacy of an anti-human APC antibody for prophylaxis of congenital factor deficiencies in preclinical models.” Blood (2023). PMID: 37294924 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [213]
Aymonnier K, Kawecki C, Venisse L et al.. “Targeting protease nexin-1, a natural anticoagulant serpin, to control bleeding and improve hemostasis in hemophilia.” Blood (2019). PMID: 31383642 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [214]
Chen Y, Schroeder JA, Chen J et al.. “The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunity.” Blood (2015). PMID: 26668132 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [215]
Ragni MV. “Platelet VIII pack evades immune detection.” Blood (2016). PMID: 26965921 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [216]
Greene TK, Wang C, Hirsch JD et al.. “In vivo efficacy of platelet-delivered, high specific activity factor VIII variants.” Blood (2010). PMID: 20852129 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [217]
Neyman M, Gewirtz J, Poncz M. “Analysis of the spatial and temporal characteristics of platelet-delivered factor VIII-based clots.” Blood (2008). PMID: 18559671 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [218]
Shi Q, Kuether EL, Chen Y et al.. “Platelet gene therapy corrects the hemophilic phenotype in immunocompromised hemophilia A mice transplanted with genetically manipulated human cord blood stem cells.” Blood (2013). PMID: 24269957 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [219]
Rivas-Pollmar MI, Álvarez-Román MT, Butta-Coll NV et al.. “Thromboprophylaxis in a patient with COVID-19 and severe hemophilia A on emicizumab prophylaxis.” Journal of thrombosis and haemostasis : JTH (2020). PMID: 32526092 ↗
L4CASE_REPORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management), 10. Complications - [220]
Gao C, Schroeder JA, Xue F et al.. “Nongenotoxic antibody-drug conjugate conditioning enables safe and effective platelet gene therapy of hemophilia A mice.” Blood advances (2019). PMID: 31515232 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [221]
Haribhai D, Luo X, Chen J et al.. “TGF-β1 along with other platelet contents augments Treg cells to suppress anti-FVIII immune responses in hemophilia A mice.” Blood advances (2016). PMID: 28164173 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [222]
Locke M, Albiez J, Receveur N et al.. “Next-generation FVIIIa-mimetic bispecific antibody NXT007: evaluation in preclinical models of hemostasis and thrombosis.” Blood advances (2026). PMID: 41269788 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [223]
Joo JH, Wang X, Singh S et al.. “Intraosseous delivery of platelet-targeted factor VIII lentiviral vector in humanized NBSGW mice.” Blood advances (2022). PMID: 35849710 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [224]
Wang X, Fu RY, Li C et al.. “Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice.” Blood advances (2020). PMID: 33216891 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [225]
Zhang E, Virk ZM, Rodriguez-Lopez J et al.. “Hereditary hemorrhagic telangiectasia may be the most morbid inherited bleeding disorder in women.” Blood advances (2024). PMID: 38593443 ↗
L2OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [226]
Childers KC, Peters SC, Lollar P et al.. “SAXS analysis of the intrinsic tenase complex bound to a lipid nanodisc highlights intermolecular contacts between factors VIIIa/IXa.” Blood advances (2022). PMID: 35255502 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [227]
Yu H, Schroeder JA, Mattson JG et al.. “Impact of antiplatelet therapy on the hemostatic efficacy of platelet-targeted FVIII gene therapy in hemophilia A mice.” Blood advances (2026). PMID: 41529228 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [228]
Abache T, Fontayne A, Grenier D et al.. “A mutated factor X activatable by thrombin corrects bleedings in vivo in a rabbit model of antibody-induced hemophilia A.” Haematologica (2020). PMID: 33054058 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [229]
Swieringa F, Kuijpers MJ, Lamers MM et al.. “Rate-limiting roles of the tenase complex of factors VIII and IX in platelet procoagulant activity and formation of platelet-fibrin thrombi under flow.” Haematologica (2015). PMID: 25769543 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [230]
Eladnani RP, Schaeper U, Diab R et al.. “Enhancing hemostasis potency in hemophilia with a small interfering ribonucleic acid targeting protein S.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40154791 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [231]
Jewell MP, Ashour Z, Baird CH et al.. “Concizumab improves clot formation in hemophilia A under flow.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38815755 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [232]
Desage S, Lienhart A, Janbain M et al.. “Discrepancy between one-stage clotting and chromogenic factor VIII activity in women with hemophilia A and hemophilia A carriers: a retrospective clinical study.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40056988 ↗
L4OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [233]
Chen Y, Li J, Schroeder JA et al.. “Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39127324 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [234]
Childers KC, Peters SC, Spiegel PC. “Structural insights into blood coagulation factor VIII: Procoagulant complexes, membrane binding, and antibody inhibition.” Journal of thrombosis and haemostasis : JTH (2022). PMID: 35722946 ↗
L5REVIEW_NARRATIVECited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [235]
Ju Y, Jiang W, Liu H et al.. “Perioperative Hematological Outcomes of Simultaneous Double Total Joint Arthroplasty for Hemophilic Arthritis of the Hip and Knee: A Retrospective Study.” The Journal of arthroplasty (2024). PMID: 39622424 ↗
L4COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [236]
Zhang Q, Zhao L, Riva N et al.. “Incidence of deep venous thrombosis in patients with hemophilia undergoing bilateral simultaneous total knee arthroplasty: a retrospective cohort study.” BMC musculoskeletal disorders (2024). PMID: 38658972 ↗
L2COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [237]
Pacheco Zavala E, Vargas Oliva C, Santibañez Bedolla KE et al.. “Adult People with Hemophilia A Have Low Annualized Bleeding Rate, However the Arthropathy Remains a Burden: A Retrospective Cohort Study.” Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion (2024). PMID: 39011249 ↗
L4COHORTCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [238]
Kraemmer D, Ay C, Rejtő J et al.. “Comparison of People with Hemophilia A and Patients with Nonvalvular Atrial Fibrillation on Oral Anticoagulation by Thrombin Generation.” Thrombosis and haemostasis (2026). PMID: 42190734 ↗
L4OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [239]
Bosch A, Alberio L, Fontana P et al.. “The Swiss Haemophilia Registry-Report From the First 8 Years.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42012793 ↗
L2OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [240]
Sidonio RF, Corrales-Medina FF, Johnsen JM et al.. “Prophylaxis for von Willebrand disease: Is it time for parity with established practice in hemophilia A?” Therapeutic advances in hematology (2026). PMID: 41947822 ↗
L5REVIEW_NARRATIVECited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [241]
Steeghs TJ, van Engelshoven L, Coolen NMM et al.. “A chemiluminescent microfluidic thrombin generation assay for real-time monitoring in patient plasma.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41692093 ↗
L5OTHERCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [242]
Kumar R, Dunn AL, Schneiderman JE et al.. “Moderate-intensity aerobic exercise vs desmopressin in adolescent males with mild hemophilia A: a randomized trial.” Blood (2022). PMID: 35839450 ↗
L1RCTCited in: History and Evolution of Treatment - [243]
Klamroth R, Windyga J, Radulescu V et al.. “Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.” Blood (2021). PMID: 33150384 ↗
L1RCTCited in: History and Evolution of Treatment - [244]
Shapiro AD, Angchaisuksiri P, Astermark J et al.. “Subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors: phase 2 trial results.” Blood (2019). PMID: 31444162 ↗
L2RCTCited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [245]
Mahlangu J, Powell JS, Ragni MV et al.. “Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A.” Blood (2013). PMID: 24227821 ↗
L1RCTCited in: History and Evolution of Treatment - [246]
Leissinger C, Gringeri A, Antmen B et al.. “Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors.” The New England journal of medicine (2011). PMID: 22047559 ↗
L1RCTCited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [247]
Konkle BA, Stasyshyn O, Chowdary P et al.. “Pegylated, full-length, recombinant factor VIII for prophylactic and on-demand treatment of severe hemophilia A.” Blood (2015). PMID: 26157075 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [248]
Lusher JM, Arkin S, Abildgaard CF et al.. “Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and development of inhibitors. Kogenate Previously Untreated Patient Study Group.” The New England journal of medicine (1993). PMID: 8421474 ↗
L4TRIAL_NONRANDOMCited in: History and Evolution of Treatment - [249]
Di Minno MND, Calcaterra IL, Baldacci E et al.. “Intensive FVIII replacement in hemophilia patients with hypertrophic synovium: a randomized study.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39476971 ↗
L1RCTCited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [250]
High KA. “The gene therapy journey for hemophilia: are we there yet?” Blood (2012). PMID: 22829631 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [251]
van Stam LE, Daisy Horstman BJ, Angchaisuksiri P et al.. “The MAPTO survey: worldwide approaches on unmasking factor VIII inhibitors in children with emicizumab treatment: communication from the ISTH SSC Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41643940 ↗
L4GUIDELINECited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [252]
Srivaths L, Larson J, Fijnvandraat K et al.. “Chromogenic vs one-stage assay to diagnose women and girls with hemophilia A-mapping global approaches and assessing challenges: communication from the SSCs of the ISTH.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40374114 ↗
L4GUIDELINECited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [253]
Alcedo Andrade PE, Mannucci PM, Kessler CM. “Emicizumab: the hemophilia A game-changer.” Haematologica (2024). PMID: 37916312 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment - [254]
Batty P, Lillicrap D. “Adeno-associated viral vector integration: implications for long-term efficacy and safety.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39097231 ↗
L5REVIEW_NARRATIVECited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [255]
Mokhtar G, El-Beshlawy A, Alfy ME et al.. “Updated Egyptian national guidelines for management of hemophilia A in children & adolescents.” Annals of hematology (2025). PMID: 41065813 ↗
L5GUIDELINECited in: History and Evolution of Treatment - [256]
de Biasi R, Miraglia E, Mastrullo L et al.. “Kaposi's sarcoma as clinical manifestation of the acquired immunodeficiency syndrome in a hemophilic patient.” Haematologica (1989). PMID: 2511103 ↗
L4CASE_REPORTCited in: History and Evolution of Treatment - [257]
Krumb E, Lambert C, Van Damme A et al.. “Proactive systematic hemophilia carrier screening: a step toward gender equity in hemophilia care.” Blood advances (2024). PMID: 39167764 ↗
L2OTHERCited in: History and Evolution of Treatment, 12. Special Populations & Prevention - [258]
Schweiger H, Rejtő J, Hofbauer CJ et al.. “Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors.” Blood advances (2022). PMID: 34847225 ↗
L3OTHERCited in: History and Evolution of Treatment, 10. Complications - [259]
Agosti P, Siboni SM, Scardo S et al.. “Minimum factor VIII levels to prevent joint bleeding in mild hemophilia A.” Blood advances (2023). PMID: 37871302 ↗
L3OTHERCited in: History and Evolution of Treatment - [260]
Merlin S, Famà R, Borroni E et al.. “FVIII expression by its native promoter sustains long-term correction avoiding immune response in hemophilic mice.” Blood advances (2019). PMID: 30862611 ↗
L2OTHERCited in: History and Evolution of Treatment - [261]
Kim B, Song J, Kang J et al.. “A first-in-human study assessing the safety, pharmacokinetics, and pharmacodynamics of TU7710, a recombinant factor VIIa-transferrin fusion protein, in warfarin-pretreated healthy male participants.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41651288 ↗
L1RCTCited in: History and Evolution of Treatment - [262]
Tiede A, Abdul Karim F, Jiménez-Yuste V et al.. “Factor VIII activity and bleeding risk during prophylaxis for severe hemophilia A: a population pharmacokinetic model.” Haematologica (2021). PMID: 32327501 ↗
L2OTHERCited in: History and Evolution of Treatment - [263]
Astermark J, Oldenburg J, Escobar M et al.. “The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.” Haematologica (2005). PMID: 15996930 ↗
L3OTHERCited in: History and Evolution of Treatment - [264]
Abrantes JA, Solms A, Garmann D et al.. “Relationship between factor VIII activity, bleeds and individual characteristics in severe hemophilia A patients.” Haematologica (2019). PMID: 31371418 ↗
L2OTHERCited in: History and Evolution of Treatment - [265]
Melchiorre D, Linari S, Manetti M et al.. “Clinical, instrumental, serological and histological findings suggest that hemophilia B may be less severe than hemophilia A.” Haematologica (2015). PMID: 26494839 ↗
L3OTHERCited in: History and Evolution of Treatment - [266]
Lorenzo JI, Moscardó F, López-Aldeguer J et al.. “Progression to acquired immunodeficiency syndrome in 94 human immunodeficiency virus-positive hemophiliacs with long-term follow-up.” Haematologica (2001). PMID: 11357820 ↗
L2OTHERCited in: History and Evolution of Treatment - [267]
Quon DV, Escobar M, Boggio L et al.. “A New Risk-Based Scoring Approach to Individualize Prophylaxis in Patients with Hemophilia A: Results from the PREDICT Study.” Advances in therapy (2026). PMID: 41886249 ↗
L2TRIAL_NONRANDOMCited in: History and Evolution of Treatment, 11. Prognosis & Natural History - [268]
Makkar M, Dhinakaran MS, Shukla P et al.. “Effectiveness of myofascial therapy (MFT) along with traditional physiotherapy and intermittent prophylaxis on short-term improvement of joint health in hemophilic arthropathy: a randomized control trial.” Expert review of hematology (2025). PMID: 40249018 ↗
L1RCTCited in: History and Evolution of Treatment - [269]
Carcao M, Schiavulli M, Kulkarni R et al.. “A post hoc analysis of previously untreated patients with severe hemophilia A who developed inhibitors in the PUPs A-LONG trial.” Blood advances (2024). PMID: 38266154 ↗
L1TRIAL_NONRANDOMCited in: 10. Complications - [270]
Carlson AL, Althouse J, Ahmed N et al.. “Acquired hemophilia A following SARS-CoV-2 infection and vaccination: clinical summary and insights.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41110512 ↗
L1SR_OBSCited in: 10. Complications - [271]
Hay CRM, Nissen F, Pipe SW. “Mortality in congenital hemophilia A - a systematic literature review.” Journal of thrombosis and haemostasis : JTH (2021). PMID: 33331043 ↗
L1SR_OBSCited in: 10. Complications, 11. Prognosis & Natural History - [272]
Muczynski V, Christophe OD, Tanner L et al.. “Alternative AAV gene therapy for hemophilia A using expression of Bi8, a novel single-chain FVIII-mimetic antibody.” Blood (2025). PMID: 40983037 ↗
L2OTHERCited in: 10. Complications - [273]
Lai J, Hough C, Tarrant J et al.. “Biological considerations of plasma-derived and recombinant factor VIII immunogenicity.” Blood (2017). PMID: 28432221 ↗
L5REVIEW_NARRATIVECited in: 10. Complications - [274]
Pratt KP, Gunasekera D, Vir P et al.. “Anti-FVIII antibodies in Black and White hemophilia A subjects: do F8 haplotypes play a role?” Blood advances (2023). PMID: 36459498 ↗
L3OTHERCited in: 10. Complications - [275]
Vander Kooi A, Wang S, Fan MN et al.. “Influence of N-glycosylation in the A and C domains on the immunogenicity of factor VIII.” Blood advances (2022). PMID: 35511725 ↗
L3OTHERCited in: 10. Complications - [276]
Lai JD, Swystun LL, Cartier D et al.. “N-linked glycosylation modulates the immunogenicity of recombinant human factor VIII in hemophilia A mice.” Haematologica (2018). PMID: 30002126 ↗
L5OTHERCited in: 10. Complications - [277]
Peyron I, Hartholt RB, Pedró-Cos L et al.. “Comparative profiling of HLA-DR and HLA-DQ associated factor VIII peptides presented by monocyte-derived dendritic cells.” Haematologica (2017). PMID: 29025906 ↗
L5OTHERCited in: 10. Complications - [278]
Rayes J, Ing M, Delignat S et al.. “Complement C3 is a novel modulator of the anti-factor VIII immune response.” Haematologica (2017). PMID: 29146705 ↗
L5OTHERCited in: 10. Complications - [279]
Famà R, Borroni E, Merlin S et al.. “Deciphering the Ets-1/2-mediated transcriptional regulation of F8 gene identifies a minimal F8 promoter for hemophilia A gene therapy.” Haematologica (2021). PMID: 32467137 ↗
L5OTHERCited in: 10. Complications - [280]
Chen L, Lin S, Zhou W et al.. “Prosthesis survival situation and complications following total hip arthroplasty in hemophilic patients: a systematic review.” BMC musculoskeletal disorders (2025). PMID: 40634963 ↗
L2SR_OBSCited in: 10. Complications - [281]
Rungjirajittranon T, Suwanawiboon B, Nakkinkun Y et al.. “First-line immunosuppressive therapies for acquired hemophilia A: A 25-year cohort experience and network meta-analysis.” Thrombosis research (2024). PMID: 38970991 ↗
L2SR_OBSCited in: 10. Complications - [282]
Sun C, Yu J, Sun J et al.. “Case Report: Coexisting cold agglutinin disease and acquired hemophilia A: a rituximab-responsive dual autoimmune disorder.” Frontiers in medicine (2025). PMID: 41179883 ↗
L4CASE_REPORTCited in: 10. Complications - [283]
Laan S, Del Castillo Alferez J, Cannegieter S et al.. “DDAVP response and its determinants in bleeding disorders: a systematic review and meta-analysis.” Blood (2025). PMID: 39854691 ↗
L1SR_OBSCited in: 11. Prognosis & Natural History, 12. Special Populations & Prevention - [284]
Tagariello G, Iorio A, Santagostino E et al.. “Comparison of the rates of joint arthroplasty in patients with severe factor VIII and IX deficiency: an index of different clinical severity of the 2 coagulation disorders.” Blood (2009). PMID: 19357395 ↗
L2SR_OBSCited in: 11. Prognosis & Natural History - [285]
Kraemmer D, Königsbrügge O, Moik F et al.. “Pharmacokinetic-guided versus standard prophylaxis in hemophilia: a systematic review and meta-analysis.” Journal of thrombosis and haemostasis : JTH (2023). PMID: 37739039 ↗
L2SR_OBSCited in: 11. Prognosis & Natural History, 12. Special Populations & Prevention - [286]
Leebeek FWG, Miesbach W. “Gene therapy for hemophilia: a review on clinical benefit, limitations, and remaining issues.” Blood (2021). PMID: 34232980 ↗
L5REVIEW_NARRATIVECited in: 11. Prognosis & Natural History - [287]
Glaeser-Khan S, Ito S, Sra M et al.. “Emicizumab for preventing intracranial hemorrhage in infants with severe hemophilia A: a cost-effectiveness analysis.” Blood advances (2025). PMID: 40795232 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [288]
Lim MY, Cheng D, Recht M et al.. “Inhibitors and mortality in persons with nonsevere hemophilia A in the United States.” Blood advances (2020). PMID: 33007074 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [289]
Hassan S, Baselli G, Mollica L et al.. “Predicting inhibitor development using a random peptide phage-display library approach in the SIPPET cohort.” Blood advances (2024). PMID: 38593222 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [290]
Fischer K, Pouw ME, Lewandowski D et al.. “A modeling approach to evaluate long-term outcome of prophylactic and on demand treatment strategies for severe hemophilia A.” Haematologica (2011). PMID: 21273268 ↗
L2OTHERCited in: 11. Prognosis & Natural History - [291]
Zou M, Zhan K, Feng X et al.. “Autoimmune Bullous Disease Combined With Acquired Hemophilia A: A Systematic Review and Case Analysis.” The Journal of dermatology (2025). PMID: 40325518 ↗
L4SR_OBSCited in: 11. Prognosis & Natural History - [292]
BaHeTe A, Shao Y, Kang P. “Clinical outcomes of total hip and knee arthroplasty for end-stage hemophilic arthropathy in patients with hemophilia: a retrospective study.” Journal of orthopaedic surgery and research (2025). PMID: 40420097 ↗
L4COHORTCited in: 11. Prognosis & Natural History - [293]
Swystun LL, Ogiwara K, Rawley O et al.. “Genetic determinants of VWF clearance and FVIII binding modify FVIII pharmacokinetics in pediatric hemophilia A patients.” Blood (2019). PMID: 31350267 ↗
L2TRIAL_NONRANDOMCited in: 12. Special Populations & Prevention - [294]
Escobar M, Lassila R, Bekdache C et al.. “Use of antithrombotic therapy in patients with hemophilia: a selected synopsis of the European Hematology Association - International Society on Thrombosis and Haemostasis - European Association for Hemophilia and Allied Disorders - European Stroke Organization Clinical Practice Guidance document.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39571935 ↗
L1GUIDELINECited in: 12. Special Populations & Prevention - [295]
Malec L, Mathias M, Dunn AL et al.. “Post hoc analysis of bleeding episodes and clinically relevant pharmacokinetic parameters among children <12 years old with severe hemophilia A receiving once-weekly efanesoctocog alfa prophylaxis in the XTEND-Kids phase 3 multinational trial.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40701256 ↗
L2TRIAL_NONRANDOMCited in: 12. Special Populations & Prevention - [296]
Leebeek FWG, Duvekot J, Kruip MJHA. “How I manage pregnancy in carriers of hemophilia and patients with von Willebrand disease.” Blood (2020). PMID: 32797211 ↗
L5CASE_REPORTCited in: 12. Special Populations & Prevention - [297]
Shapiro AD. “Concizumab: a novel anti-TFPI therapeutic for hemophilia.” Blood advances (2021). PMID: 33570646 ↗
L5OTHERCited in: 12. Special Populations & Prevention - [298]
Oleshko O, Werwitzke S, Klingberg A et al.. “Targets of autoantibodies in acquired hemophilia A are not restricted to factor VIII: data from the GTH-AH 01/2010 study.” Blood advances (2023). PMID: 35947142 ↗
L3OTHERCited in: 12. Special Populations & Prevention - [299]
Kurnik K, Kreuz W, Horneff S et al.. “Effects of the factor V G1691A mutation and the factor II G20210A variant on the clinical expression of severe hemophilia A in children--results of a multicenter studys.” Haematologica (2007). PMID: 17606451 ↗
L2OTHERCited in: 12. Special Populations & Prevention - [300]
Russick J, Delignat S, Milanov P et al.. “Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.” Haematologica (2019). PMID: 31289204 ↗
L5OTHERCited in: 12. Special Populations & Prevention - [301]
Sherief LM, Elagamy O, Darwish A et al.. “Emicizumab prophylaxis beyond clinical trials: a multicenter, prospective real-world study of pediatric hemophilia patients with and without inhibitors.” European journal of pediatrics (2026). PMID: 41964698 ↗
L4TRIAL_NONRANDOMCited in: 12. Special Populations & Prevention - [302]
Carcao M, Königs C, Andersson NG et al.. “Predictors of immune tolerance induction success in 231 children with severe hemophilia A with high-titer inhibitors - lessons learned from the PedNet prospective cohort study.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 40706963 ↗
L2COHORTCited in: 12. Special Populations & Prevention - [303]
Suita N, Kanemaru A, Komori N et al.. “Role of cross-mixing tests in differentiating etiologies of prolonged aPTT: a single-center retrospective study.” International journal of hematology (2026). PMID: 42204127 ↗
L4COHORTCited in: 12. Special Populations & Prevention - [304]
Wilson RD, De Bie I, Armour CM et al.. “Joint SOGC-CCMG Opinion for Reproductive Genetic Carrier Screening: An Update for All Canadian Providers of Maternity and Reproductive Healthcare in the Era of Direct-to-Consumer Testing.” Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC (2016). PMID: 27638987 ↗
L1bCited in: 1. Definition, Classification & Nomenclature - [305]
Rosas S, Buller LT, Plate J et al.. “Total Knee Arthroplasty among Medicare Beneficiaries with Hemophilia A and B Is Associated with Increased Complications and Higher Costs.” The journal of knee surgery (2019). PMID: 31499568 ↗
L3bCited in: 1. Definition, Classification & Nomenclature - [306]
Omura K, Tsuchiya S. “The Patient Experience of Hemophilia and Human Immunodeficiency Virus: A Systematic Review of Qualitative Evidence.” JBI library of systematic reviews (2012). PMID: 27820530 ↗
L1aCited in: 1. Definition, Classification & Nomenclature - [307]
Al Moosawi M, Nicolson H, Wong SKW et al.. “Treatment changes in hemophilia A with chromogenic factor VIII assay implementation.” Research and practice in thrombosis and haemostasis (2023). PMID: 37063773 ↗
L3bCited in: 1. Definition, Classification & Nomenclature - [308]
Rodeghiero F, Ghiotto L, Pontalto L et al.. “Mild or moderate hemophilia is not always a mild or moderate bleeding disorder: Back to the clinical phenotype.” HemaSphere (2025). PMID: 40134524 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [309]
Dushimova Z, Pashimov M, Kaibullayeva J et al.. “Therapeutic advances in hemophilia: from molecular innovation to patient-centered global care.” Frontiers in medicine (2025). PMID: 41080961 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [310]
Ramiz S, Hartmann J, Young G et al.. “Clinical utility of viscoelastic testing (TEG and ROTEM analyzers) in the management of old and new therapies for hemophilia.” American journal of hematology (2018). PMID: 30328141 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [311]
Hirniak S, Samuel C, Aditi F et al.. “Symptoms, Diagnosis, and Treatment for Women and Girls With Hemophilia: A Narrative Review.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42438295 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [312]
Payne AB, Miller CH, Kelly FM et al.. “The CDC Hemophilia A Mutation Project (CHAMP) mutation list: a new online resource.” Human mutation (2012). PMID: 23280990 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [313]
Alexander WA, Jensen I, Hathway J et al.. “Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.” Journal of managed care & specialty pharmacy (2022). PMID: 35343812 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [314]
Punj S, Akkari Y, Huang J et al.. “Preconception Carrier Screening by Genome Sequencing: Results from the Clinical Laboratory.” American journal of human genetics (2018). PMID: 29754767 ↗
L5Cited in: 1. Definition, Classification & Nomenclature - [315]
Cygan PH, Weidman EA, Wang X et al.. “Integrative modeling to improve bleeding risk prediction in adult female hemophilia A carriers.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41679506 ↗
L3bCited in: 2. Pathophysiology & Mechanism - [316]
Huang YC, Wang WL, Lin HY et al.. “Genotype-Specific Postural Control Deficits in Hemophilia A: Insights from Center of Pressure Analysis Beyond Radiographic Arthropathy.” International journal of molecular sciences (2026). PMID: 41828546 ↗
L4Cited in: 2. Pathophysiology & Mechanism - [317]
Marco-Rico A, Calvo-Villas JM, López-Jaime FJ et al.. “Real-World Evidence on Joint Condition in Non-Severe Hemophilia A Patients: A Multicenter Study.” Journal of blood medicine (2025). PMID: 40417706 ↗
L4Cited in: 2. Pathophysiology & Mechanism - [318]
Måseide RJ, Berntorp E, Astermark J et al.. “Nonneutralizing antibodies in Nordic persons with moderate hemophilia A and B (the MoHem study).” Research and practice in thrombosis and haemostasis (2024). PMID: 39807249 ↗
L3bCited in: 2. Pathophysiology & Mechanism - [319]
Lin SY, Chen M, Chang SP et al.. “Non-Inversion Variants in Sporadic Hemophilia A Rarely Recur.” International journal of molecular sciences (2026). PMID: 42123421 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [320]
Zhou Y, Shen Y, Yao SX et al.. “Pioglitazone and metformin attenuate hemophilic arthropathy progression via peroxisome proliferator-activated receptor signaling pathway activation.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42107709 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [321]
Hemaliya C, Singh AK, Bharti A et al.. “Molecular Characterization of Factor VIII Gene Variants in Hemophilia A: A Genotype-Haplotype Study from Eastern and Northern-Central India.” Nanotheranostics (2026). PMID: 42099969 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [322]
Kao YT, Yen CC, Ro-Lin Chang G et al.. “Non-viral gene therapy for hemophilia A: long-term outcomes of minicircle FVIII delivery in a mouse model.” Frontiers in pharmacology (2026). PMID: 42038313 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [323]
Avishai E, Dardik R, Rubinstein L et al.. “Deleterious NKAP Mutations Are Associated with Musculoskeletal Abnormalities in Hemizygous Males and Skewed X Chromosome Inactivation in Heterozygous Females.” International journal of molecular sciences (2026). PMID: 41828556 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [324]
Contente S, Ahmed AE, Konkle BA et al.. “Human leukocyte antigen alleles associated with inhibitor development in severe hemophilia A: analysis of the "My Life, Our Future" hemophilia A cohort.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41644240 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [325]
Manderstedt E, Lind-Halldén C, Halldén C et al.. “Noncarrier mothers of hemophilia A patients with Intron 22 inversions often have other rearrangements.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41500367 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [326]
Liu Z, Srivastava V, Hussain A et al.. “Ribosomal read through as an alternative therapy for patients with hemophilia with nonsense mutations.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41083003 ↗
L5Cited in: 2. Pathophysiology & Mechanism - [327]
de Vaan A, Kruip MJHA, Eikenboom J et al.. “Enhanced peripartum hemostatic management does not decrease postpartum hemorrhage incidence in hemophilia carriers: the Pregnancy and Inherited Bleeding Disorders study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 41796747 ↗
L2bCited in: 3. Epidemiology, Etiology & Risk Factors - [328]
Mahlangu J, Matino D, Benítez Hidalgo O et al.. “Management of breakthrough bleeds and surgical procedures in participants with hemophilia A or B without inhibitors receiving marstacimab prophylaxis in the phase 3 BASIS study.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42107711 ↗
L2bCited in: 3. Epidemiology, Etiology & Risk Factors - [329]
da Conceição Bezerra AF, Batista-Rodrigues YK, Rezende SM et al.. “The role of interleukin-10 gene variants in inhibitor development in hemophilia: A meta-analysis.” Thrombosis research (2025). PMID: 40815904 ↗
L2aCited in: 3. Epidemiology, Etiology & Risk Factors - [330]
Ma S, Sun Y, Zhou W et al.. “Lipopolysaccharide-binding protein functions as factor VIII inhibitor in bullous pemphigoid associated with acquired hemophilia A.” Archives of dermatological research (2025). PMID: 40095178 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [331]
Ay Tuncel D, Şaşmaz Hİ, Antmen B. “Outcome and Predisposing Factors for Intracranial Hemorrhage in Turkish Children with Hemophilia.” Journal of clinical medicine (2025). PMID: 39941359 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [332]
Mrakotsky C, Walsh KS, Buranahirun Burns C et al.. “The eTHINK Study: Cognitive and Behavioral Outcomes in Children with Hemophilia.” The Journal of pediatrics (2024). PMID: 38734133 ↗
L3bCited in: 3. Epidemiology, Etiology & Risk Factors - [333]
Jiménez-Yuste V, Oldenburg J, Tzeng E et al.. “Emicizumab is efficacious in people with hemophilia A with comorbidities aged ≥50 years: analysis of 4 phase III trials.” Research and practice in thrombosis and haemostasis (2024). PMID: 38783987 ↗
L2bCited in: 3. Epidemiology, Etiology & Risk Factors - [334]
Olasupo OO, Noronha N, Lowe MS et al.. “Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.” The Cochrane database of systematic reviews (2026). PMID: 41873813 ↗
L1aCited in: 3. Epidemiology, Etiology & Risk Factors - [335]
Olasupo OO, Noronha N, Lowe MS et al.. “Non-clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B.” The Cochrane database of systematic reviews (2024). PMID: 38411279 ↗
L1aCited in: 3. Epidemiology, Etiology & Risk Factors - [336]
Bordbar M, Beigipour R, Tahami M et al.. “Skeletal complications in patients with hemophilia: a single-center experience.” Journal of orthopaedic surgery and research (2023). PMID: 38017431 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [337]
Perrone S, Tomasello R, Raso S et al.. “Incidence of infections in patients treated with rituximab for autoimmune disorders of hematological Interest or non-Hodgkin lymphoma.” Annals of hematology (2026). PMID: 42105103 ↗
L4Cited in: 3. Epidemiology, Etiology & Risk Factors - [338]
Abumahfouz MAM, Al-Sadi A, Alshurafa A et al.. “Successful eradication of acquired factor VIII inhibitors with rituximab: a report of two cases.” Hematology (Amsterdam, Netherlands) (2024). PMID: 39526835 ↗
L1bCited in: 4. Clinical Presentation - [339]
Kumar M, Badagabettu S, Pai KM et al.. “Evidence-based dental management strategies for individuals with congenital hemophilia: a systematic review.” BMC oral health (2026). PMID: 41618283 ↗
L1aCited in: 4. Clinical Presentation - [340]
Razmpoosh E, Olasupo OO, Bhatt M et al.. “Clotting factor concentrates for preventing bleeding and bleeding-related complications in previously untreated or minimally treated children with hemophilia A or B.” The Cochrane database of systematic reviews (2025). PMID: 40838439 ↗
L1aCited in: 4. Clinical Presentation - [341]
Ceglédi A, Bátai Á, Dolgos J et al.. “Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol.” Pathology oncology research : POR (2024). PMID: 38846411 ↗
L3bCited in: 4. Clinical Presentation - [342]
Garcia J, Hussain T, Dillenbeck J et al.. “T2* Magnetic Resonance Imaging Uncovers Hemosiderin Burden in Pediatric Hemophilia: A Call for Sensitive Imaging Biomarkers.” Pediatric blood & cancer (2026). PMID: 42496612 ↗
L5Cited in: 4. Clinical Presentation - [343]
Zhang N, Carcao M, Ignas DM et al.. “Comparison of Magnetic Resonance Imaging Scales for Assessment of Interval Changes of Arthropathy in Boys with Severe Hemophilia.” Journal of clinical medicine (2025). PMID: 40649172 ↗
L5Cited in: 4. Clinical Presentation - [344]
Lee JS, Schuldt R, Xia Z et al.. “Real-world adherence to and persistence with emicizumab in people with hemophilia A using a national claims database.” Journal of managed care & specialty pharmacy (2026). PMID: 41636686 ↗
L3bCited in: 5. Diagnosis & Workup - [345]
Hilberg T, Schmidt A, Strauss AC et al.. “Pain diagnostics in people with hemophilia - pain pressure thresholds and influence of age and joint status.” Journal of thrombosis and haemostasis : JTH (2025). PMID: 41197804 ↗
L3bCited in: 5. Diagnosis & Workup - [346]
El-Ghamrawy M, Abdelhady M, Zahran SMF et al.. “Characterization of Inherited Bleeding Disorders in Egyptian Children in a Tertiary Care Center: A 10 Years Experience.” Journal of blood medicine (2026). PMID: 42039087 ↗
L3bCited in: 5. Diagnosis & Workup - [347]
Hochart A, Wibaut B, Terriou L et al.. “Prepartum Acquired Hemophilia A: Managing a Double Challenge for Mother and Child.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42431314 ↗
L4Cited in: 5. Diagnosis & Workup - [348]
Seidizadeh O, Peyvandi F, Mannucci PM. “Hemophilia A and von Willebrand disease: parallel therapeutic advances in the most common inherited bleeding disorders.” Haematologica (2026). PMID: 42489058 ↗
L5Cited in: 5. Diagnosis & Workup - [349]
Mortarino M, Garagiola I, Nicotra V et al.. “Preimplantation Genetic Testing for Families at Risk of Haemophilia: Ten-Year Single-Centre Experience.” Haemophilia : the official journal of the World Federation of Hemophilia (2026). PMID: 42415645 ↗
L5Cited in: 5. Diagnosis & Workup - [350]
Kharat S, Jivani F, Patil K et al.. “A rapid point-of-care test for the diagnosis of factor VIII inhibitors in hemophilia A patients.” Journal of thrombosis and haemostasis : JTH (2026). PMID: 42019567 ↗
L5Cited in: 5. Diagnosis & Workup - [351]
Yin S, Mu H, Yang W et al.. “Outcomes of low-dose immune tolerance induction with single-dose rituximab in severe hemophilia A: a single-center retrospective experience.” Frontiers in immunology (2026). PMID: 42148133 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [352]
Molinari AC, Baldacci E, Barillari G et al.. “Integrating Clinical, Functional, and Patient-Reported Outcomes in Haemophilia Care: A Delphi-Based Consensus on a New Monitoring Tool.” Journal of clinical medicine (2026). PMID: 41976833 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [353]
Shi M, Ma Y, Peng X et al.. “Clinical validation and application of targeted long-range polymerase chain reaction and long-read sequencing-based analysis for hemophilia: experience from a hemophilia treatment center in China.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 39260745 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [354]
Chang CY, Chiou SS, Weng TF et al.. “Clinical Predictors and Prediction Models for rFVIII-Fc Half Life in Real-World People with Severe Hemophilia A.” Journal of clinical medicine (2023). PMID: 36983209 ↗
L3bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [355]
Bernardo Á, Caro A, Martínez-Carballeira D et al.. “Applicability of the Thrombin Generation Test to Evaluate the Hemostatic Status of Hemophilia A Patients in Daily Clinical Practice.” Journal of clinical medicine (2022). PMID: 35743412 ↗
L3bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [356]
Marco-Rico A, Calvo-Villas JM, Lopez-Jaime FJ et al.. “Joint Damage Prediction in Non-Severe Hemophilia A with Artificial Intelligence.” Journal of blood medicine (2026). PMID: 41883838 ↗
L2bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [357]
Li Z, Chen Z, Liu G et al.. “Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.” Research and practice in thrombosis and haemostasis (2021). PMID: 34278191 ↗
L2bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [358]
Fedewa SA, Buckner TW, Parks SG et al.. “Racial and Ethnic Differences in Distress, Depression, and Quality of Life in people with hemophilia.” Journal of racial and ethnic health disparities (2023). PMID: 37133726 ↗
L3bCited in: 6. Staging, Risk Stratification & Prognostic Scoring - [359]
Badulescu OV, Sirbu PD, Ciocoiu M et al.. “Venous Thromboembolism Prophylaxis in Hemophilic Patients Undergoing Total Hip or Knee Arthroplasty: Insights from a Single-Center Experience.” Medicina (Kaunas, Lithuania) (2025). PMID: 40282860 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [360]
Reich L, Gatzke F, Rauchfuss S et al.. “Prognostic factors for recurrence in acquired hemophilia A-results from a long-term observational study.” Research and practice in thrombosis and haemostasis (2025). PMID: 40177223 ↗
L4Cited in: 6. Staging, Risk Stratification & Prognostic Scoring - [361]
Peng M, Li S, Wu X et al.. “Perioperative blood management and clinical outcomes in patients with hemophilia undergoing total joint arthroplasty: Our long-term results.” Joint diseases and related surgery (2026). PMID: 42542909 ↗
L3bCited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [362]
Radhakrishnan N, Singh A, Pandharipande A et al.. “Managing massive gastrointestinal and abdominal haemorrhage in inherited bleeding disorders: experience from a pediatric cohort.” International journal of hematology (2026). PMID: 41746495 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [363]
Chang IW, Truman M, Yee C et al.. “Characteristics and posttransplant outcomes of patients with congenital and acquired von Willebrand disease and hemophilia A and with renal transplants.” Research and practice in thrombosis and haemostasis (2025). PMID: 41509549 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [364]
George AR, Sylvester KW, Kanaan DM et al.. “Real World Experience with use of Coagulation Factor VIIa at an Academic Medical Center.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2025). PMID: 41379429 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [365]
Olcar S, Elverdi T, Bolayırlı İM et al.. “Citrullinated Histone 3 as a Marker of NETosis at Opposite Ends of Hemostasis: Evidence From Thrombosis-Prone MPN and Bleeding-Prone Hemophilia.” Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis (2026). PMID: 42330249 ↗
L4Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management) - [366]
Morris JJ, Davidson RJ, Watson CT et al.. “Factor VIII Aurora: A Naturally Occurring Gain of Function FVIII Variant with Enhanced FIXa Affinity.” Blood (2026). PMID: 42446089 ↗
L5Cited in: 9. Transfusion, Anticoagulation & Cytoreduction (Hematology-Distinctive Management)